

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number  
**WO 01/20331 A1**

(51) International Patent Classification<sup>7</sup>: **G01N 33/566**,  
33/48, C12Q 1/68, C12N 1/68, 15/63, 15/85, C07H 21/04

(21) International Application Number: PCT/US00/25439

(22) International Filing Date:  
14 September 2000 (14.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/154,071 14 September 1999 (14.09.1999) US

(71) Applicant (for all designated States except US): **XENOPORT, INC.** [US/US]; 2631 Hanover Street, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DOWER, William, J.** [US/US]; 2307 Branner Drive, Menlo Park, CA 94025 (US). **GALLOP, Mark** [NZ/US]; 511 Orange Avenue, Los Altos, CA 94022 (US). **BARRETT, Ronald, W.** [US/US]; 12900 Arroyo de Arguello, Saratoga, CA 95070 (US). **CUNDY, Kenneth, C.** [US/US]; 20433 Via Portofino,

Cupertino, CA 95104 (US). **CHERNOV-ROGAN, Tania** [US/US]; 1231 Monte Verde Court, Los Altos, CA 94024 (US).

(74) Agents: **AUSENHUS, Scott, L.** et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th floor, San Francisco, CA 94111-3834 (US).


(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:  
— With international search report.

[Continued on next page]

(54) Title: SUBSTRATES AND SCREENING METHODS FOR TRANSPORT PROTEINS



(57) Abstract: A variety of methods for assaying libraries of test compounds as ligands and/or substrates of transport proteins, including both carrier-type and receptor-type transport proteins, are provided. Both *in vitro* and *in vivo* screening methods are disclosed. Also provided are methods for screening DNA libraries to identify members that encode transport proteins. Pharmaceutical compositions including compounds identified via the screening methods are also provided.

WO 01/20331 A1



- 
- *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## SUBSTRATES AND SCREENING METHODS FOR TRANSPORT PROTEINS

### CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/154,071, filed September 14, 1999, which is incorporated herein by reference in its entirety.

### FIELD OF INVENTION

This invention relates to the fields of combinatorial chemistry and pharmaceutical agent delivery.

### BACKGROUND OF THE INVENTION

Recent advances in biotechnology and chemistry have made available an increasing number of potential therapeutic agents. However, many agents fail at the preclinical or early clinical stage due to poor pharmacokinetics. Other potential targets for pharmaceutical agents are largely ignored due to anticipated problems of pharmaceutical agent delivery. Oral delivery of compounds is advantageous for reducing treatment costs and increasing patient acceptance. However, formulating compounds for efficient oral bioavailability has proven particularly difficult because of problems associated with uptake and susceptibility to metabolic enzymes in the intestinal tract. Likewise, delivery of compounds across the blood brain barrier or targeting compounds to specific tissues has proven problematic.

There are two major specific transport systems of xenobiotics into and through cells: carrier-mediated systems and receptor-mediated systems. Some xenobiotics can also be taken up by passive diffusion between or through cells. Carrier-mediated systems are effected by transport proteins that are anchored to the cell membrane, typically by a plurality of membrane-spanning loops and function by transporting their substrates via an energy-dependent flip-flop mechanism. Carrier-mediated transport systems are involved in the active transport of many important nutrients such as vitamins, sugars, and amino acids, as well as xenobiotic compounds. The carrier systems are involved in transport of such

molecules from the lumen of the intestine into the systemic circulation or across the blood brain barrier. Carrier-mediated transporters are also present in organs such as liver and kidney, where the proteins are involved in the excretion or reabsorption of circulating compounds.

5                    Receptor-mediated transport systems differ from the carrier-mediated systems in that rather than ferrying the substrate/ligand across the membrane, substrate binding triggers an invagination and encapsulation process that results in the formation of various transport vesicles to carry the substrate (and sometimes other molecules) into and through the cell. This process of membrane deformations that result in the internalization of certain  
10 substrates and their subsequent targeting to certain locations in the cytoplasm is referred to as endocytosis. Endocytosis encompasses several specific variations, including, for example, receptor mediated endocytosis (RME).

RME involves several defined steps beginning with the binding of a substrate to a cell-surface receptor and subsequent invagination of the membrane to form an internal  
15 vesicle variously called an early endosome, a receptosome or CURL (compartment of uncoupling receptor and ligand). In some endocytic events, after a substrate binds to its specific receptor, the substrate-receptor complex accumulates in coated pits that contain high concentrations of clathrin subunits that appear to aid in the membrane invagination process. Following internalization, the clathrin coat is lost and the pH in the endosome is lowered,  
20 thus resulting in the dissociation of the receptor-substrate complex. The endosome moves randomly or along microtubules to the trans-Golgi reticulum where the endosome is converted into one of a variety of different sorting vesicles (e.g., tubulovesicular complexes and late endosomes or multivesicular bodies). The fate of the receptor and substrate depends upon the type of sorting vesicle formed. Some ligands and receptors are recycled to the cell  
25 surface where the substrate is released and the receptor reinternalized into the membrane. In other instances, the substrate is directed to and destroyed in a lysosome, and the receptor is recycled. One type of RME is transcytosis, which refers to the process wherein an endocytotic vesicle is transported to the opposite membrane surface of a polarized cell.

RME is capable of transporting a variety of compounds, including  
30 immunoglobulins, lectins, vitamins and metal ions. Although some conflicting data has been obtained, it has been reported that certain small particles such as nanoparticles can be transported by endocytotic routes, particularly through both enterocytes and M-cells located in the intestine. Nanoparticles can be made of a variety of materials, and are typically between 1-999 nm in diameter.

A number of attempts have been made to assay or identify substrates of various transport proteins or to modify pharmaceutical agents to be improved substrates of transport proteins. (See, e.g., Kramer *et al*, *J. Biol. Chem.* (1994), 269:10621; Mills *et al*, *Biochim. Biophys. Acta* (1992), 1126: 35; Börner *et al*, *Eur. J. Biochem.* (1998) 255: 698; 5 Dieck *et al*, *Glia*, (1999) 25: 10; Otto *et al*, *Am. J. Physiol.* (1996) 271:C210; Abe *et al*, *Bioconjugate Chem.* (1999) 10: 24); Hussain *et al*, *Pharm. Res.* 1997, 14, 613 and McClean *et al*, *Eur. J. Pharm. Sci.* 1998, 6, 153). Some assays have involved measuring the uptake or transcellular flux of labeled compounds. Some assays have involved measuring uptake of unlabelled compound by HPLC. There have been a few successes. For example, Valtrex, a 10 derivative of Zovirax, has 54% oral availability compared with Zovirax's 10-20% oral bioavailability. However, existing assays are tedious, low throughput, and the delivery of many pharmaceutical agents and potential pharmaceutical agents remains to be improved.

#### SUMMARY OF THE INVENTION

15 Disclosed herein are a variety of methods for screening individual or test complexes for activity as ligands for various transport proteins. Certain methods can be performed to distinguish compounds that are substrates and internalized within a cell from compounds that simply bind to a cell surface. Because the methods are amenable to high throughput screening formats and can be used to screen large libraries of complexes, one can 20 accumulate data on structural and electronic features of those compounds that are substrates, thus allowing structure-activity relationships to be discerned. Such information in turn can be utilized in the design of pharmaceutical agents having improved cellular uptake.

By screening complexes that include a reporter, compounds that are substrates for various transport proteins can be readily detected. Use of a reporter has the additional 25 advantage in that it can serve as a surrogate for a pharmaceutical agent. Thus, certain methods involve initially screening a library of complexes to identify a substrate and then replacing the reporter with a pharmaceutical agent and rescreening to determine whether the substrate-drug conjugate is able to be taken up by the cell. Thus, the methods can be used to develop complexes for use in drug delivery.

30 The methods can be performed in a variety of formats, including multiplexed formats, as well as being performed in vitro and in vivo. Some assays are conducted with complexes that include a particle such as a nanoparticle to which a compound is attached or internalized. Complexes found to be active can be formulated as pharmaceutical compositions.

Thus, more specifically, certain methods are designed to screen for a carrier-type transport protein and/or a ligand thereto. Such methods initially involve providing a library comprising different complexes, each complex comprising a compound and a reporter, the compound varying between different complexes. A population of cells is also  
5 provided, one or more of which expresses one or more carrier-type transport proteins. The population of cells is contacted with a plurality of complexes from the library. Subsequently, a signal from the reporter of a complex that is bound to a cell or internalized within a cell is detected. The signal provides an indication that a complex whose reporter generated the signal comprises a compound that is a ligand for a carrier-type transport protein.

10 Such screening methods can optionally utilize various techniques to selectively detect signal from inside the cell rather than signal arising from complexes located at the cell surface or in solution. One simple means for achieving this end is to wash or soak the cells in a wash solution to remove unincorporated complexes. Other methods are performed with fluorescent complexes and the cells being assayed are contacted with a  
15 quenching solution that quenches signal from unincorporated complexes.

Other methods employ various conditional reporters. A signal from reporters of this type is not generated (or at least not substantially generated) until the reporter is internalized within the cell (e.g., less than 5 to 30% of the total signal detected is from non-internalized complexes). Thus, signal arising from complexes that are bound to the cell  
20 surface or that are in solution is minimal.

Certain methods using such reporters utilize a reporter that includes a fluorophore and a quencher moiety. Outside the cell, the quencher is disposed relative to the fluorophore such that it quenches fluorescence from the fluorophore. However, if the reporter is internalized within the cell, the intracellular conditions are such that the quencher  
25 can no longer effectively quench fluorescence emitted from the fluorophore. In certain systems, an intracellular enzyme cleaves the complex to release the quencher from the complex so that it no longer is in sufficiently close proximity to quench the fluorophore.

Reporters in other systems include a detection moiety disposed to interact with an intracellular agent located within the cells. If a complex is transported into the cell, the  
30 detection moiety interacts with the intracellular agent to generate a detectable signal. Certain methods using this type of reporter utilize a nucleic acid-binding dye that binds to nucleic acids within the cells to generate a signal. Other conditional reporters include a substrate for an enzyme. If a compound complexed with the reporter is a substrate for the carrier-type

protein, the complex is transported into a cell where an intracellular enzyme (either endogenous or exogenous) metabolizes the enzyme substrate to form a detectable product.

A variety of conditional reporters include bioactive moiety that can cause some type of change within the cell. For instance, the reporter can include an agent that causes a morphological change upon internalization within a cell, which morphological change can be detected. Other reporters once internalized within a cell act to promote the aggregation of subunits of a multimeric enzyme expressed within the cells. Still other reporters promote transcription from a promoter within a cell resulting in expression of an expression product that generates a detectable signal. The reporter can also confer a selective advantage within cells. In methods utilizing such reporters, after the cells being assayed have been contacted with complexes, the cells are propagated under conditions that enrich for cell(s) on which the selective advantage has been conferred.

As indicated above, the methods can be performed in multiplex formats in which different cells expressing different transport proteins and/or different complexes having different compounds are assayed within a single reaction vessel. To facilitate analysis, various methods can be utilized to differentiate between different cells and different complexes. For instance, if different cells expressing different transporters are simultaneously assayed, the cells can be selected to have different morphological characteristics or can be differentially stained. Different complexes can be distinguished by using complexes that have different labels.

In another aspect, the methods can be performed in an iterative fashion to identify compounds having enhanced activity. Thus, a compound identified as being a substrate in an initial screen can serve as the basis for generating another library, the members of which are variants that are related to the compound identified in the initial screen.

Once a compound that functions as a substrate is identified, the reporter can be replaced with a drug and the resulting complex then rescreened for activity to identify compounds that can effectively transport pharmaceutical agents.

Alternatively, or in addition, the methods can also be utilized to screen for new transport proteins using cells that have been transformed with a DNA library. Cells demonstrating the ability to bind to or be internalized within a complex can be isolated, the DNA therein removed, and the DNA characterized to identify a DNA molecule that encodes for a transport protein that exhibits activity with the compound of the complex that bound to, or was internalized by, the isolated cell.

The invention also provides a variety of screening methods to identify substrates for receptor-type transport proteins. Certain of these methods are related to methods for screening carrier-type transport proteins. For instance, certain methods involve providing a library comprising different complexes, each complex comprising a compound and a reporter, the compound varying between different complexes. A population of cells, one or more of which expresses one or more receptor-type transport proteins, is also provided. This population of cells is then contacted with a plurality of complexes from the library. A signal from the reporter of a complex that is bound to a cell, internalized within a cell or has been transported through a cell is then detected. Such a signal provides an indication that a complex whose reporter generated the signal comprises a compound that is a ligand for a receptor-type transport protein. These methods can also be adapted to be performed using the various conditional reporters described for the assays of carrier-type transporter and can also be conducted in multiplex format.

Certain screens are conducted using complexes that include a support, with the compound and reporter attached or enclosed therein. Various supports can be utilized including, for example, nanoparticles. In certain methods, the ability of a compound to pass through a cell via transcytotic mechanisms can be detected by forming a monolayer of cells and then detecting the position of reporter relative to the cells in the monolayer. In some methods, detection is done at intervals to track internalization of a complex into a cell.

A variety of in vivo screening methods are also provided. Certain of these methods involve introducing into a body compartment of an animal a population of complexes, each complex comprising a support, a test compound, and a reporter, the test compound varying between complexes. Typically the reporter is the same, although different complexes bearing different compounds can in some instances also bear different reporters. Subsequently, complexes are recovered by means of their reporter from a tissue or fluid of the animal after transport of at least some of the complexes through cells lining the body compartment. The body compartment through which transport is monitored often is the lumen of the gastrointestinal tract.

Certain of the in vivo methods involve repeating the method with the recovered complexes such that recovered complexes from one cycle form the population of complexes to be introduced into the body compartment of the animal in the next cycle. In such iterative methods, the animal used in each cycle can be the same or different.

Recovered complexes showing activity can be used to screen for potential transport proteins. For instance, certain methods involve contacting recovered complexes



with a population of polarized cells transformed with a DNA library at least some members of which encode potential transport proteins, the cells being arranged as a monolayer on a membrane and the complexes contacting the apical side of the cells. Complexes transported through the polarized cells to the membrane are detected by virtue of the reporter of the complexes. Polarized cells in proximity to the transported complexes are recovered and then clonally expanded.

Compounds identified via the various screening mechanisms can be utilized to prepare pharmaceutical compositions. Certain of these compositions include a nanoparticle, a drug within or linked to the nanoparticle and a ligand linked to or within the nanoparticle, the ligand being effective to promote cellular uptake and/or transport of the particle by receptor-type transport proteins. The nanoparticles of some compositions also include a second ligand attached to, or internalized within, the nanoparticle. The second ligand can be utilized for various purposes. In some instances, the ligand binds to a first cellular receptor, and the second ligand binds to a transport protein, which binding results in internalization of the nanoparticle. In other instances, the ligand binds to a receptor-type transport protein, which binding results in internalization of the nanoparticle, and the second ligand binds to a second transport protein within a cell that effects basolateral trafficking of the internalized nanoparticle to the basolateral exterior of the cell. The nanoparticle can also be linked or contain other agents, such as a buffering agent, an antacid and/or a cell lysing agent, for example.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 illustrates transport of a substrate into a cell by a carrier-type transporter.

Figs. 2A and 2B illustrate transport of a substrate into a cell by a receptor-type transporter in which substrates bind to cell-surface receptors and are subsequently encapsulated into vesicles and transported into and/or through the cell from the intestinal lumen to the blood system.

Fig. 3 illustrates a two-membrane system (a "transwell system") for detecting the movement of substrates through a layer of polarized cells by transcytosis.

Fig. 4 is a schematic diagram illustrating the process of trans-stimulation, or the process of substrate-mediated efflux of labeled substrate from within the cell to the cell exterior.

Fig. 5 is a chart showing uptake of the PEPT1 substrate XP 10486 (see Example 4 for synthesis) into CHO cells expressing PEPT1 and control cells that do not express PEPT1.

Figs. 6A and 6B provide charts summarizing competition experiments conducted in both 96 and 384 well formats.

Fig. 7 shows ten pools of compounds obtained during synthesis of a 200 member fluorescent dipeptide library.

Fig. 8 shows an example of the synthetic steps involved in preparing a dipeptide library for use in screening against certain transporters.

Fig. 9 shows an example of the synthetic steps involved in preparing a  $\beta$ -lactam library for use in screening against certain transporters.

Fig. 10 depicts the major steps in the synthesis of the PEPT1 substrate XP 10486.

Fig. 11 presents the three major structural motifs in which the reporter NBD is positioned at different locations on a dipeptide backbone.

Figs. 12-14 show steps in the synthesis of different NBD-containing sub-libraries.

Fig. 15 depicts a luciferase vector construct used to transfect cells such that they express luciferase.

Figs. 16-18 illustrate the synthesis of various luciferin conjugated substrates.

Figs. 19-21 present the synthesis of conditionally fluorescent substrates that include mask moieties that mask signal formation until the substrate has been internalized within a cell.

Figs. 22-24 describe the process of synthesizing complexes in which a pharmaceutical agent is substituted for a reporter in a complex. Fig. 22 shows the major steps in the synthesis of cholyl-L-Lys-( $\epsilon$ -NBD)-OH that is a substrate for the rat intestinal bile acid transporter. Fig. 23 shows the synthesis of a related compound in which the NBD reporter is replaced with the drug Naproxen and which retains activity with the rat intestinal bile acid transporter. Fig. 24 depicts the preparation of the propharmaceutical agent Cholyl-L-Dopa.

Fig. 25 shows the results of a LC/MS/MS analysis used to determine uptake of the unlabeled substrate Gly-Sar (Glycylsarcosine) in PEPT1-transfected CHO EE 412 test cells and CHO K1 control cells not expressing PEPT1.

Figs. 26A and 26B are charts showing the results of trans-stimulation assays. Fig. 26A shows the efflux of tritiated Gly-Sar when CHO cells expressing PEPT1 are

contacted with varying concentrations of untritiated Gly-Sar. Fig. 26B shows the results from related experiments in which the efflux of tritiated taurocholate is detected from CHO cells expressing LBAT when contacted with the untritiated cholate analogs Gly-CDC-acid (glycochenodeoxycholic acid) and Gly-CDC-ethyl ester.

5 Figs. 27A and 27B present results demonstrating the inhibitory effect of inhibitors on the activity of known substrates for two different transport proteins. Fig. 27A shows inhibition plots for CHO cells expressing IBAT when contacted with one of two known substrates (cholic acid or taurocholate) in the presence of tritiated taurocholate. Fig. 27B presents the inhibition plot for cells expressing PEPT1 when contacted with either of the  
10 known substrates Gly-Sar or Enalapril and the tritiated inhibitor Gly-Sar.

Figs. 28-30 show the major steps in the synthesis of various libraries of fluorescent Zanamivir bile acid pro pharmaceutical agents. Compounds from such libraries can be used in studies of intestinal absorption (see Example 15).

## 15 DETAILED DESCRIPTION

### I. Definitions

A "transport protein" is a protein that has a direct or indirect role in transporting a molecule into and/or through a cell. The term includes, for example, membrane-bound proteins that recognize a substrate and effects its entry into a cell by a  
20 carrier-mediated transporter (see Fig. 1) or by receptor-mediated transport (see Figs. 2A and 2B). Transport proteins are sometimes referred to as "transporter proteins" or simply "transporters." The term also includes intracellularly expressed proteins that participate in trafficking of substrates through or out of a cell. The term also includes proteins or glycoproteins exposed on the surface of a cell that do not directly transport a substrate but  
25 bind to the substrate holding it in proximity to a receptor or transporter protein that effects entry of the substrate into or through the cell. Transport proteins involved in carrier-mediated transport are referred to as carrier-type transport proteins or simply carrier-type transporters. Those transport proteins involved in receptor-mediated transport are referred to as receptor-type transport proteins or simply receptor-type transporters.

30 Some examples of transporter proteins effecting carrier-mediated transport of nutrients, vitamins and xenobiotics include, but are not limited to: glutamate/neutral amino acid transporter; facilitated glucose transporter; d2/NBAT and 4F2 transporter; sodium/glucose transporter; GABA transporter; amino acid permease transporter; sodium/bile acid transporter; proton/oligopeptide transporter; monoamine transporter; folate transporter;

organic anion/prostaglandin transporter; organic cation/organic anion transporter; sodium/ascorbic acid transporter; fatty acid transporter; sodium/nucleoside transporter and facilitated nucleoside transporter. Other examples of carrier proteins include: the ileal bile acid transporter (ASBT or IBAT); the liver bile acid transporters (NTCP); dipeptide  
5 transporters; oligopeptide transporters; simple sugar transporters (e.g., SGLT1); phosphate transporters; monocarboxylic acid transporters; ATP-binding cassette (ABC) family (e.g., P-glycoprotein); organic anion transporters (OATP); organic cation transporters; amino acid transporters; nucleoside transporters; vitamin transporters; and electrogenic transporters that carry charged substrates. Examples of receptor-mediated transport proteins include: viral  
10 receptors, immunoglobulin receptors, bacterial toxin receptors, plant lectin receptors, bacterial adhesion receptors, vitamin transporters and cytokine growth factor receptors.

Abbreviated references to transporters sometimes begin with a small letter to indicate the source of the transporter. Thus, for example, hPEPT1 and hMDR1 refer to the human PEPT1 and MDR1 transporters, respectively. Likewise rpept1 and rmdr1 refer to the  
15 pept1 and mdrl transporters in rat. Specific examples of transport proteins include hPEPT1, rpept1, hPEPT2, rpept2, hIBAT, hLBAT, rLBAT, hMDR1, rmdr1a, rmdr1b, hMRP3, hMRP1, rat oatp1, rat oatp2, rat oatp3, hOATP-A, hOATP-C, rat oatp-c, hBSEP, rBSEP, rat mrp3, hMRP2, rat mrp2, rat oat2, rat oat3, hOCT1, rat oct1 and rat mEH.

A "substrate" of a transport protein is a compound whose uptake into or  
20 passage through a cell is facilitated by the transport protein. Some existing drugs that are substrates for the PEPT1 transporter include: antibacterial drugs (e.g., Cefadroxil, Cefitibuten, and Cyclacillin), antihypertensive drugs (e.g., Enalapril, Lisinopril and Captopril), vasodilators (e.g., pGlu-L-Dopa-Pro), anticancer drugs (e.g., Bestatin) and antiviral drugs (e.g., Valacyclovir). Some natural substrates of the bile acid transporter include cholic acid  
25 and taurocholic acid. Some drugs that are substrates for OATPs include Microcystin LR, Deltorphan and BQ-123.

The term "ligand" of a transport protein includes substrates and other compounds that bind to the transport protein without being taken up or transported through a cell. Some ligands by binding to the transport protein inhibit or antagonize uptake of the  
30 compound or passage of the compound through a cell by the transport protein. Some ligands by binding to the transport protein promote or agonize uptake or passage of the compound by the transport protein or another transport protein. For example, binding of a ligand to one transport protein can promote uptake of a substrate by a second transport protein in proximity with the first transport protein.

A “small molecule” means a synthetic molecule having a molecular weight of less than 1000 daltons, more typically 500 daltons or less. Such molecules include, for example, sterols, amino acids, lipids and nucleic acids.

An “expression cassette” is a nucleic acid construct, generated recombinantly or synthetically, that has control elements that are capable of effecting expression of a structural gene that is operably linked to the control elements in hosts compatible with such sequences. Expression cassettes include at least promoters and optionally, transcription termination signals. Typically, the recombinant expression cassette includes at least a nucleic acid to be transcribed (e.g., a nucleic acid encoding a transport protein) and a promoter. Transcription termination signals, enhancers, and other nucleic acid sequences that influence gene expression, can also be included in an expression cassette.

An “encoded library” is a library of compounds in which each compound is linked to a tag recording at least one step in synthesis of the compound. Conversely, a non-encoded library is a library of compounds lacking tags.

An “exogenous” species is refers to a species that is not normally present in a cell, but can be introduced into a cell by one or more genetic, biochemical or other methods. Normal presence in the cell is determined with respect to the particular developmental stage and environmental conditions of the cell. Thus, for example, a molecule that is present only during embryonic development of muscle is an exogenous molecule with respect to an adult muscle cell. An exogenous species can be, among other things, a small molecule, such as is generated by a combinatorial chemistry process, or a macromolecule such as a protein, nucleic acid, carbohydrate, lipid, glycoprotein, lipoprotein, polysaccharide, or any modified derivative of the above molecules, or any complex comprising one or more of the above molecules.

By contrast, an “endogenous” species is one that is normally present in a particular cell at a particular developmental stage under particular environmental conditions.

The term “statistically significant difference” refers to a statistical confidence level, P, that is  $< 0.25$ , preferably  $< 0.05$ , and most preferably  $< 0.01$ .

The terms “pharmaceutical agent,” and “drug” are used interchangeably to refer to an agent suitable for delivery via a transport protein which induces a desired effect in the individual to which delivery is effected. The terms include agents that are therapeutically effective, as well as agents that are prophylactically effective.

## II. General

The invention is based, in part, on the provision of a variety of assays that permit rapid detection of compounds that are substrates for, or which otherwise bind to, transport proteins. Such assays typically generate an optical signal that provides an indication of the activity, if any, of a test compound as a ligand for a transport protein. The assays can be performed *in vitro* or *in vivo*. Some assays can distinguish compounds that are substrates of a transporter protein from compounds that bind to a transporter protein without being substrates. In certain methods, this is accomplished by using reporters that preferentially generate a signal once internalized within a cell. The methods are amenable to multiplexing, enabling high-throughput screens to be performed. For example, different populations of cells expressing different transport proteins can be screened simultaneously within a single reaction vessel; similarly, different complexes having different compounds can be simultaneously screened against a single type of transport protein. Alternatively, cells expressing different transport proteins and different complexes can be screened at the same time within a single reaction vessel.

While methods can be performed with individual compounds, the assays also permit libraries of test compounds to be screened for potential activity as ligands. The libraries can be random libraries or can include variants of known substrates. The assays also permit screening of DNA libraries to identify members that encode transport proteins. Optionally, DNA libraries and compound libraries can be screened in the same assay. By screening libraries of complexes composed of substrates and/or reporters that vary with respect to substrates and reporters of complexes known to be transported, structure-activity relationships can be established. Information obtained by screening such libraries provides information, for example, on steric and/or electronic features that correlate with transport activity. Such information can be used in turn to rationally design complexes that are transported by a transport protein of interest.

Substrates of transport proteins identified by the methods can be linked to pharmaceutical agents thereby facilitating uptake of the pharmaceutical agents by a patient. In such methods, the reporter essentially acts as a surrogate for the pharmaceutical agent during initial screening. Once a substrate is identified, the reporter can be replaced with a pharmaceutical agent of interest. For example, a substrate for an intestinal epithelial cell transporter can be linked to a pharmaceutical agent via a linker that is either enzymatically and/or chemically cleavable or is non-cleavable. In the case of a cleavable linkage, the pharmaceutical agent derivative can be regarded as a prodrug. A wide variety of cleavable linkages can be used in prodrugs depending on the

nature of the functionality groups available for derivatization in the pharmaceutical agent molecule (*vide infra*).

Substrates for a receptor-type transporters can be linked to a particle containing a pharmaceutical agent to form a pharmaceutical composition. The particles can be taken orally by the patient, with the substrate facilitating passage of the particles through the layer of intestinal epithelial cells lining the gut. In some instances, the pharmaceutical compound is released from the particle and the intact particle subsequently excreted. In other instances, the particle is digested by intracellular enzymes resulting in release of the pharmaceutical agent. Some particles also include a ligand that directs trafficking of the particle to particular cellular organelles after the particle has been internalized within a cell.

Other ligands of transport proteins that are not themselves substrates are also useful. Some such ligands promote uptake of a substrate linked to the ligand. Such can be effected, for example, when a ligand binds to a cellular outer surface molecule in proximity with a carrier or receptor for the substrate thereby bringing the substrate into contact with the carrier or receptor. Some inhibitors of transport proteins are also useful as pharmaceutical agents. For example, inhibitors of nutrient transporters can be used in managing obesity, diabetes and hypercholesterolemia, for example.

New transporter proteins identified by the methods can themselves be screened for suitable substrates and other ligands, and these substrates and ligands used as described above. Structural information on new transporter proteins is also useful in designing pharmaceutical agents that bind or are transported by these proteins.

### **In vitro Systems for Screening for Transport Proteins and Substrates**

#### **I. General Screening Methods**

The methods involve contacting one or more cells expressing one or more transporter proteins with one or more complexes, each complex comprising at least a compound and a reporter. Typically, the reporter is capable of generating an optical signal. After incubating for a period sufficient to permit transport of the complex into the cell or to permit binding to the cell, the location of signal from the reporter is detected. Detection of the signal at a location within a cell, or at a location that indicates that a complex has passed through a cell, indicates that the complex comprises a compound that is a substrate for a transporter protein expressed by the cell. Detection of signal on the surface of a cell exposed to complexes (and not within a cell or at a surface distal to complexes) indicates that the complex contains a compound that binds to a cellular surface molecule. Such compounds

include compounds that agonize or antagonize transport of substrates, as well as compounds that bind to cell surface components unrelated to transport.

Following detection of signal, one can isolate and characterize either or both the complex(es) responsible for generation of signal and the cell(s) that transported or bound such complexes. Complexes can be isolated from within or proximate to cells generating signal. The identity of a compound borne by such a complex can be decoded from an optional tag that is a component of such a complex or by deconvolution by a variety of chemical analyses, such as HPLC, mass spectrometry, infra red spectroscopy and nuclear magnetic resonance spectroscopy. Cells that have transported compounds can also be isolated from the location of signal within or proximate to a cell. Having isolated a cell, one can isolate from the cell a DNA fragment encoding the protein transporter responsible for transporting a complex that generated the signal within or proximate to the cell.

Although the methods can be performed in a single cell format, they are typically performed using a population of cells. Cells are contacted with libraries of complexes, or can be contacted with a single type of complex. In some methods, multiple copies of each complex type are present. Some methods also include conducting parallel screening experiments with a control cell or multiple control cells. The control cells do not express the transport protein(s) expressed by the test cells. Using such cells, it is possible to distinguish between bona fide uptake by the transport protein and other uptake processes (e.g., passive diffusion or cell lysis).

The cells can express natural endogenous transport proteins or can be transformed with DNA segment(s) encoding exogenous transport proteins. In the latter case, the cells can be transformed with a library of DNA fragments, such that different cells receive different fragments and express different candidate transport proteins. Alternatively, all cells can be transformed with the same DNA segment such that the cells express the same known transport protein or candidate transport protein. Exogenous DNA introduced into cells can exist integrated into the cell chromosomes or can exist in an episomal vector. The latter is preferred for ease of isolation.

The format of the assay depends, in part, on the cell type and the nature of the reporter. Certain assays are performed with both cells and complexes suspended in solution. Some assays are performed with cells linked to a solid phase, such as a plate or membrane. Other assays are performed on a monolayer of cells. As described in more detail below, the latter format is particularly suitable for polarized cells in that it allows complexes to be contacted with the apical surface of such cells, and detected on passage through the basal



surface. Many assays can be performed in multi-well plates including 96 well plates, and similarly sized plates that include 384, 864, 1536 or 3456 wells. Assays conducted with these latter plates are useful in that smaller volumes are utilized and higher throughput is obtained. In many assays, the detection step can be performed homogeneously, i.e., without prior separation of cells from unincorporated and unbound complexes.

Still other assays are not conducted with whole cells but instead performed with membrane preparations or vesicles prepared from cells expressing the target transporters. Such membrane preparations and vesicles can be prepared according to established methods such as described by H. Bonisch, "Transport and Drug Binding Kinetics in Membrane Vesicle Preparation," *Methods in Enzymology* 296:259 (1998). Membrane preparations and vesicles prepared in this way can be used to assay uptake using the same general methods utilized with whole cells. However, assays conducted with vesicles instead of whole cells can be useful in assaying transporters such as from the ABC family that are efflux pumps. Assaying such transporters with vesicles is possible because a significant percentage of the vesicles in the preparation are "inside out," thereby allowing efflux pump transporters to cause uptake into the vesicle for detection. This is not possible using intact cells. Assays utilizing vesicles are described further in Example 17 supra.

The nature of the complex used in the screening methods depends, in part, on the type of transport protein being utilized in the assay. In general, assays of carrier-type transport proteins are conducted with complexes that comprise a substrate and a reporter. As described in greater detail *infra*, assays with receptor-type transport proteins can be conducted using complexes in which the substrate and reporter are optionally attached to a support (e.g., a bead or nanoparticle). Receptor-type transport proteins can accommodate complexes that include supports because the vesicles formed to effectuate transport are sufficiently large to contain such particles. Thus, while screening methods using cells that express receptor-type transport proteins can be conducted with complexes that contain particles, the methods can also be conducted with complexes that lack supports and that simply include a compound and a reporter.

## II. Compound Identification and Assessment of Structure-Activity Relationships

The methods can be used in a variety of ways. In some methods, the goal is to identify compounds that are ligands for any transport protein expressed by a particular cell type, typically a natural cell. In such methods, a library of complexes bearing test compounds is contacted with a population of the cell type. Complexes binding to,

internalizing within, or passing through cells are then identified, and compounds borne by such complexes are characterized. Optionally, complexes can be subject to a further iteration of the screening process with or without prior characterization. In other methods, the goal is to identify compounds that are ligands for a particular known transport protein. Such

5 methods can proceed as just described using a cell type expressing the known transporter, typically with a substantially isogenic control cell type lacking the transporter. Alternatively, such methods can be performed using a population of cells transformed with DNA segments expressing the known transport protein.

Coupling the screening methods disclosed herein with the synthesis and use of

10 selected combinatorial libraries, provides an efficient mechanism for defining structure-activity relationships (SAR) for transport proteins. It has unexpectedly been shown using the methods described herein that transporter structure-activity relationships can be effectively mapped out by screening combinatorial libraries of potential substrates that are conjugated to reporter groups. The ability to rapidly understand the requisite physiochemical

15 characteristics (e.g., steric and electronic) that a molecule needs to possess to serve as a substrate for a transport protein significantly facilitates the design of pharmaceutical agents having improved cellular uptake (e.g., improved intestinal permeability).

Determination of the electronic and steric features that are correlated with complex internalization can be achieved in a variety of ways. In general, once a compound

20 of a complex has been identified as a substrate for a transport protein, the compound and/or reporter of the complex are varied to obtain at least one variant complex, and more typically a library of variant complexes. Hence, certain variant complexes of libraries of variant complexes include compounds that are variants of one or more known substrates. A variant substrate is one in which certain features of the known substrate are maintained while other

25 features are varied. The type of features that can be varied include, but are not limited to, electronic features (e.g., polarity and charge), steric features (e.g., size or position of substituents), chemical features (different functional groups) or stereochemical features. Thus, for example, the size of one or more substituents of the substrate can be varied, and/or a functional group altered, omitted or replaced.

30 Alternatively, a variant complex can include a compound from a complex known to be transported but a reporter that differs in some way from the reporter of the transported complex. Features of the reporter similar to those just described for the compound can be varied. In some instances, variant complexes simply involve placement of the same reporter at different sites on the substrate backbone. Of course, a library of variant

complexes in which both compound and reporter are varied can be prepared. The libraries of variant complexes prepared from complexes showing activity with a transport protein are referred to as focused libraries.

Once a variant complex or population thereof has been generated, the complex(es) can be rescreened against the transport protein of interest. This process can be repeated in iterative fashion for as many times as desired, but preferably until the information necessary to infer structure-activity relationships is obtained. By characterizing the various compounds that are identified as substrates of a transport protein, certain features of the compounds emerge as key elements that correlate with activity. As indicated supra, such information can be used to provide valuable insight in the design of substrate-drug conjugates that can be readily taken up by transport proteins. Example 4 illustrates in further detail how sub-libraries can be generated from an active compound to obtain SAR information.

### III. Screening DNA Libraries to Identify Transport Proteins

In other methods the goal is to clone hitherto unknown transport protein(s) of a known substrate. In such methods, a complex bearing the known substrate is contacted with a populations of cells transformed with a library of DNA segments encoding different candidate transport proteins. Cells binding to, internalizing or passing through complexes are isolated and cloned DNA segments are isolated therefrom and characterized, (e.g., by sequencing). With or without characterization, the DNA segments can be transformed into fresh cells for a secondary screen with the same compound.

In other methods, the goal is to clone new transport proteins regardless of the specific substrate. Such methods are performed by contacting a library of complexes bearing different compounds with a population of cells transformed with a library of DNA segments encoding different potential transport proteins. Cells binding to, internalizing or passing through a complex are isolated and DNA segments from these cells characterized. These DNA segments can then be retransformed into fresh cells. These cells, either as individual clones or as a mixed population, can then be rescreened against the original library of complexes to identify compounds that are ligands to each cloned transport protein.

### IV. Alternative and Secondary Screening Methods

For complexes bearing compounds identified as binding to a cell but not being internalized or passing through the cell, a secondary screen is needed to determine whether the compound either agonizes or antagonizes transport of a substrate for a transport protein.

An agonist screen can be performed using complexes that further comprise the compound being tested for agonism as well as a known or candidate substrate compound and a reporter. Complexes internalizing or passing through cells are isolated. Then a further screen is performed, optionally in a competition format, to compare the rate or extent of uptake or passage through a cell of a complex bearing a substrate and reporter, versus a complex bearing the substrate and a potential agonist and a reporter. A greater rate or extent of uptake or passage by the cell of the latter complex indicates that the potential agonist does indeed have agonist activity.

An inhibitor screen can be performed by incubating a complex comprising a known substrate for a transporter protein and a reporter with a population of cells bearing the transport protein in the presence and absence of the potential inhibitor and determining whether there is any decrease in rate or extent of uptake or passage when the inhibitor is present.

#### V. Multiplexed Methods

The screening methods disclosed herein can be conducted in a multiplex format in which multiple different cells expressing different transporter proteins and/or multiple different complexes, each having a different compound, are screened within a single reaction vessel (e.g., a single well of a multi-well plate). The different cells within a reaction vessel can be distinguished in a variety of ways. A simple multiplexed situation is one in which control cells (e.g., cells failing to express the transporter of interest) are assayed together with test cells that express the transport protein of interest. The test cells and control cells can potentially be distinguished if complexes are internalized within one group of cells but not the others as evidenced by signal coming from one group but not another group of cells. It can be inferred in this situation, that those cells from which no signal is detected are control cells. This can be confirmed using one of the methods that follow.

If the different cells are selected to have characteristic morphologies, then the different cells can simply be distinguished on the basis of different morphological characteristics. Alternatively, or in addition, different cells in a multiplex assay can be distinguished by differentially staining the cells. If the cells express different cell surface antigens that can be differentially stained, then all of the various cells can be stained together by adding the various dyes to a single reaction vessel. More typically, the cells are differentially stained in separate reaction vessels and then combined for the multiplex assay. Another option is to use cells that express different cell-surface markers to provide a basis for

discriminating between cells. Such markers can be endogenous or exogenous. For example, different cells can be engineered to express different epitopes that can be selectively stained with labeled antibodies, with antibodies for different epitopes bearing different labels.

Different complexes within a reaction vessel can be distinguished by  
5 differentially labeling the various complexes. For example, different complexes can be labeled with different fluorophores that have different emission maxima. Alternatively, the complexes can bear different radioisotopes. A variety of other labels can be similarly utilized including, but not limited to, mass labels, luminescent labels, chromophores, spin labels, and substrates for different enzymes. A mass label refers to a compound or moiety capable of  
10 generating a distinctive mass fragment that can be detected using various size-based separation techniques (e.g., mass spectroscopy).

Although the foregoing methods facilitate a rapid and unambiguous means to sort out which cell or complex has activity, it is not necessary to use cells and/or complexes that are distinguishable from one another to conduct multiplex assays. For example,  
15 multiplexed assays can be conducted in which cells expressing different transporters are not distinguishable; a signal in a reaction vessel (e.g., well of a multi-well plate) indicates that the complex(es) in that reaction vessel are substrates for one or more of the transport proteins expressed by the cells. A second stage assay can then be conducted in which the different cells in the active reaction vessels are separately assayed to determine the specificity of the  
20 compounds. Likewise, multiplexed assays can be performed with multiple different complexes that are not differentially labeled. In this instance, a reaction vessel exhibiting activity is an indication that at least one of the complexes added to that particular reaction vessel has activity. The specific complex(es) responsible for the observed activity can be identified in a second screen in which the complexes are individually assayed.

25 Such approaches are not unduly burdensome as the vast majority of reaction vessels in a screen typically will not show activity. It is usually only necessary to deconvolute which cell and/or complex is active in a relatively small number of reaction vessels. These approaches also avoid the expense and complexity of using differentially labeled complexes and different cell types.

## 30 VI. Transcytosis Methods

Some methods are particularly adapted to screen for proteins that direct the transcellular movement (transcytosis) of complexes from the apical side of a cell to the basolateral side of a polarized cell. Polarized cells are present in many tissues. In all epithelial

layers, the layers of cells separating the body from the outside world, the cells are polarized. Epithelial cell layers are characterized by the presence of tight junctions that form a very effective seal between all the cells of the layer. It is this seal that divides the cells into an apical (outside) and a basal (inside) surface. The areas between the cells on the inside side are lateral; hence, the entire inside surface of the epithelial cell is known as the "baso-lateral" surface. The cytoskeletal structure, which is connected to the sites of the tight junctions, serves as an internal indicator of the orientation of the cell, and provides a signal to guide the proteins and organelles to their appropriate location in the polarized cell.

In some such methods, a population of polarized cells (e.g., CaCo-2, HCT-8, T84, HT29 and MDCK) is grown on a first membrane of what is typically a two membrane system (see Fig. 3). The cells can be natural cells or cells transfected with DNA encoding potential transport proteins as described above. The first membrane or upper membrane is a porous membrane that includes pores that are larger than the complexes being screened. A monolayer of polarized cells is positioned on the upper membrane. A second or lower porous membrane is positioned under the first membrane and is structured to retain any complexes capable of traveling through the polarized cells and through the pores in the upper membrane.

In those cases where the movement of the complexes through cells and membranes are monitored by imaging from below, the second membrane is chosen to be optically transparent. The preferred membranes in this case are polyester in composition, and are available from Corning Costar. In those cases where the process is monitored by imaging from above, the following arrangement is preferred. Any of the commercial transwell plate configurations can be used, depending on the particular assay, having from 6 to 24 or more wells, each well having a membrane of 24 to 6.5 mm dia. The membrane chosen for the transwell is a large pore (3  $\mu\text{m}$ ) transparent (polyester, 10  $\mu\text{m}$  thickness) type upon which the layer of epithelial cells are grown at a density of  $\sim 10^6$  cells/cm<sup>2</sup> at confluence. Below this cell support membrane is suspended a second membrane constructed of polycarbonate with small pores (100 nm or less, 10  $\mu\text{m}$  thickness). The small pore size of the lower membrane is selected to provide a barrier to the further passage of particles larger than 100 nm. The second membrane is usually placed immediately below the primary cell support membrane, and the two membranes can be placed in contact with one another. This arrangement results in the accurate immobilization of particles immediately below the cell(s) through which they have passed.

An alternative method accurately to immobilize the particles is by the use of a thin gel matrix underlying the cell support membrane. A layer of agarose approximately 1

mm thick is poured on an optically transparent plastic plate. Before the agarose solidifies, the transwell device is lowered into the agarose to form an intimate contact between membrane and agarose. Occasionally, it is necessary to feed the wells from below or from both above and below. In this situation, a thin layer of agarose can be poured directly on the bottom surface of the membrane of an inverted transwell insert. A supporting mesh, such as fine nylon grid with openings ~1mm across is placed across the gel to retain it in place once the transwell is returned to the upright position. When the agarose has gelled, the transwell is placed suspended in the receiving wells as usual. Both of these arrangements allow imaging from below with any of the usual cell support membrane types (e.g., polyester, polycarbonate, or PFTE), or from above if a transparent cell support membrane is used (polyester or PFTE).

A complex or, more typically, a library of complexes is contacted with the cell monolayer. The location of complexes that pass through the cell layer can be detected by any of a variety of optical methods. The second membrane immobilizes the complexes in the vicinity of the cell(s) expressing the cDNA that promotes the transcytosis of a complex, thus enabling the selection of cells expressing a protein capable of directing the transcytosis of at least some compounds. The cDNA located within such cells can then be used to identify the transport protein encoded by the gene.

To determine the test compounds in the library that induce transcytosis, cells identified as promoting transcytosis are picked and clonally expanded. The various members of the test compound library are exposed (sequentially) to each of the expanded clones in a transwell format similar to that just described for the expression library. Each clone transports those complexes that belong to a single family, such complexes are recovered from the bottom compartment of the transwell. Complexes that are not transported are removed from the top compartment of the transwell and placed on the next clone of cells, and the process repeated. At the end of this process, the pool of complexes recovered from below each cell clone layer represents a population enriched for test compounds that are able to direct the transcytosis of an attached particle. This can be a single compound or a group of related (or even non-related) test compounds that bind to the specific transport protein that has been cloned and over-expressed by the corresponding clones. By virtue of this enrichment, the test compound can be more easily and reliably identified by techniques described below.

## VII. Libraries of complexes

### A. General

Each complex in such libraries typically contains a compound and a reporter capable of generating a detectable signal, preferably optical. The compound varies between complexes whereas the reporter is typically the same in different complexes, although  
5 reporters can vary as described *supra*. In some libraries, the compound and reporter are linked directly to each other by a chemical bond. Other libraries further comprise a support. The support can be a solid support, such as a bead or other particle. The support can also be a molecular scaffold or linker that holds the compound and reporter together. In such  
10 arrangements, both compound and reporter can be linked to the support. Alternatively, the compound can be linked to the support and the reporter to the compound or vice versa. Some complexes further comprises a tag encoding at least one step in synthesis of a compound present in the same complex as the tag. The tag is useful because typically its structure can more readily be determined or “decoded” than can the structure of the test compound itself, thus providing a useful way to identify the test compound attached to the bead. The tag can  
15 be attached to the support directly, via a linker, or via the compound or reporter.

The compound present in such complexes can be from random libraries, combinatorial libraries, libraries of variants of a known substrate, natural product libraries. Other suitable types of compound to be included in random libraries include, for example, polypeptides, oligonucleotides,  $\beta$ -lactams and other heterocyclic compounds, bile acids, oligo  
20 N-substituted glycines, polycarbamates, oligosaccharides, and lipids.

### B. Libraries constructed on a support

#### 1. General Structure

The different components or elements of the library can be organized in a  
25 variety of different arrangements. For example, the test compound, reporter and tag (if present), can all separately be attached to the support. Alternatively, various elements of the library can be joined together. For example, the reporter can be attached to the test compound or the tag. In such arrangements, either the reporter, test compound or tag can be the component that is directly attached to the support. Thus, the following arrangements are  
30 possible: -test compound-reporter; -tag-reporter; -reporter-test compound; and -reporter-tag (the element listed first is the element attached to the support). When different elements are connected, they can be directly connected or connected through a linker. Similarly, in some instances, rather than directly connecting an element to the support, the element is attached to the support via a linker.



## 2. Supports

The support can be made of a variety of materials, so long as the material is compatible with the chemistries that occur during the synthesis and/or attachment of the test compound, reporter and/or tag. Examples of materials that can be used include glass, latex, cross-linked polystyrene or similar polymers (including polyesters and cross-linked polyacrylamide), and gold or other colloidal metal particles. Such solid supports are derivatized with functional groups typical for solid state synthesis of the intended compounds (e.g., amino, carboxyl, hydroxyl, epoxide and sulfhydryl). Synthesis can also be performed on soluble polymers such as functionalized polyethylene glycols, that can be selectively precipitated from appropriate solvent systems (see, e.g., Gravert and Janda, 1997 *Chem. Rev.* 97:489-509).

The size of the support is chosen such that the support is sufficiently large that the test compound, reporter and/or tag can readily be attached thereto. However, the support should be small enough that it can be taken up by the transport process. In general, the solid support size is in the range of 1 nm to 100 microns in diameter; more typically, the supports range from less than 50 nm to about 10 microns in diameter. In certain applications the supports are only about 10 nm to about 100 nm in diameter. A more massive support of up to 1 mm in size can sometimes be used. MONOBEADS<sup>TM</sup> (Pharmacia Fine Chemicals AB, Uppsala Sweden) or their equivalent are one example of a commercially available support that can be used, although its size (10  $\mu$ m) is on the upper end of the size range that is typically used.

The particular shape of the support is not critical, although typically the support is roughly spherical or bead-shaped. Nor is it critical whether the beads have similar sizes, shapes or composition. Beads can be formed as single beads or be linked to one or more other beads. When linked together, it is possible to synthesize different compounds on a set of beads. Such separation can be useful, for example, when the chemistries used to synthesize the test compound and the tag are significantly different.

Depending upon the type of support (for those instances in which the library includes a support), the support can naturally contain a variety of surface groups to facilitate attachment of the other elements of the library, such as hydrophilic, ionic or hydrophobic groups. For example, the support can include one or more chemical functional groups to facilitate attachment (e.g., hydroxyl, amino, carboxyl and sulfhydryl). Alternatively, the

support can be derivatized to add such functional groups. For example, certain nanoparticles are formed of polystyrene and are derivatized to contain free amino groups.

Nanoparticles are one type of bead-like support that is useful with certain methods of the invention. Nanoparticles suitable for use in the invention can be prepared from a variety of materials, such as cross-linked polystyrene, polyesters and polyacrylamides or similar polymers. For use *in vivo*, biodegradable nanoparticles are particularly preferred. Such particles can be prepared from biocompatible monomers as homopolymers or as block copolymer materials. These include polyesters such as polylactic acid, polyglycolic acid, polyhydroxybutyric acid and polycaprolactone, polyanhydrides and polyphosphazenes. Frequently these particles are fabricated to contain an exterior surface comprising a hydrophilic polymer such as poly(alkylene glycol), poly(vinyl alcohol), polysaccharide or polypyrrolidine to resist uptake of the particles *in vivo* by the reticuloendothelial system. Such particles are described in US Patents 5,578,325 and 5,543,158.

The nanoparticles utilized with the methods described herein can be synthesized according to several known methods (See e.g., US 5,578,325) or can be purchased from commercial suppliers such as Polysciences and Molecular Probes. The nanoparticles can be labeled with fluorescent molecules, and such nanoparticles are commercially available from Molecular Probes, for example. For example, nanoparticles can be prepared from block copolymers by emulsion/evaporation techniques using the pre-formed copolymer. The polymer, and optionally, a substrate to be encapsulated for delivery, are dissolved in an organic solvent and emulsified with an aqueous phase by vortexing and sonication (higher energy sources giving smaller particles). The solvent is evaporated and the nanoparticles collected by centrifugation. Typically, the nanoparticles include a functionalized group on the surface to facilitate the attachment of the test compound, reporter and tag.

Various other supports can also be utilized, including molecular scaffolds, liposomes, (see, e.g., Deshmuck, D.S., et al., Life Sci. 28:239-242 (1990); and Aramaki, Y., et al., Pharm. Res. 10:1228-1231 (1993)), protein cochleates (stable protein-phospholipid-calcium precipitates; see, e.g., Chen, et al., J. Contr. Rel 42:263-272 (1996)), and clathrate complexes. Dendrimers can also be used in some applications; these compounds can be synthesized to have precise shapes and sizes and to include a variety of surface groups (e.g., hydrophilic, ionic or hydrophobic) to facilitate attachment of the other elements of the library. (See, e.g., Tomalia, D.A., Angew. Chemie Int. Edn. 29:138-175 (1990); and

Sakthivel, T., et al., Pharm. Res. (Suppl) 13:S-281 (1996)) (Each of the foregoing publications incorporated by reference in its entirety for all purposes.)

### 3. Encoding Tags

5           The encoding tags encode one or more reaction steps taken in synthesizing the test compound. For those test compounds wherein the synthesis yields a single product in high yield (e.g., peptide and oligonucleotide synthesis), the tag explicitly specifies one, and usually all, of the components of the test compound and its structure. In some situations, for example, when only a small number of monomer units of an oligomer are varied, it is not  
10       necessary to identify all the monomers utilized in the synthesis, but only those monomers which vary among the oligomers. For other syntheses that give variable yields and frequently multiple products (such as regio- and stereoisomeric structures), a mixture of compounds is sometimes obtained on each bead. In such instances, the encoding tag can not uniquely specify the chemical structure of the synthesized test compound. Instead, the encoding tag  
15       encodes the synthetic protocol (e.g., reagents and reaction conditions) by which a test compound in a library was prepared.

          Encoding tags are selected to have a readily identifiable feature that is, for example, microscopically or otherwise distinguishable in shape, size, mass, charge, or emissions. This recognizable feature can arise from the spectral, chemical, electronic, or  
20       magnetic properties of the encoding tag, or from some combination of such properties. Through the use of encoding tags to record the synthesis pathway that each member of a chemical library has taken, the structure of any chemical in the library can be determined from the tag.

          Nucleic acids and inert hydrocarbons are examples of the type of molecules  
25       that have utility as encoding tags in the present invention. Nucleic acids by virtue of the different bases and known chemistries regarding their attachment provide a natural and straightforward means for encoding the different synthetic steps. When decoding a nucleotide tag, several options are available. For example, the encoding tag can be read directly from the bead by sequencing or hybridization. Alternatively, or in addition, a nucleic  
30       acid tag can be amplified (e.g., by PCR) to facilitate identification. Hydrocarbons provide another useful option, because their identity can readily be determined by a variety of well-known chromatographic techniques, for example, GC and GC/MS. Other options are described in Ohlmeyer et al (*Proc. Natl. Acad. Sci. USA* 1993, 90, 10922-26 and WO 94/08051, each of which is incorporated herein by reference for all purposes.

The time at which the encoding tag is attached to the support is not critical. For example, an encoding tag can be attached immediately before, during, or after a round of monomer addition to compounds or other reaction, so long as such timing is compatible with the type of tag, modes of attachment, and the chemistries involved in preparing the test compound. The necessary encoding of the synthesis steps can be achieved using a single or multiple tags.

### C. Synthesizing Test Compound

#### 1. General

Libraries of compounds are usually synthesized by solid phase chemistry on particle. However, solution-phase library synthesis can also be useful. Strategies for combinatorial synthesis are described by Dolle and Nelson, *J. Combinatorial Chemistry* 1. 235-282 (1999)) (incorporated by reference in its entirety for all purposes). Synthesis is typically performed in a cyclic fashion with a different monomer or other component being added in each round of synthesis. Some methods are performed by successively fractionating an initial pool. For example, a first round of synthesis is performed on all supports. The supports are then divided into two pools and separate synthesis reactions are performed on each pool. The two pools are then further divided, each into a further two pools and so forth. Other methods employ both splitting and repooling. For example, after an initial round of synthesis, a pool of compounds is split into two for separate syntheses in a second round. Thereafter, aliquots from the separate pools are recombined for a third round of synthesis. Split and pool methods result in a pool of mixed compounds. These methods are particularly amenable for tagging as described in more detail below. The size of libraries generated by such methods can vary from 2 different compounds to  $10^2$ ,  $10^4$ ,  $10^6$ ,  $10^8$ ,  $10^{10}$ ,  $10^{12}$  or  $10^{15}$ , or any range therebetween.

Other components of a complex, such as the reporter, can be added before, after or during synthesis of compounds. Typically, reporter is added after compounds have been synthesized. In some methods, complexes are used as is. In other methods, compounds are cleaved from supports before use. In these methods, the reporter is attached directly or through a linker to the complexes, and such attachment can occur before or after synthesis of compounds.

In some instances, the various library elements are connected to one another by linkers. The linkers typically are bifunctional (i.e., the linker contains a functional group at each end that is reactive with groups located on the element to which the linker is to be

attached); the functional groups at each end can be the same or different. Examples of suitable linkers include straight or branched-chain carbon linkers, heterocyclic linkers and peptide linkers. Exemplary linkers that can be employed in the present invention are available from Pierce Chemical Company in Rockford, Illinois and are described in EPA 188,256; U.S. Pat. Nos. 4,671,958; 4,659,839; 4,414,148; 4,669,784; 4,680,338, 4,569, 789 and 4,589,071, Eggenweiler, H.M, *Pharmaceutical agent Discovery Today* 1998, 3, 552.

The choice of linker depends on whether the linker is intended to remain permanently in place or is intended to be cleaved before or during use. For cleavage prior to use, NVOC (6-nitroveratryloxycarbonyl) linkers and other NVOC-related linkers are examples of suitable photochemical linkers (*see, e.g.*, WO 90/15070 and WO 92/10092), as are nucleic acids with one or more restriction sites, or peptides with protease cleavage sites (*see, e.g.*, US 5,382,513). For cleavage during use, one selects a linker that is spontaneously cleaved under the conditions of the relevant assay (usually a physiological buffer). Such a linker should be stable under the conditions in which the test compound, reporter and/ or tag, are attached to the beads, but should allow release of the test compound in the course of the assay.

In Example 15 below the concept of preparing propharmaceutical agent derivatives equipped with a fluorescent reporter moiety to facilitate assay of intestinal absorption (or cellular uptake) is exemplified. In the classical concept of the propharmaceutical agent, the promoity is cleaved from the active pharmaceutical agent entity by enzymatic and/or chemical means. A wide variety of cleavable linkages are available depending on the nature of the functionality available in the pharmaceutical agent molecule. Examples of cleavable linkages include, for example, esters of simple alcohols or phenols, (acyloxy)alkyl esters, amides, O-hydroxamates, esters of simple or functionalized aliphatic carboxylic acids, esters of amino acids, esters of carbamic acids, esters of derivatized phosphoric acids, (alkyloxycarbonyloxy)alkyl ethers, (acyloxy)alkyl ethers, amides formed from simple or functionalized acyl groups, amides cleaved by intramolecular cyclization, alkyl carbamates, N-Mannich bases and N-(acyloxy)alkyl derivatives.

## 2. Synthesis of Encoded Libraries

Preparation of encoded libraries is described in a variety of publications including Needels, *et al. Proc. Natl. Acad. Sci. USA* 1993, 90, 10700; Ni, *et al J. Med. Chem.* 1996, 39, 1601, WO 95/12608, WO 93/06121, WO 94/08051, WO 95/35503 and WO 95/30642 (each of which is incorporated by reference in its entirety for all purposes).

Methods for synthesizing encoded libraries typically involve a random combinatorial approach and the chemical and/or enzymatic assembly of monomer units. For example, the method typically includes steps of: (a) apportioning a plurality of solid supports among a plurality of reaction vessels; (b) coupling to the supports in each reaction vessel a first monomer and a first tag using different first monomer and tag combinations in each different reaction vessel; (c) pooling the supports; (d) apportioning the supports among a plurality of reaction vessels; (e) coupling to the first monomer a second monomer and coupling to either the solid support or to the first tag a second tag using different second monomer and second tag combinations in each different reaction vessel; and optionally repeating the coupling and apportioning steps with different tags and different monomers one to twenty or more times. The monomer set can be expanded or contracted from step to step; or the monomer set could be changed completely for the next step (e.g., amino acids in one step, nucleosides in another step, carbohydrates in another step). A monomer unit for peptide synthesis, for example, can include single amino acids or larger peptide units, or both.

## VIII. Cells

### A. General

Since the assays described herein involve screening for substrates of transport systems and/or transport proteins, the cells should either have a naturally-occurring transport protein or be cells that are transfected with a vector containing a transport protein gene that are also capable of expressing the gene. Cells containing naturally-occurring transport proteins can be obtained from a variety of epithelial and endothelial cell types, including, for example: (a) cells from the mucosal surfaces of the nose, mouth, throat, lung, intestine, genitals and urethra; (b) cells lining the eye, the deep ear, and secretory structures such as the mammary, salivary and tear ducts; and (c) outer skin and sweat glands. Suitable cells can also be obtained from certain endothelial cell layers, as well, such as those of the capillary endothelial cells forming the blood/brain barrier for example. For expression of a transfected DNA segments encoding transport proteins, cell lines typically used in genetic engineering can be used, with mammalian cell lines being preferred (e.g., CHO, COS, HeLa, MDCK, VERO, HEK, CaCo-2, HCT-8, T84, HT29, and 3T3).

Transfected DNA segments can encode previously cloned transport proteins, or can be libraries encoding potential transport proteins. Such libraries are typically obtained from the natural endothelial and epithelial tissue types identified above. The libraries are

preferably obtained from human cells. DNA libraries are typically prepared as cDNA libraries although genomic or minigene libraries can also be used.

DNA segments are typically expressed as components of expression cassettes. Such cassettes also include one or more control sequences for the expression of the cDNA, such as a promoter, ribosome binding sites, and transcription termination sites for example. The promoter can be inducible (e.g., heat shock protein or MT promoter or a constitutive promoter, typically a strong promoter (e.g., SR $\alpha$ ). Regulated promoters can be advantageous because the host cells can be grown to high densities before expression of the transport protein is induced. High level expression of heterologous proteins slows cell growth in some situations.

Commonly used prokaryotic control sequences include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta-lactamase (penicillinase) and lactose (*lac*) promoter systems (Change *et al.* (1977) *Nature* 198: 1056), the tryptophan (*trp*) promoter system (Goeddel *et al.* (1980) *Nucleic Acids Res.* 8: 4057), the *tac* promoter (DeBoer *et al.* (1983) *Proc. Natl. Acad. Sci. U.S.A.* 80:21-25); and the lambda-derived P<sub>L</sub> promoter and N-gene ribosome binding site (Shimatake *et al.* (1981) *Nature* 292: 128).

For expression of a transport protein in yeast, exemplary promoters include GAL1-10 (Johnson and Davies (1984) *Mol. Cell. Biol.* 4:1440-1448) ADH2 (Russell *et al.* (1983) *J. Biol. Chem.* 258:2674-2682), PHO5 (*EMBO J.* (1982) 6:675-680), and MF $\alpha$  (Herskowitz and Oshima (1982) in *The Molecular Biology of the Yeast Saccharomyces* (eds. Strathern, Jones, and Broach) Cold Spring Harbor Lab., Cold Spring Harbor, N.Y., pp. 181-209). Another suitable promoter for use in yeast is the ADH2/GAPDH hybrid promoter as described in Cousens *et al.*, *Gene* 61:265-275 (1987).

For expression of transport proteins in mammalian cells, exemplary promoters include SR $\alpha$ , CMV promoter (Miller, *et al.*, *BioTechniques* 7:980), SV40 promoter (de la Luma, *et al.*, (1998) *Gene* 62:121), RSV promoter (Yates, *et al.*, (1985) *Nature* 313:812), MMTV promoter (Lee, *et al.*, (1981) *Nature* 294:228). Expression in mammalian cells can be achieved, for example, using a variety of commonly available plasmids, including pSV2, pBC12BI, and p91023, pCDNA series, pCMV1, pMAMneo, as well as lytic virus vectors (e.g., vaccinia virus, adeno virus), episomal virus vectors (e.g., bovine papillomavirus), and retroviral vectors (e.g., murine retroviruses).

For expression of the polypeptides in insect cells a suitable promoter is from the baculovirus *Autographa Californica* nuclear polyhedrosis virus (NcMNPV) (Kitts, *et al.*, (1993) *Nucleic Acids Research* 18:5667).

Construction of suitable vectors containing one or more of the above listed components uses methods described by e.g., Berger and Kimmel, *Guide to Molecular Cloning Techniques, Methods in Enzymology*, Volume 152, Academic Press, Inc., San Diego, CA (Berger); and Current Protocols in Molecular Biology, F.M. Ausubel *et al.*, eds., *Current Protocols*, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1998 Supplement) (Ausubel).

## IX. Detection Options

Complexes fall into three general classes. Complexes that simply do not interact with the target transport protein at all, those that bind to the surface of the cell and either interfere with binding of a substrate to the transport protein or bind to the transporter but are not internalized (inhibitors), and finally, complexes that are transported into the cell through the activity of the transport protein. Various detection schemes can be utilized to detect and distinguish between these different situations.

### A. Detecting Binding of Complexes to Cell Membrane

External binding of complexes at the cell membrane is typically detected using a reporter that generates a signal directly (i.e., a label), usually an optical signal. Examples of suitable labels include a fluorophore, a chromophore, a radioisotope, a magnetic particle, a mass label, a spin label, a luminescent label and an electron dense agent. Examples of fluorescently labeled substrates are discussed in e.g., Kramer *et al*, *J. Biol. Chem.* 1994, 269: 10621; Mills *et al*, *Biochim. Biophys. Acta* 1992, 1126: 35) Börner *et al*, *Eur. J. Biochem.* 1998, 255: 698), Dieck *et al.*, *Glia*, 1999, 25: 10; Otto *et al*, *Am. J. Physiol.* 1996, 271, C210).

The detector used varies according to the type of signal generated. When the label emits light, a variety of optical means can be utilized including, for example, confocal microscopy, charge coupled devices (CCD) and a variety of commercially available photomultiplier tube-based instruments. In general, such devices provide sufficient resolution to distinguish between label located within and outside a cell. Binding can also be detected by FACS methods. Some fluorophores give a different signal from outside and



inside a cell allowing distinction between compounds that are bound to a cell and compounds that are within a cell.

B. Detecting Internalization of a Complex

1. General

Internalization of a complex can be detected by detecting a signal from a reporter (e.g., one of the foregoing labels) within a cell. It can be difficult, however, with conventional detection schemes to distinguish between labeled compounds that are effectively transported *inside* the cell from compounds that are not transported but nevertheless can still bind the transporter. These latter compounds (typically transporter inhibitors) are found bound to the *outside* of transporter-expressing cells. A variety of methods can be employed for detecting internalized substrates without detecting surface-bound ligands, or to at least selectively detect internalized substrate rather than surface-bound compounds. Selective or preferential detection means that at least 70%, more typically at least 80% and most typically at least 90% of the signal detected arises from internalized complexes compared to signal arising from complexes bound to the cell surface. To score specifically for uptake (as opposed to surface binding), several strategies are available and are discussed below.

2. Distinguishing Between Substrate and Inhibitor without Conditional Reporters

Confocal Imaging: Confocal imaging provides sufficient spatial resolution directly to distinguish between fluorescence on a cell surface and fluorescence within a cell. Optionally, the movement of a complex is monitored over time to determine if it moves into a cell. In such an approach, a monolayer of cells, generally polarized cells, is contacted with a library of complexes. Each complex bears an optically detectable reporter, such as a fluorescent compound, and the complexes are allowed to settle on the cell layer. The complexes are imaged (typically from above) with confocal optics, and the behavior of the complexes tracked over time. Confocal imaging allows differentiation between those complexes that have been internalized by the cells and those remaining on the surface of the optically deep layer of cells.

Cell Stripping and Cell Quenching: In another variation, the cells are stripped of complexes bound at the surface, or treated so as to disable the fluorophores that remain outside the cells by leaving the cells in wash buffer or washing the cells several times. In yet

another method, the cells are analyzed in a solution of quencher that cannot penetrate the cells. Hence, the fluorescence of complexes bound to the surface is quenched, while internalized complexes fluoresce intensely.

5                    2.        Distinguishing Between Substrate and Inhibitor with Conditional Reporters

A powerful way of screening for *bona fide* transporter substrates is to incorporate conditional reporter groups into potential substrate molecules. The conditional reporter is a moiety that preferentially produces a readily detectable signal upon uptake by a transporter-expressing cell. In some instances, the conditional moiety can act without having to be cleaved from the complex; in other instances the conditional moiety must be chemically or enzymatically cleaved before it can generate a signal. Several such approaches are set forth below.

15                    Reporter is a substrate for intracellular enzymatic activity: One general method for restricting signal generation to complexes that have been internalized within a cell is to make the reported event dependent on the action of some enzymatic activity that specifically resides intracellularly. This enzymatic activity may be provided by some exogenous expression cassette, or may be found endogenously within the transporter-expressing cell. Once a complex is taken up by a cell, the enzyme substrate (sometimes after being cleaved from the complex by intracellular enzymes) is metabolized by the enzyme expressed within the cell to generate an optical signal that indicates uptake of the complex into the cell. Light emission can be monitored by commercial PMT-based instruments or by CCD-based imaging systems.

25                    A variety of enzymes are capable of metabolizing a reporter that includes an enzyme substrate to generate a readily detectable product. The intracellular enzyme can be an endogenous enzyme or one that is expressed from an exogenous sequence introduced into the cells. Examples of suitable enzymes include proteases, nucleases, lipases, phosphatases, and various hydrolases, including sugar hydrolases and those capable of cleaving various other ester linkages. Specific examples include, for example, luciferase (de Whet et al., *Mol. Cell. Biol.* 7, 725-737 (1987)), chloramphenicol acetyl transferase,  $\beta$ -galactosidase (e.g., Kumar et al., *Bio/Technology* 10, 82-85 (1992)) and alkaline phosphatase (Toh et al., *Eur. J. Biochem.* 182, 231-238 (1989)) and  $\beta$ -glucuronidase.

The luciferin/luciferase substrate/enzyme pair provides a useful example of this general approach. A cell line that co-expresses the enzyme luciferase and a transport protein of interest is utilized. The preparation and selection of such cells is described in greater detail in Example 7. The natural substrate for luciferase, D-luciferin, can be

5 conjugated to an appropriate transporter substrate via a labile bond (e.g., an ester, a carbonate or amide). The carboxyl and hydroxyl groups of luciferin provide useful functional groups for achieving such conjugation. Luciferin can be covalently attached to each test compound or to a support if the complex includes a support. Optionally, a spacer/linker is placed between the test compound and the luciferin or between the luciferin and the support.

10 Example 7 describes the synthesis of certain luciferin-conjugated complexes that can be used to study transport by PEPT1 and the intestinal and liver bile acid transporters.

When a complex containing luciferin is taken into a cell, enzymes expressed within the cell (e.g., hydrolases) cleave luciferin from the complex. The liberated luciferin can then react with luciferase to generate an optical signal. Because the luciferin/luciferase

15 system is very sensitive, only low amounts of complex need enter a cell in order to detect a signal. Thus, it is possible to detect substrates whose concentration is low relative to its  $K_m$ .

In some instances, the complex is modified through addition of a highly polar functionality to prevent passive uptake of the complex containing the enzyme substrate. To distinguish more clearly between passive uptake or uptake accompanying cell lysis, control

20 cells transfected with the gene encoding the enzyme, but not the gene encoding the transport protein, are contacted with the complexes under test. The signal in the control cells is then compared with the signal from cells expressing the transport protein. A higher signal in the cells expressing the transport protein that is statistically significant is indicative of authentic transport activity.

25 Masked Reporters: Some conditional reporters contain "masked" moieties that generate only a weak signal until the masking group is removed by some intracellular enzymatic activity. For instance, the reporter can include a "masked" hydroxy-coumarin moiety that is weakly fluorescent until the masking group is cleaved away by an intracellular

30 esterase, or other related activity. The resulting hydroxy-coumarin derivative is strongly fluorescent, thereby allowing transport of a complex into a cell to be read out using various fluorescent detectors (e.g., a fluorescence plate reader). The enzyme responsible for removing the masking group can be endogenously expressed within cells, or can be over-expressed so as to boost the signal from the transported substrate. Syntheses for certain

conditionally fluorescent dipeptides that can be used to measure transport into a cell by the transport protein PEPT1 are set forth in Example 8 below.

Reporter Interaction with Intracellular Agent: Other conditional reporters are ones that do not require enzymatic activation but rather rely on the interaction between some intracellular agent or structure to produce a detectable signal. An example include nucleic acid-binding dyes (e.g., TOTO and YOYO from Molecular Probes), that are weakly fluorescent in the absence of DNA, but emit strongly upon binding to nucleic acids within the cell nucleus. Conjugation of transporter substrates to such dyes provides a convenient assay for transporter-dependent cellular uptake. This approach and other suitable dyes are discussed further in Example 6 *infra*.

Internally Quenched Reporters: In this approach, the complexes under investigation include a substrate, a fluorophore and a quencher. Outside a cell, the quencher can quench fluorescence from the fluorophore such that negligible signal is generated. In the cell, however, the conditions are sufficiently different such that the quencher is no longer able to efficiently quench fluorescence from the fluorophore. One typical mechanism involves cleavage (e.g., by an intracellular enzyme) of some element of the complex (e.g., an optional linker) that results in the separation of the fluorophore and quencher. Different types of quenchers can be utilized. Some quenchers absorb fluorescence emitted from the fluorophore (e.g., via fluorescence energy transfer (FRET) mechanisms). Other quenchers modify the electronic properties of the fluorophore so as to interfere with the ability of the fluorophore to emit fluorescence.

The quencher and fluorophore can be arranged in a variety of different orientations with respect to one another in a complex. For example, the fluorophore and quencher can be attached at different sites of the compound. In other instances, the complex also includes a linker. The linker can join the quencher or fluorophore; alternatively either the fluorophore or quencher is attached to the compound while the other is attached to the linker. As indicated above, the use of a labile linker susceptible to cleavage within a cell provides an effective way to separate the quencher from the fluorophore. The linker can include a cleavage site for any of a variety of intracellular enzymes, such as various hydrolases, including those capable of cleaving ester linkages.

Certain complexes that include a linker have the general form R-X-Y-Q, where X is the substrate for the transport protein of interest, R is the fluorophore, Q is the

fluorescence quencher moiety and Y is a labile linker that typically is susceptible to cleavage by an intracellular enzyme. In the uncleaved complex, the quencher (Q) quenches fluorescence from the fluorophore (R). However, upon entry into a cell where the intracellular enzyme cleaves the labile linker, the quencher is released from the complex, thereby allowing detection of fluorescent emission from the fluorophore. Specifics regarding certain internally quenched complexes of this type are presented *infra* in Example 5.

In those instances in which donor/quencher dyes are utilized, a variety of such dyes can be selected from and are commercially available including, for example, CYA, FAM, R110, R6G, TAMRA, ROX, TET, JOE, HEX and ALEXA, which are available from suppliers such as Applied Biosystems Division of Perkin Elmer Corporation (Foster City, CA), Amersham Pharmacia Biotech (Piscataway, NJ) and Molecular Probes, Inc. (Eugene, OR). Further guidance regarding the selection of fluorophore and quencher pairs that can effectively be used with the methods of the present invention can be found, for example, in: *Fluorescence Spectroscopy* (Pesce *et al.*, Eds.) Marcel Dekker, New York, (1971); White *et al.*, *Fluorescence Analysis: A Practical Approach*, Marcel Dekker, New York, (1970); Berlman, *Handbook of Fluorescence Spectra of Aromatic Molecules*, 2<sup>nd</sup> ed., Academic Press, New York, (1971); Griffiths, *Colour and Constitution of Organic Molecules*, Academic Press, New York, (1976); *Indicators* (Bishop, Ed.). Pergamon Press, Oxford, 19723; and Haugland, *Handbook of Fluorescent Probes and Research Chemicals*, Molecular Probes, Eugene (1992).

Exemplary quenchers that disrupt the electronic properties of the fluorophore include acylated coumarins. In general, many aromatic fluorophores have an electron-pair containing heteroatom directly attached to a conjugated ring system. Acylation of these heteroatoms can frequently be used to block the fluorescence of the fluor by blocking the ability of the heteroatom to donate electrons into the ring system.

Reporter as a Bioactive Moiety. Certain other reporters include a bioactive molecule capable of triggering the formation of a detectable signal upon entry into a cell. For example, the complex can include a reporter capable of aggregating (e.g., dimerizing) intracellularly-expressed enzyme fragments, thereby activating an enzyme that reacts with a non-fluorescent substrate to generate a fluorescent signal. The reporter can also be an activator of a transcriptional promoter linked to a gene that expresses a protein that generates a signal. In certain methods, the promoter drives production of a reporter gene that is, as above, an enzyme capable of generating a signal (e.g., a fluorescent protein such as green

fluorescent protein (GFP)). In other methods, the promoter drives expression of a cell surface marker that can be stained with a fluorescently-labeled ligand or antibody at the cell surface and then detected by FACS.

The reporter can also be an activator that, once inside the cell, induces, either recombinationally, transcriptionally or post-transcriptionally, a selectable marker conferring a growth advantage on the cell containing the complex. When the cell population is placed under selective pressure, those cells expressing the transport genes are capable of surviving and can be isolated from the other cells.

In another instances, the reporter is an agent that triggers a morphological change in the cell into which it is taken up either in uncleaved form or after being cleaved from the rest of the internalized complex. One such agent is one that inhibits various cytoskeleton components (e.g., cytocholasin). Other suitable agents include, but are not limited to, colchicine, latrunculin-A, taxol and nocodazole. Detection in this instance typically is by microscopy to detect the morphological change occasioned by entry of reporter into the cell.

### 3. Distinguishing between an authentic substrate and passive diffusion

One approach for methods such as those just described in which the reporter for a complex includes a substrate for an intracellular enzyme, involves conducting a second set of parallel screens using control cells expressing the enzyme but not the transport protein. Incorporation of complex into the control cells provides a measure for uptake through mechanisms other than authentic transport activity, such as passive diffusion or cell lysis.

Another approach also utilizes one set of cells that express transport protein, and another set of cells that does not. These two groups of cells are differentially labeled (e.g., with fluorescent stains) so that the different cell types have different optical properties. Typically, the two cell types are mixed in near equal proportions and exposed to the complex(es) being tested. Using multi-color confocal microscopy, the two cell types can be distinguished and uptake separately monitored for each cell type. Thus, non-specific binding and passive diffusion due to a library complex can be distinguished from specific interaction with the transport protein. Commercial instruments capable of high resolution, high throughput confocal analysis of cells in multi-well plates are available (e.g., Cellomics, Praelux).

### C. Detecting Transport Through a Cell

As described above, one method for detecting movement of a complex through a cell, such as via transcytosis for example, involves growing a monolayer of cells on a porous membrane support. A second membrane capable of immobilizing complexes that are transported through the cells and the first membrane is sometimes also used.

5 Movement of complexes through the layer of cells can be observed by direct optical observation, such as through the use of confocal microscopy, for example. The second membrane, if present, immobilizes the complex in the vicinity of the cell(s) expressing the cDNA that promote transcytosis. These active cells are then picked using e.g., micromanipulation techniques and the DNA segment located therein sequenced to determine  
10 the gene encoding a transport protein capable of transporting at least certain compounds.

Alternatively, movement of complexes through cells can be monitored using a reporter that is a substrate for an enzyme that is impregnated in a membrane supporting the cells. Localization of the signal “under” the cell layer by confocal microscopy identifies the cells expressing transport systems capable of transcellular transport. This assay can also be  
15 performed in the reverse format in which the reporter is the enzyme and substrate is impregnated in the membrane. The enzyme can be any of those described above in the section on detecting internalization.

In another approach, complexes bear a reporter that is an activator of a metabolic process in indicator cells. The indicator cells are then impregnated into a  
20 membrane supporting a cell monolayer. After passage of a complex through the monolayer, the reporter induces a metabolic event in the indicator cells that generates a signal in proximity to the cell(s) passing complex(es). Examples of suitable reporter include a bioactive compound that activates a cell surface receptor and a linked transcriptional promoter installed into the indicating layer of cells. The promoter drives a secondary  
25 reporter that can include, for example, an enzyme capable of generating a fluorescent signal, a fluorescent protein such as GFP, or a cell surface marker that can be stained by a fluorescently-labeled ligand or antibody at the cell surface for detection by FACS. Optical alignment of the active reporter cells with the polarized layer of library cells allows identification and recovery of the positive library cells in the layer above the reporter cells.

#### 30 X. Steps Subsequent to Detection

Once a substrate of a transport process has been identified through one of the screening mechanisms described above, the identity of the test compound is determined according to methods described below. For screening methods in which a library of

complexes is screened against cells expressing a known transport protein, the complexes yielding a positive result can be analyzed directly using the identification methods described below to determine the identity of the test compound.

5 If the screening methods involve screening a library of complexes against a population of cells expressing a cDNA library, those cells giving a positive signal can be identified as described above and then isolated from the other cells by hand picking, by various known micromanipulation techniques or by compartmentalizing the cell. The cDNA from positive cells is removed using standard techniques and typically amplified to facilitate the sequencing of the cDNA to identify a potential transport protein. For screens of this type, 10 typically another round of screening is necessary to identify the test compounds in the complex library that are substrates of the transport protein expressed by the cells. In general this involves expanding positive clones and rescreening the compound library against each of the expanded clones according to the methods set forth herein. Determination of the structure of complexes that yield a positive signal is then performed by the decoding, deconvolution 15 and direct structural methods described below.

Regardless of the screening methods, test compounds or cells that yield positive results in the initial round of screening can be rescreened in isolation to verify the authenticity of the apparent activity.

## 20 XI. Identifying and Synthesizing Positive Test Compound

Once a complex is identified through the screening methods set forth above, the test compound associated with transport activity can be identified through various methods. One approach is to directly determine the structure using standard chemical techniques such as mass spectrometry (MS), infrared spectroscopy (IR), high performance 25 liquid chromatography (HPLC), nuclear magnetic resonance (NMR).

When the complex includes a tag the tags can be decoded according to conventional methods. For example, if the tags are nucleic acids, they can be decoded by PCR amplification and sequencing. Other types of tags can be decoded by, for example, mass spectrometry, FACS, gas chromatography or HPLC. The information obtained by 30 decoding the tag identifies the compound (or component(s) thereof) originally from the same complex as the tag. Based on this information, a test compound associated with transport activity can be synthesized *de novo*. For example, if the compound is a peptide, it can be synthesized on a peptide synthesizer. If a substantial collection of test compounds are



identified after an initial round of screening, the compounds can be resynthesized on supports and rescreened by reiteration of the methods described above.

## XII. Additional Screens

### A. Screening Substrates for those Capable of Carrying Pharmaceutical Agent

#### 1. Screening methods

Screening libraries of potential transporter substrates conjugated with reporter moieties provides an efficient method for discovery of substrates that can also be conjugated with diverse substances such as pharmaceutical agents to confer substrate activity on such conjugates. Rather than directly developing a separate screen for uptake of each pharmaceutical agent of interest, the reporter can serve as a surrogate for the pharmaceutical agent during the preliminary screens. Essentially, the reporter serves as a place holder for the pharmaceutical agent. This approach has the advantage that uptake of a substrate bearing a reporter by the transport system is readily detected; whereas, a pharmaceutical agent coupled to a substrate often does not provide a readily detectable signal. The ability of the transporter to tolerate incorporation of some reporter moieties within a substrate motif suggests that conjugation of a fragment of a pharmaceutical agent having structural and chemical features that are at least somewhat similar to the reporter should generate a complex that is also recognized as a substrate by the transporter protein. Moreover, should a diversity of reporters be accepted when conjugated at a particular site within a substrate molecule, this indicates that the site is especially favorable for conjugation of a pharmaceutical agent.

Hence, once a substrate for a transport protein is identified, variant libraries such as described *supra* can be prepared in which different reporters are conjugated to the substrate and then the resulting complexes screened to determine whether activity of the substrate is retained. The type of different reporters attached to the substrate in the variant library can vary with regard to charge, size, isomeric form and other chemical or physical parameters. Alternatively, libraries can be generated in which the same reporter is simply positioned at different sites of the substrate backbone (see Example 4). As indicated above, substrates demonstrating the ability to retain activity with a wide range of reporter types suggest that the substrate is a candidate for the transport of a wide array of pharmaceutical agents.

Once the preliminary screens with various reporters has identified one or more candidate substrates, the pharmaceutical agent(s) of interest is (are) substituted for the reporter and the resulting substrate-pharmaceutical agent conjugates rescreened according to

the methods disclosed herein. The pharmaceutical agents used to replace the reporter often are selected to be approximately isostructural and/or to have similar electronic characteristics with the reporters shown to be transported. Likewise, the pharmaceutical agent is positioned at the same sites(s) shown in the preliminary assays with reporters to correlate with transport.

5 This process is illustrated further in Example 10 *infra*.

Various known transporters are attractive candidates for the development of substrate-drug conjugates developed according to the foregoing methods. For example, the development of substrates for the intestinal bile acid transporter (ASBT) is attractive because this transport protein is responsible for the absorption of large quantities of bile acids in  
10 through the ileum. In humans, approximately 20 g of free and conjugated bile acids are absorbed each day. Bile acids are synthesized in the liver and are secreted in the small intestine to facilitate absorption of lipophilic vitamins and cholesterol.

## 2. Detection of transport for complexes bearing pharmaceutical agents

15 Complexes synthesized to include an agent (e.g., a drug) at the site at which a reporter was initially attached often require specialized methods for detecting cellular uptake as often the attached agent is not readily detectable. Various options are available to accomplish detection in such situations.

One detection approach is to utilize various analytical techniques to separate  
20 and detect substrate that is internalized within a cell. For example, LC/MS/MS (LC = liquid chromatography; MS = mass spectroscopy) can be utilized in such a manner. Test cells and control cells are contacted with the substrate/pharmaceutical agent conjugate for a sufficient length of time to allow uptake by the cells. The cells are then washed to remove substrate that has not been internalized, the cells lysed to release internalized substrate and the released  
25 substrate detected by LC/MS/MS (see Example 11). Other chromatographic and spectroscopic methods can be used individually or in combination to achieve similar detection as will be appreciated by those with skill in the art.

Trans-stimulation assays can also be used to detect substrate uptake. The general theory of this method is illustrated in Fig. 4. As depicted in this figure, the method  
30 takes advantage of the fact that the flip-flop conformational change of a transport protein can exchange labeled substrates within a cell for unlabeled substrates outside the cell. Initially, cells expressing a transport protein of interest are contacted with a known labeled substrate (e.g., radiolabeled substrates) so that the cells become loaded with the labeled substrate. The cells are washed to remove non-internalized labeled substrate and then contacted with

unlabeled test complexes. The efflux of labeled substrate is measured. In the case of radiolabeled substrates, such efflux can be detected by scintillation counting. Substrate activity of the test complex is indicated by accelerated efflux of the labeled substrate from the cell.

5 In the case of screens in which one is screening complexes wherein a drug has been substituted for the reporter, the test complex is the substrate-drug conjugate. The labeled known substrate loaded into the cells can be the same substrate conjugated to the drug or another known substrate. If the substrate-drug conjugate accelerates efflux of the labeled substrate from the cell, such activity indicates that the test substrate is able to transport the  
10 pharmaceutical agent into the cell. This approach is discussed further in Example 11.

It should be recognized that the LC/MS/MS and trans-stimulation assays just described are generally adaptable to high throughput screening assays for libraries of complexes that lack a reporter. Hence, the assays can be used to screen unlabeled compounds for potential activity with a transporter of interest. The methods, however, are  
15 not limited to simply screening complexes in which an agent has been substituted for a reporter but can be used generally to assay complexes lacking a reporter.

#### B. Competition assays

With the above methods, a number of new substrates for specific transport  
20 proteins can be identified. Such newly identified substrates can then be utilized to conduct high throughput competition assays. In general, the method involves contacting a cell or multiple cells expressing a transport protein with a complex that includes a known substrate for the expressed transport protein and a reporter and detecting a signal generated by the reporter within the cell. In a parallel reaction, cells of the same type are contacted with the  
25 same amount and type of complex and also contacted with a test compound. Another signal is detected for the second set of cells and compared with that obtained for the first set of cells. Reduced signal for those cells contacted with the test compound relative to those cells not contacted with the test compound indicates that the test compound is a substrate or an inhibitor of the transport protein expressed by the cells. If desired, tests such as those  
30 described above can be performed to ascertain whether the test compound is a substrate or an inhibitor. The test compound used in the competition assays can be of virtually any chemical type. Use of a competition assay is detailed in Example 2 below.

### **In Vivo Methods for Screening for Substrates of Transport Proteins**

## I. Initial Screening

### A. General

The methods described above have focused on *in vitro* methods for screening for substrates of transport proteins and *in vitro* methods for identifying new transport  
5 proteins. However, the invention also provides a number of *in vivo* screening methods that can be used solely or in combination with *in vitro* methods to screen a library of complexes to identify new substrates for transport proteins. In general, the *in vivo* methods involve introducing a population of complexes into a body compartment in a test animal and then recovering and identifying the subset of introduced complexes transported through cells  
10 lining the body compartment into which the complexes were placed. More specifically, the screens typically involve monitoring a tissue or body fluid (e.g., the mesenteric blood and lymph circulation) for the presence of complexes that have entered the blood or lymph of the test animal.

### B. Structure of Library Complexes

The structure of the library complexes introduced into the animal compartment have the same general structure of the complexes in the bead libraries discussed above. Hence, the library complexes typically include a support, a test compound, a reporter and an optional encoding tag (i.e., a tag encoding for the test compound). Similarly, the libraries are  
20 of the same chemical type and can be synthesized according to the methods set forth above. In some methods, the support is a nanoparticle. Libraries of soluble compounds not attached to supports can also be used. These also have the same composition, structure, and size attributes described earlier, as well as being synthesized as described above.

Typically, the reporter used in the *in vivo* screen methods is a capture tag that  
25 facilitates retrieval and concentration of the transported complexes from the blood and lymph circulatory system of the test animal. Examples of suitable capture tags include, biotin, magnetic particles associated with the library complex, haptens of high affinity antibodies, and high density metallic particles such as gold or tungsten. The complexes can also include a detection tag to further enhance the retrieval and detection process. As the name implies,  
30 detection tags are molecules that are readily identifiable and can be used to monitor the retrieval and concentration of transported complexes. Examples of such compounds include fluorescent molecules, amplifiable DNA molecules, enzymatic markers, and bioactive molecules.

C. Location at which Complexes Deposited

The complexes can be deposited into any body compartment that contains transport proteins capable of transporting a complex into a second body compartment, provided transported complexes can be retrieved from the second compartment. Typically, the complexes are placed into a body cavity wherein transported complexes are transported into the blood and lymph circulation system of the test animal. Thus, for example, the complexes can be deposited into the intestinal lumen of the test animal, and the transfer of the particles into blood and subsequently other organs can be monitored.

Another preferred application is the tracking of particle transported from the circulation, through the blood brain barrier and into the CNS compartment. In these methods, the particles are injected intravenously, and their appearance in the cerebral spinal fluid or the brain tissue is followed. CSF monitoring can be done periodically on an anesthetized animal. Analysis of particle transit into the tissues of the brain requires that the animals be anesthetized, the brain vasculature flushed by saline perfusion, and the tissue removed for homogenization prior to particle isolation. The particles are then isolated by physical capture techniques as described below for recovery from the blood.

D. Methods by Which Complexes Deposited

In instances in which the complexes are deposited into the intestinal lumen, it is sometimes useful to close the intestine on either side of the site of deposit. This maneuver increases the residence time of the complexes in the relevant portion of the gut, thus allowing increased transport and ultimately more sensitive detection of transport.

E. Retrieving/ Concentrating and Identifying Transported Complexes

As described above, the reporter (capture tag) and detection tags are used to filter, detect and concentrate transported complexes from the compartment into which the complexes are transported. In some instances, this involves retrieving and concentrating transported complexes from the large blood volume that perfuses the intestine.

Once the transported complexes have been retrieved and suitably concentrated, the identity of the test compound responsible for conferring transportability can be determined by any of the direct chemical analysis, decoding or deconvolution methods set forth above. Further details are also set forth in Example 16, below.

F. Animals

Essentially any animal can be used to conduct the *in vivo* screening tests described herein subject to regulations concerning test animals. For example, the screening tests can be performed with humans, monkeys, chimpanzees, horses, sheep, pigs, rabbits, dogs, cats, rats, and mice.

5

## II. Variation

In some screening methods, the test compound library is supplied in large library-equivalent excess (i.e., there is a large number of copies of each member of the library, such as from about 1,000 to about 1,000,000 copies for example). However, in other respects, the method is as generally set forth above. Although in some instances the size of the library particles consists primarily of smaller particles (e.g., about 10 to 100 nm). Methods utilizing this approach enable many copies of each transported complex to be retrieved. In fact, the number of beads recovered with a given compound is a good indication of the effectiveness of the transport pathway taken by that compound, the affinity for the transported complex and/or the capacity of the transport protein.

15

Regardless of the particular *in vivo* method, the initial enrichment process can be repeated with the recovered complexes in the same or a different animal for additional enrichment (although typically at the expense of yield in complexes retrieved). If at the conclusion of multiple rounds of screening, there are only a relatively few remaining complexes, the identity of the test compound associated with each transported complex can be determined directly according to the methods described above, providing the final yield of complexes is sufficiently high.

20

Another screening option after *in vivo* enrichment, is to further enrich the pool of transported complexes according to one of the *in vitro* methods described herein. Since the *in vivo* screens are directed at identifying substrates that can be transported across a cell, further *in vitro* screening is typically performed using the bilayer transwell system described above which is a way to identify cells that are capable of transporting complexes through a cell monolayer. If such further screening is performed, initially a portion of the pool of complexes retrieved from the animal circulation is typically exposed to the transwell system, and cells transporting a complex identified, selected and each clonally expanded.

30

Next, the remaining complexes from the pool selected in the animal are exposed (sequentially) to each of the expanded clones in the same transwell format. Each clone passes complexes that belong to a single ligand family and these can be recovered from the bottom compartment of the transwell. The remaining complexes of the pool (those not

transported) are removed from the top compartment of the transwell and placed on the next clone of cells, and so on. At the end of this process, the pool of complexes recovered from below each cell clone layer represents a population enriched for compounds able to direct the cellular transport (e.g., transcytosis) of an attached particle utilizing the transport protein expressed in the clone of cells the particle passed through. By virtue of this enrichment, the compound can be more easily and reliably identified by direct structural analysis, or by identification of a representative tag. In addition, this process maps or correlates the compound families to their corresponding transport protein.

In another variation, a series of separate pools of complexes are sequentially applied to a single animal, retaining the ability to determine which group of compounds each bead belongs to by "pool tagging". Each library or final pool (from the final synthesis step) is labeled with a distinguishable tag (e.g., fluorescence). Each library or pool can be administered to the intestinal loop or the intact intestine of the test animal, and the transported beads recovered by the methods described above. The library or pool from which the beads derive is determined by the pool tag associated with each bead. This method can be used sequentially as a means to deconvolute a library of compounds.

For example, one group of compounds having a certain structural characteristic is labeled with a fluorescent molecule that generates a first color; a second set of compounds having a different structural characteristic than the first set is labeled with a fluorescent molecule that generates a second color. Once the compounds that have passed through the cells have been recovered, it is possible from the relative amount of each colored compound to determine the relative number of each group of compounds that were capable of being transported through the cells. The group of compounds having the highest activity can then be further subdivided into subfamilies, each subfamily having a certain characteristic structure, and the process repeated as many times as desired. Each time the process is repeated it becomes possible to more closely identify what structural characteristics are associated with transport activity.

### **Pharmaceutical Compositions**

Substrates for a transport protein identified according to one of the methods described above can be attached to an existing pharmaceutical agent to confer more efficient and/or more specific uptake on the pharmaceutical agent. The ability of substrate so attached to the pharmaceutical agent to transport the pharmaceutical agent can be confirmed according to the screening method described above.

## I. Primary Components

Some pharmaceutical composition contain a ligand for a transport protein directly attached to a pharmaceutical agent or indirectly attached thereto via a linker.

- 5 Optionally, the linker is cleavable. Other pharmaceutical compositions include a ligand of a transport protein, a pharmaceutical agent, and a nanoparticle. The nanoparticles are preferably from 50-200 nm in diameter. The nanoparticles provide an attachment point for the substrate and pharmaceutical agent, and can also protect the pharmaceutical agent by enclosing it non-covalently in a biodegradable particle. The pharmaceutical agent can be
- 10 attached to the nanoparticle or located within it. The ligand is exposed on the exterior surface of the nanoparticles and is effective in promoting cellular uptake and/or transport of the nanoparticle through a cell. The ligand can be directly attached to the nanoparticle or attached via a linker. Typically, the ligand is effective in promoting uptake over at least 5, 10, 20, 50 or 90% of nanoparticles administered bearing the ligand and pharmaceutical agent.
- 15 Typically, the ligand is a substrate of the transporter, such as a receptor for receptor mediated transcytosis. However, ligands that bind to a cellular molecule and thereby juxtapose a pharmaceutical agent in proximity to a suitable receptor can also be used.

The nanoparticles used in pharmaceutical compositions have the general composition, size, and shape as set forth above. The pharmaceutical agent attached to or

20 located within the nanoparticle can vary widely provided it can be attached or encapsulated by the nanoparticle. For example, the pharmaceutical agent can be an antibacterial pharmaceutical agent, an antihypertensive pharmaceutical agent, a vasodilator, an antiviral pharmaceutical agent and an anticancer pharmaceutical agent. Ligands and pharmaceutical agents can be attached to nanoparticles by the same types of linkages discussed in synthesis

25 of compound libraries.

## II. Secondary Components

### A. Additional Ligands

- Some pharmaceutical compositions include a second ligand of a transport
- 30 protein. In such compositions, typically one ligand is a substrate of a membrane bound transporter protein, and the other ligand binds to an exposed cellular molecule in proximity to the transporter protein. For example, one ligand can bind to a receptor on the cell surface and induce the formation of a pit to initiate the events that lead to internalization. The other ligand binds to a proximate cellular molecule.



Alternatively, one ligand is a substrate for a cell membrane bound transporter protein, and the other ligand binds to an intracellular transport protein that directs the basolateral trafficking of vesicles from the central sorting endosome. Binding of the first ligand results in internalization of the particle. In the absence of the second ligand, the particle is sometimes recycled to the same cell surface (e.g., the apical side) from which it originated rather than moved to the basolateral side. By selecting a second ligand that can direct basolateral trafficking in such a situation, the particle is transferred from the initially-bound receptor to another receptor and associated vesicle destined for the basolateral side of the cell.

In some pharmaceutical compositions, the second ligand is attached so that it be released from the nanoparticle in use. Such compositions are useful when the second ligand is needed to induce the internalization response, but is unable to do so unless released into the local environment to activate endocytosis. The first ligand, meanwhile, acts to retain the bead in the pit as it invaginates to form a transport vesicle.

**B. Optional agents within the nanoparticle**

Other components can be contained within or otherwise attached to nanoparticles. For example, nanoparticles can include a compound to inhibit the acidification of a vesicle enclosing the particle, thereby reducing or preventing damage to the pharmaceutical agent compound as it is transported in the vesicle. A similar result is obtained by placing a buffering compound in the nanoparticle. The buffering agent can be designed to remain in the bead, buffering only the interior of the bead itself, or can elute from the bead to buffer the vesicular compartment. In situations in which the bead is to be directed to the cytosol (and subsequently to other cellular compartment outside of the vesicular system), an agent causing lysis of the vesicle can be included within or attached to the nanoparticle. Suitable agents include adenovirus coat protein.

In some pharmaceutical compositions, nanoparticles are decorated on their outside with a substance that resists rapid clearance of particles by the reticuloendothelial system (RES). PEG is a suitable substance for this purpose (e.g. see Bocca *et al*, *Int. J. Pharm.* 1998, 175, 185). Example 6 below describes the use of commercially available amino-functionalized fluorescent nanoparticles for library synthesis by the split-pool method. Note that the bead surface is first coupled with a mixture of PEGylated carboxylic acid and a  $\beta$ -amino acid spacer. The  $\beta$ -amino acid serves as linker upon which the dipeptide is

synthesized. The ratio of PEG to dipeptide on the nanoparticle surface can be varied as required.

Once a nanoparticle is released from the vesicle and exposed to the cytoplasm, additional targeting strategies can be employed to direct to the beads to the desired cellular compartments. For example, a short peptide motif known to target proteins and vesicles to certain cellular destinations can be attached to the nanoparticle. Examples of such basolateral targeting peptide motifs are known as “di-leucine” and “tyrosine-dependent type” (e.g. LeuLeu and TyrXXPhe, respectively) found in the cytoplasmic domains of certain basolaterally localized proteins such as LDL receptor, mannose 6-phosphate receptor, lysosomal acid phosphatase, and various viral proteins such as Influenza Virus hemagglutinin. (LeBorgne and Hayflick, *Curr Opin Cell Biol.* 1998, 10, 499-503; Kirchhuasen, *et al. Curr. Opin. Cell. Biol.* 1997, 9, 488-495; Jacob, *et al. J. Biol. Chem.* 1999, 274, 8061-8067).

### III. Other Components and Delivery

The pharmaceutical compositions can also include, depending on the formulation desired, pharmaceutically-acceptable, non-toxic carriers of diluents, which are defined as vehicles commonly used to formulate pharmaceutical compositions for animal or human administration. The diluent is selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, buffered water, physiological saline, PBS, Ringer's solution, dextrose solution, and Hank's solution. In addition, the pharmaceutical composition or formulation can also include other carriers, adjuvants, or non-toxic, nontherapeutic, nonimmunogenic stabilizers, excipients and the like. The compositions can also include additional substances to approximate physiological conditions, such as pH adjusting and buffering agents, toxicity adjusting agents, wetting agents, detergents and the like (see Remington's Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, PA, 17th ed. (1985). For a brief review of methods for pharmaceutical agent delivery, see, Langer, *Science* 249:1527-1533 (1990), each incorporated by reference in their entirety).

The compositions can be administered for prophylactic and/or therapeutic treatments. The pharmaceutical agent attached to or encapsulated by the nanoparticle in the pharmaceutical compositions is typically present in a therapeutic amount, which is an amount sufficient to remedy a disease state or symptoms, or otherwise prevent, hinder, retard, or reverse the progression of disease or any other undesirable symptoms in any way whatsoever. The concentration of the pharmaceutical agent in the pharmaceutical

composition can vary widely, i.e., from less than about 0.1% by weight, usually being at least about 1% by weight, to as much as 20% by weight or more.

In therapeutic applications, compositions are administered to a patient already suffering from a disease, as just described, in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. An appropriate dosage of the pharmaceutical composition or polypeptide of the invention is readily determined according to any one of several well-established protocols. For example, animal studies (e.g., mice, rats) are commonly used to determine the maximal tolerable dose of the bioactive agent per kilogram of weight. In general, at least one of the animal species tested is mammalian. The results from the animal studies can be extrapolated to determine doses for use in other species, such as humans for example. An effective dose also depends on the nature and severity of the disease or condition, and on the general state of the patient's health.

In prophylactic applications, compositions containing the compounds of the invention are administered to a patient susceptible to or otherwise at risk of a particular disease or infection. Such an amount is defined to be a "prophylactically effective" amount or dose. In this use, the precise amounts again depends on the patient's state of health and weight.

The pharmaceutical compositions can be administered in a variety of different ways. Examples include administering a composition containing a pharmaceutically acceptable carrier via oral, intranasal, rectal, topical, intraperitoneal, intravenous, intramuscular, subcutaneous, subdermal, transdermal, intrathecal, and intracranial methods. The route of administration depends on the substrate present in composition. For example, substrates for ileal transport proteins are useful for oral administration.

For oral administration, the active ingredient can be administered in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. The active component(s) can be encapsulated in gelatin capsules together with inactive ingredients and powdered carriers, such as glucose, lactose, sucrose, mannitol, starch, cellulose or cellulose derivatives, magnesium stearate, stearic acid, sodium saccharin, talcum, magnesium carbonate. Examples of additional inactive ingredients that can be added to provide desirable color, taste, stability, buffering capacity, dispersion or other known desirable features are red iron oxide, silica gel, sodium lauryl sulfate, titanium dioxide, and edible white ink. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar

coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric-coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.

Compositions prepared for intravenous administration typically contain 100 to 500 ml of sterile 0.9% NaCl or 5% glucose optionally supplemented with a 20% albumin solution. Methods for preparing parenterally administrable compositions are described in more detail in various sources, including, for example, Remington's Pharmaceutical Science, Mack Publishing, Philadelphia, PA, 17th ed., (1985).

Particularly when the compositions are to be used in vivo, the components used to formulate the pharmaceutical compositions of the present invention are preferably of high purity and are substantially free of potentially harmful contaminants (e.g., at least National Food (NF) grade, generally at least analytical grade, and more typically at least pharmaceutical grade). Moreover, compositions intended for in vivo use are usually sterile. To the extent that a given compound must be synthesized prior to use, the resulting product is typically substantially free of any potentially toxic agents, particularly any endotoxins, which can be present during the synthesis or purification process. Compositions for parental administration are also sterile, substantially isotonic and made under GMP conditions.

The following examples are provided to illustrate certain aspects of the invention and are not to be construed to limit the invention.

### EXAMPLE 1

#### Preparation of Cells Expressing Exogenous Transport Proteins

##### I. Transfection and Selection of Transporter-Expressing Cell Lines

CHO K1 cells ( $10^7$ /ml) were transfected by electroporation (400V, 250  $\mu$ farads) with 40  $\mu$ g of transporter DNA with neo as the selectable marker. After allowing two days for integration of the DNA into the cellular genome, G418 (1.0 mg/ml) was added. The cells were selected for ten days. The selected population was then incubated at 37 °C for 30 min in transport buffer containing a fluorescent substrate for the transporter. For hPEPT1 and rPEPT1, 500  $\mu$ M XP10486 was used as the fluorescent substrate (see Example 4 for the preparation and structure of XP10486); the transport buffer utilized with these particular transporters contained 150 mM NaCl, 3 mM KCl, 1 mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 1 mM  $\text{NaH}_2\text{PO}_4$ , 5 mM glucose and 5 mM MES, pH 6.0.

The cells were then cloned using a Cytomation MoFlo flow cytometer gated on the most highly fluorescent cell population and the live cell population (forward vs. side scatter). The resultant clones were transferred to additional 96-well plates and assayed for transport activity using a radioactive substrate. The clone with the highest transport activity was selected and expanded for screening libraries of potential fluorescent substrates.

## EXAMPLE 2

### Protocols for Direct Uptake Assays

#### I. Methods for Detecting Fluorescent Substrate Uptake

##### A. Bile Acid Transporters

Day 1: Seed cells (e.g., CHO IBAT or CHO LBAT) at 100K/well into clear bottom black 96-well tissue culture treated plates.

Day 2: Wash cells 2x with HBSS buffer (HBSS from Gibco, 10 mM Hepes, pH 7.0) at 100 µl/well.

Add 50 µl of various concentrations of compounds dissolved in HBSS buffer (Hanks Balanced Salt Solution).

or buffer alone to each well.

Incubate 1 hr at RT in the dark (to minimize any negative effects of light on fluorescent properties of putative substrate).

Read Input Fluorescent Units (FU) in Tecan Spectrafluor instrument, measuring from the bottom of the well. Appropriate excitation and emission wavelengths are utilized as determined by instrument at optimal gain.

Wash each well 4x with 100 µl/well HBSS at 4 °C.

Add HBSS at 50 µl/well.

Determine amount of fluorescent substrate transported by measuring FU in wells as above, using the same gain.

CHO K1 cells used as control for non-transporter dependent transport.

##### B. PEPT1 Transporters

Day 1: Seed CHO hPEPT1 cells at 100K/well into clear bottom black 96-well tissue culture treated plates.

Day 2: Wash cells 2x with pH 6.0 buffer (1 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 150 mM NaCl, 3 mM KCl, 1 mM NaH<sub>2</sub>PO<sub>4</sub>, 5 mM D-glucose and 5 mM MES, pH 6.0) at RT.

Add 50  $\mu$ l of various concentrations of compounds dissolved in pH 6.0 buffer or buffer alone to each well.

Incubate 1 hr RT in the dark (to minimize any negative effects of light on fluorescent properties of putative substrate).

5 Read Input Fluorescent Units (FU) in Tecan Spectrafluor instrument (read from bottom of plate). Use appropriate excitation and emission wavelengths, using optimal gain, determined by instrument.

10 Wash 2x 100  $\mu$ l/well pH 6.0 at 4 °C. Add 100  $\mu$ l/well of the same buffer, let sit for 10 min. at RT. Wash 2x 100  $\mu$ l/well pH 6.0 at 4 °C. This washing procedure helps minimize the non-specific adherence of fluorescent compounds to the outside of the cells.

Add above buffer at 50  $\mu$ l/well.

Determine amount of fluorescent substrate transported by measuring FU in wells as above, using the same gain.

15 Untransfected CHO K1 cells used as control for non-transporter dependent transport.

Results demonstrating the uptake of XP10486 in CHO cells expressing PEPT1 as compared to control cells not expressing PEPT1 are presented in Fig. 5.

## II. Methods for Determining Radioactive Substrate Uptake

### 20 A. Bile Acid Transporters

Day 1: Seed cells (e.g., CHO IBAT or CHO LBAT) at 100K/well into clear bottom white 96-well tissue culture treated plates.

Day 2: Wash cells 2x with HBSS buffer pH 7.0 at 100  $\mu$ l/well.

25 Add 50  $\mu$ l of various concentrations of radiolabeled compounds dissolved in HBSS buffer or buffer alone to each well.

Incubate 1 hr. RT.

Wash cells 4x 100  $\mu$ l/well with HBSS at 4 °C.

Add 200  $\mu$ l scintillation fluid/well. Shake for 5-15 min. RT.

Count in Wallac microbeta counter for 1 min/well.

30 Untransfected CHO K1 cells used as control for non-transporter dependent transport.

### B. PEPT1 Transporters

Day 1: Seed CHO hPEPT1 cells at 100K/well into clear bottom white 96-well tissue culture treated plates.

Day 2: Wash cells 2x with pH 6.0 buffer (1 mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 150 mM  $\text{NaCl}$ , 3 mM  $\text{KCl}$ , 1 mM  $\text{NaH}_2\text{PO}_4$ , 5 mM D-glucose and 5 mM MES, pH 6.0) at RT at 100  $\mu\text{l}$ /well.

Add 50  $\mu\text{l}$  of various concentrations of radiolabeled compounds dissolved in pH 6.0 buffer or buffer alone to each well.

Incubate 1 hr. RT.

Wash 2x 100  $\mu\text{l}$ /well pH 6.0 at 4 °C. Add 100  $\mu\text{l}$ /well of the same buffer, let sit for 10 min. at RT. Wash 2x 100  $\mu\text{l}$ /well pH 6.0 at 4 °C. This wash procedure minimizes the non-specific adherence of radioactivity to the cells.

Add 200  $\mu\text{l}$  scintillation fluid/well. Shake for 5-15 min. RT.

Count in Wallac microbeta counter for 1 min/well.

Untransfected CHO K1 cells used as control for non-transporter dependent transport.

### III. Methods for Detecting Radioactive Substrate Uptake in Competitive Format

#### A. Bile Acid Transporters – 96 Well Format

Day 1: Seed cells (e.g., CHO IBAT or CHO LBAT) at 100K/well into clear bottom white 96-well tissue culture treated plates.

Day 2: Wash cells 2x with HBSS buffer pH 7.0 at 100  $\mu\text{l}$ /well.

To each well, add:

25  $\mu\text{l}$ /well of buffer (HBSS, pH 7.0) or test compounds at 2X final concentration in buffer; and  
25  $\mu\text{l}$ /well of  $^3\text{H}$ -taurocholate at 50,000 CPM/well in HBSS buffer containing 10  $\mu\text{M}$  cold taurocholate for IBAT cells, or 20  $\mu\text{M}$  cold Taurocholate for LBAT cells (final concentration of taurocholate in assay is 5  $\mu\text{M}$  or 10  $\mu\text{M}$ , respectively).

Incubate 1 hr. RT.

Wash cells 4x 100  $\mu\text{l}$ /well with HBSS at 4 °C.

Add 200  $\mu\text{l}$  scintillation fluid/well. Shake for 5-15 min. RT.

Count in Wallac microbeta counter for 1 min/well.

#### B. PEPT1 Transporters – 96 Well Format

Day 1: Seed CHO hPEPT1 cells at 100K/well into clear bottom white 96-well tissue culture treated plates.

Day 2: Wash cells 2x with pH 6.0 buffer (1 mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 150 mM NaCl, 3 mM KCl, 1 mM  $\text{NaH}_2\text{PO}_4$ , 5 mM D-glucose and 5 mM MES, pH 6.0) at RT at 100  $\mu\text{l}$ /well.

To each well, add:

25  $\mu\text{l}$ /well of pH 6.0 buffer or test compounds at 2X final concentration in buffer;

25  $\mu\text{l}$ /well of  $^3\text{H}$ -Gly-Sar (Glycylsarcosine) at 100,000 CPM/well in pH 6.0 buffer containing 400  $\mu\text{M}$  unlabeled GlySar (final concentration will be 200  $\mu\text{M}$ ).

Incubate 1 hr. RT.

Wash 2x 100  $\mu\text{l}$ /well pH 6.0 at 4 °C. Add 100  $\mu\text{l}$ /well of the same buffer, let sit for 10 min. at RT. Wash 2x 100  $\mu\text{l}$ /well pH 6.0 at 4 °C. This wash procedure minimizes the non-specific adherence of radioactivity to the cells.

Add 200  $\mu\text{l}$  scintillation fluid/well. Shake for 5-15 min. RT.

Count in Wallac microbeta counter for 1 min/well.

C. A. Bile Acid Transporters – 384 Well Format

Day 1: Seed cells (e.g., CHO IBAT or CHO LBAT) at 50K/well into clear bottom white 384-well tissue culture treated plates.

Day 2: Wash cells 2x with HBSS buffer pH 7.0 at 70  $\mu\text{l}$ /well.

To each well, add:

25  $\mu\text{l}$ /well of buffer (HBSS, pH 7.0) or test compounds at 2X final concentration in buffer; and

25  $\mu\text{l}$ /well of  $^3\text{H}$ -taurocholate at 75,000 CPM/well in HBSS buffer containing 0.2  $\mu\text{M}$  cold Taurocholate for LBAT cells (final concentration of taurocholate in assay is 0.1  $\mu\text{M}$ ).

Incubate 1 hr. RT.

Wash cells 3x 70  $\mu\text{l}$ /well with HBSS at 4 °C.

Add 200  $\mu\text{l}$  scintillation fluid/well. Shake for 5-15 min. RT.

Count in Wallac microbeta counter for 1 min/well.

D. Results



Results of competition experiments conducted with CHO cells expressing the liver bile acid transporter (LBAT) in a 96-well and 384-well format are shown in Figs 6A and 6B.

### EXAMPLE 3

#### Library Screening Methods for Cells Expressing Carrier-Type Transport Proteins

##### I. Screening 200 Member Fluorescent Dipeptide Library

##### A. Synthesis of Dipeptide Library

Wang resin preloaded with the following 20 protected amino acids can be obtained from Novabiochem: Fmoc-Gly, Fmoc-Ala, Fmoc-Val, Fmoc-Leu, Fmoc-Ile, Fmoc-Met, Fmoc-Pro, Fmoc-Cys(Trt), Fmoc-Ser(O<sup>t</sup>Bu), Fmoc-Thr(O<sup>t</sup>Bu), Fmoc-Asn(Trt), Fmoc-Gln(Trt), Fmoc-Asp(O<sup>t</sup>Bu), Fmoc-Glu(O<sup>t</sup>Bu), Fmoc-Lys(Boc), Fmoc-Arg(Pmc), Fmoc-Phe, Fmoc-Tyr(O<sup>t</sup>Bu), Fmoc-His(Trt), Fmoc-Trp(Boc). 100 mg of each resin (loading ~ 1 mmole/g) is pooled and shaken with 20 mL of a 20% (v/v) solution of piperidine in DMF for 20 min. The resins are washed with DMF (3x), CH<sub>2</sub>Cl<sub>2</sub>, MeOH, and CH<sub>2</sub>Cl<sub>2</sub> again, then dried *in vacuo* and divided into 2 equal aliquots. The first is treated with 20 mL of a DMF solution containing α-Fmoc-γ-Alloc-diaminobutyric acid (250 mM), HATU (250 mM) and DIEA (500 mM). The resin is agitated for 8 h then filtered and washed with DMF (3x), CH<sub>2</sub>Cl<sub>2</sub>, MeOH, and CH<sub>2</sub>Cl<sub>2</sub> again, then dried *in vacuo*. The second aliquot of resin is similarly treated with α-Fmoc-ε-Alloc-lysine. The Alloc protecting group is removed from these 2 aliquots by separately treating each with Pd(PPh<sub>3</sub>)<sub>4</sub> (0.23 g) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) followed by addition of tetrabutylammonium fluoride (0.78 g) and azidotrimethylsilane (1.06 mL). The resin is shaken under nitrogen for 30 min, then drained and the resin washed with CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 mL). The deprotection procedure is then repeated.

The resins are subsequently treated with a 3% (v/v) solution of sodium diethyldithiocarbamate in DMF containing 5% (v/v) DIEA (20 mL) to remove any residual palladium. After shaking for 10 min, the mixture is drained and then washed with DMF (3x), CH<sub>2</sub>Cl<sub>2</sub>, MeOH, and CH<sub>2</sub>Cl<sub>2</sub> again, then dried *in vacuo*. Each aliquot is then equally divided into 5 sub-pools for reaction with one of 5 DMF solutions containing 1 mmole of a different fluorescent reagent, i.e. (a) 4,4-difluoro-5,7-dimethyl-4-bora-3a, 4a-diaza-s-indacene-3-propionic acid, succinimidyl ester (BODIPY FL, SE); (b) fluorescein-5-isothiocyanate

(FITC); (c) 5 and 6-carboxytetramethylrhodamine, succinimidyl ester (5(6)-TAMRA, SE); (d) 7-methoxycoumarin-3-carboxylic acid, succinimidyl ester; (e) 1-(3-isothiocyanatophenyl)-4-(5-(4-methoxyphenyl)oxazol-2-yl))pyridinium bromide (PyMPO-ITC). After shaking for 4 h, the supernatants are drained and the resins washed extensively with DMF (6x), CH<sub>2</sub>Cl<sub>2</sub> (2x), MeOH (2x), and CH<sub>2</sub>Cl<sub>2</sub> (2x) again, then dried *in vacuo*. Each of the 10 pools is treated with 2 mL of a 20% (v/v) solution of piperidine in DMF for 20 min. The resins are washed with DMF (3x), CH<sub>2</sub>Cl<sub>2</sub>, MeOH, and CH<sub>2</sub>Cl<sub>2</sub> again, then dried *in vacuo*. A small portion (~5 mg) of each pool is reserved for single bead screening while the remainder is cleaved by addition of 10 mL of a 90:5:5 solution of TFA: H<sub>2</sub>O: Et<sub>3</sub>SiH. After agitation for 30 min, the supernatants are drained, the resins washed with 50% TFA:CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and the combined filtrates evaporated to dryness. The resulting 10 pools are shown in Fig. 7.

#### B. Library Screening for hPEPT1 Substrates

CHO cell lines expressing the human dipeptide transporter PETP1 are prepared as described in Example I, with CHO-K1 cells serving as a negative-control cell-line. The library just described in section I.A. of this example is then screened according to the protocol set forth in Example II. The best peptide substrate (i.e., with the greatest  $V_{\max}/K_m$ ) is selected for use as a fluorescent probe for screening libraries for hPEPT1 substrates in competition assays.

### II. Screening 400-Member Dipeptide Library and 400-Member $\beta$ -Lactam Libraries for PEPT1 Substrate

#### A. Synthesis of 400 Member Dipeptide Library

A summary of the major steps in the synthesis of this library is presented in Fig. 8. Wang resin preloaded with the following 20 protected amino acids can be obtained from Novabiochem: Fmoc-Gly, Fmoc-Ala, Fmoc-Val, Fmoc-Leu, Fmoc-Ile, Fmoc-Met, Fmoc-Pro, Fmoc-Cys(Trt), Fmoc-Ser(O<sup>t</sup>Bu), Fmoc-Thr(O<sup>t</sup>Bu), Fmoc-Asn(Trt), Fmoc-Gln(Trt), Fmoc-Asp(O<sup>t</sup>Bu), Fmoc-Glu(O<sup>t</sup>Bu), Fmoc-Lys(Boc), Fmoc-Arg(Pmc), Fmoc-Phe, Fmoc-Tyr(O<sup>t</sup>Bu), Fmoc-His(Trt), Fmoc-Trp(Boc). 1 g of each resin (loading ~ 1 mmole/g) is divided into 20 x 50 mg aliquots and individual aliquots are added to 5 deep-well microtiter plates (80 wells per plate) fitted with filter frits (e.g. available from Polyfiltronics or Robbins Scientific). To each well is added 0.5 mL of a 20% (v/v) solution of piperidine in DMF. The

plates are agitated for 20 min and the supernatants drained (by evacuation). The resins are washed with DMF (3x), CH<sub>2</sub>Cl<sub>2</sub>, MeOH, and CH<sub>2</sub>Cl<sub>2</sub> again, then dried *in vacuo*.

Separate DMF solutions are prepared containing one of the 20 protected amino acids [i.e. Fmoc-Gly, Fmoc-Ala, Fmoc-Val, Fmoc-Leu, Fmoc-Ile, Fmoc-Met, Fmoc-Pro, Fmoc-Cys(Trt), Fmoc-Ser(O<sup>t</sup>Bu), Fmoc-Thr(O<sup>t</sup>Bu), Fmoc-Asn(Trt), Fmoc-Gln(Trt), Fmoc-Asp(O<sup>t</sup>Bu), Fmoc-Glu(O<sup>t</sup>Bu), Fmoc-Lys(Boc), Fmoc-Arg(Pmc), Fmoc-Phe, Fmoc-Tyr(O<sup>t</sup>Bu), Fmoc-His(Trt), Fmoc-Trp(Boc)] at 250 mM, plus HATU (250 mM) and DIEA (500 mM). 1 mL of each solution is added to an aliquot of each resin and the plates agitated for 8 h to form the 400 discrete protected dipeptides. The supernatants are drained and the resins washed with DMF (3x), CH<sub>2</sub>Cl<sub>2</sub>, MeOH, and CH<sub>2</sub>Cl<sub>2</sub> again, then dried *in vacuo*. To each well is added 0.5 mL of a 20% (v/v) solution of piperidine in DMF, the plates agitated for 20 min, then the supernatants are drained and the resins washed with DMF (3x), CH<sub>2</sub>Cl<sub>2</sub>, MeOH, and CH<sub>2</sub>Cl<sub>2</sub> again, then dried *in vacuo*. The 400 dipeptides are cleaved from resin by addition to each well of 0.5 mL of a 90:5:5 solution of TFA: H<sub>2</sub>O: Et<sub>3</sub>SiH. After agitation for 30 min, the supernatants are drained into deep well microtiter plates, the resins washed with CH<sub>2</sub>Cl<sub>2</sub> (0.5 mL) and the combined filtrates evaporated to dryness using a Genevac concentrator.

#### B. Parallel Synthesis of a 400 Member $\beta$ -Lactam Library

A scheme for synthesizing a  $\beta$ -lactam library for use in screening methods is presented in Fig. 9. Sasrin resin preloaded with the following 20 protected amino acids can be obtained from Bachem: Fmoc-Gly, Fmoc-Ala, Fmoc-Val, Fmoc-Leu, Fmoc-Ile, Fmoc-Met, Fmoc-Pro, Fmoc-Cys(Trt), Fmoc-Ser(O<sup>t</sup>Bu), Fmoc-Thr(O<sup>t</sup>Bu), Fmoc-Asn(Trt), Fmoc-Gln(Trt), Fmoc-Asp(O<sup>t</sup>Bu), Fmoc-Glu(O<sup>t</sup>Bu), Fmoc-Lys(Boc), Fmoc-Arg(Pmc), Fmoc-Phe, Fmoc-Tyr(O<sup>t</sup>Bu), Fmoc-His(Trt), Fmoc-Trp(Boc). 1 g of each resin (loading ~ 0.6 mmole/g) is treated with 10 mL of a 20% (v/v) solution of piperidine in DMF for 20 min. The resins are washed with DMF (3x), CH<sub>2</sub>Cl<sub>2</sub>, MeOH, and CH<sub>2</sub>Cl<sub>2</sub> again, then dried *in vacuo*. Each sample is divided into 10 x 100 mg aliquots and the resins suspended in a 80% (v/v) solution of trimethylorthoformate in CH<sub>2</sub>Cl<sub>2</sub> (1 mL). 200 different imines are formed by addition of one of ten aldehydes: (i) benzaldehyde; (ii) cinnamaldehyde; (iii) cyclohexyl aldehyde; (iv) 2-furyl aldehyde; (v) 2-thiophene aldehyde; (vi) 2-pyridyl aldehyde; (vii) 3-quinolyl aldehyde; (viii) 3,4-dichlorobenzaldehyde; (ix) 4-carbomethoxybenzaldehyde; (x) 4-

biphenylaldehyde. 1 mL of a 1.6 M solution of the aldehyde in  $\text{CH}_2\text{Cl}_2$  is added, the resins shaken for 3 h then drained and washed with  $\text{CH}_2\text{Cl}_2$  (2x).

The resins are resuspended in  $\text{CH}_2\text{Cl}_2$  (2 mL) and cooled to  $-78^\circ\text{C}$ .

Triethylamine (1.2 mmol) and phthalimidoacetyl chloride (0.9 mmol) are added to each and the resins warmed to room temperature overnight with stirring. The resins are drained and washed with  $\text{CH}_2\text{Cl}_2$  (2x). The phthalimido protecting group is removed by treatment with a DMF solution of N-methylhydrazine (1M) and the samples cleaved from resin by treatment with a 3% (v/v) solution of TFA in  $\text{CH}_2\text{Cl}_2$ . The resulting products are dried *in vacuo* using a Genevac concentrator to yield 200 samples containing approximately equimolar mixtures of  $\beta$ -lactams as two cis-diastereomers.

### C. Screening the Dipeptide and $\beta$ -Lactam Libraries for hPEPT1 Substrates

The libraries prepared as just described (i.e., sections II. A and II. B of this example) are screened for the presence of hPEPT1 substrates in a two-part protocol. Initially a competition assay is used to identify the most effective inhibitors of uptake of a reporter substrate (e.g., either radiolabeled Gly-Sar, or the fluorescent substrate identified in section I.B. of this Example). The selected inhibitors are then retested in either a CHO/hPEPT1 uptake assay or a transepithelial flux assay across a confluent Caco-2 cell monolayer. The transported substrates are detected by LC-MS analysis using an HP 1100 MSD instrument and a reversed-phase C18 column (5  $\mu\text{m}$ , 2.1 mm x 10 cm) eluting with MeCN/ $\text{H}_2\text{O}$ /0.1% formic acid.

#### 1. Fluorescence Competition Assay

CHO/hPEPT1 cells are seeded in microtiter plates at a density of  $5 \times 10^4$  cells/well. At 2 days post-seeding, the medium is removed and the cells washed twice with pH 6.0 uptake buffer (1 mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 150 mM NaCl, 3 mM KCl, 1 mM  $\text{NaH}_2\text{PO}_4$ , 5 mM D-glucose and 5 mM MES). The library samples are dissolved in uptake buffer at concentrations ranging from 5  $\mu\text{M}$  to 10 mM together with the fluorescent reporter substrate at 50  $\mu\text{M}$  and added to the CHO/hPEPT1 cells in duplicate experiments. At various time points (10, 20, 30, 45, 60 and 90 min) the supernatants are removed and the cells washed with ice-cold uptake buffer (3x). The cells are visualized by confocal fluorescence microscopy and scored for accumulation of the fluorescent reporter in the cytoplasm. Compounds strongly inhibiting reporter uptake are selected for further analysis.

## 2. CHO/hPEPT1 Uptake Assay

CHO/hPEPT1 cells are seeded in six-well culture plates at a density of  $10^5$  cells/cm<sup>2</sup>. At 2 days post-seeding, the medium is removed and the cells washed twice with  
5 pH 6.0 uptake buffer (1 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 150 mM NaCl, 3 mM KCl, 1 mM NaH<sub>2</sub>PO<sub>4</sub>, 5 mM D-glucose and 5 mM MES). The library samples are dissolved in uptake buffer at concentrations ranging from 5  $\mu$ M to 10 mM and added to the CHO/hPEPT1 cells in duplicate experiments. At various time points (10, 20, 30, 45, 60 and 90 min) the supernatants are removed and the cells washed with ice-cold uptake buffer (3x). Water (1  
10 mL) is added to each well and incubated for 30 min at 25 °C. Cells are harvested and sonicated for 2 min. ZnSO<sub>4</sub> solution (8%, 0.2 mL) is added to the cell lysate, vortexed vigorously and centrifuged for 5 min at 3000 rpm. After passage through a 0.45  $\mu$ m filter, the samples are analyzed for the presence of library compound by LC-MS. Samples for which uptake exceeded that observed for the control CHO-K1 cell line are identified as  
15 hPEPT1 substrates.

## 3. Caco-2 Transepithelial Flux Assay

Caco-2 cells, which naturally express the hPEPT1 transporter, are cultured for ~20 days on permeable polycarbonate Transwell cell culture inserts (diameter 24.5 mm,  
20 Costar) at starting densities of  $4 \times 10^4$  cells/cm<sup>2</sup>. The lower (receiver) compartment contained 2.5 mL medium and the upper (donor) compartment contained 1.5 mL medium. Transepithelial flux of library compounds is performed at 37 °C by addition of uptake buffer (pH 6.0, 1.5 mL) containing the sample (1 mM) to the donor side. At time intervals of 10, 30, 60 and 120 min, 0.2 mL samples are taken from the receiver compartment and replaced  
25 with fresh buffer (pH 7.5). Samples are analyzed for the presence of transported compound by LC-MS. Integrity of the Caco-2 monolayer is confirmed by measuring the flux of [<sup>14</sup>C]-mannitol.

## EXAMPLE 4

30 Library Screening Methods to Assess  
Structure-Activity Relationships

### I. Compound and Library Synthesis

A. Synthesis of XP 10486

Fig. 10 depicts the major steps in the preparation of XP 10486. To  $\alpha$ -N-Boc-diaminopropionic acid (1.0 g) and finely powdered, potassium carbonate (1.35 g, 2 eq) in a 100 mL round-bottom flask was added ethanol (30 mL) and 4-chloro-7-nitrobenzofurazan (NCB-Cl, 1.07 g, 1.1 eq). The mixture was heated at 65-70 °C for 1 h, then cooled to room temperature. The solvent was removed *in vacuo* and the solid material dissolved in water (30 mL). This aqueous solution was extracted with ether (2 x 30 mL). The aqueous solution was acidified to pH=1-2 with 1M HCl solution, extracted with dichloromethane (3 x 30 mL) and the organic layer dried over anhydrous sodium sulfate. The solvent was removed *in vacuo* to yield  $\alpha$ -N-Boc- $\beta$ -N-NBD-diaminopropionic acid (1.63 g, 91% based on starting diaminopropionic acid).

Freshly prepared  $\alpha$ -N-Boc- $\beta$ -N-NBD-diaminopropionic acid (0.8 g) was dissolved in dichloromethane (40 mL) containing HOBt (0.33 g, 1.5 eq), asparagine t-butyl ester hydrochloride (0.59 g, 1.2 eq) and DIEA (0.46 mL, 1.2 eq). DIC (0.51 mL, 1.5 eq) was added dropwise and the reaction mixture stirred at room temperature for 18 h. The reaction mixture was diluted with dichloromethane (40 mL) and extracted with 1M HCl solution (2 x 10 mL) and then saturated sodium bicarbonate solution (2 x 10 mL). The organic layer was dried over anhydrous sodium sulfate and the solvent removed *in vacuo*. Column chromatography on silica gel provided the pure protected dipeptide. TFA (20 mL) was added to this product and the reaction mixture stirred at room temperature for 12 h. The solvent was removed *in vacuo* to yield XP10486 (575 mg, 69% based on starting  $\alpha$ -N-Boc- $\beta$ -N-NBD-diaminopropionic acid). Electrospray mass spectrometry showed the expected molecular ion at  $m/z = 382$  ( $M+H^+$ ).

B. Synthesis of NBD-Containing Dipeptide Libraries

Structure-activity relationships for hPEPT1 substrates can be assessed by synthesizing variant structures based upon the XP 10486 just described in the foregoing section. More specifically, sub-libraries are prepared in which the NBD moiety is conjugated at different sites on the dipeptide backbone of XP 10486. The different types of general structures that can be prepared are shown in Fig. 11.

1. Sub-library A

As shown in Fig. 12,  $\alpha$ -N-Boc- $\beta$ -N-NBD-diaminopropionic acid (80 mg), prepared as described above in section A of this example, is dissolved in dichloromethane (4 mL) containing HOBt (33 mg, 1.5 eq), DIEA (46  $\mu$ L, 1.2 eq) and one of the following ten tert-butyl protected  $\alpha$ -amino acids (1 eq): Gly-O<sup>t</sup>Bu, Ala-O<sup>t</sup>Bu, Val-O<sup>t</sup>Bu, Pro-O<sup>t</sup>Bu, Ser(O<sup>t</sup>Bu)-O<sup>t</sup>Bu, Asn-O<sup>t</sup>Bu, Glu(O<sup>t</sup>Bu)-O<sup>t</sup>Bu, Lys(Boc)-O<sup>t</sup>Bu, Phe-O<sup>t</sup>Bu, His(Trt)-O<sup>t</sup>Bu. DIC (51  $\mu$ L, 1.5 eq) is added to each solution and the mixtures stirred at room temperature for 18 h. The mixtures are diluted with dichloromethane (4 mL) and extracted with 1M HCl (2 x 1 mL) and then saturated sodium bicarbonate (2 x 1 mL). The organic layers are dried over anhydrous sodium sulfate and the solvent removed *in vacuo*. Flash chromatography on silica gel provided the pure protected dipeptides. TFA (2 mL) is added to each of these products and after 1 h at room temperature the solvent is removed *in vacuo* to afford the NBD-containing dipeptides, which are characterized by electrospray mass spectrometry.

## 2. Sub-library B

The synthesis of sub-library B is shown in Fig. 13. As shown, to 3-aminopropan-1-ol (10 mmol) is added allyl 1-benzotriazolyl carbonate (10 mmol, 1 eq) in DMF (40 mL) containing DIEA (12 mmol, 1.2 eq) and the reaction mixture stirred at room temperature for 12 h. The solvent is removed *in vacuo* and the residue dissolved in dichloromethane (40 mL) and extracted with 1M HCl (2 x 10 mL) and then saturated sodium bicarbonate (2 x 10 mL). The organic layer is dried over anhydrous sodium sulfate and the solvent removed *in vacuo*. Chromatography on silica gel provided the pure Alloc-protected amino alcohol. The reaction sequence is repeated starting with 5-aminopentan-1-ol to afford 5-N-Alloc-aminopentan-1-ol.

Two gram samples of Wang resin loaded with each of the 10 following protected amino acids (at 1 mmol/g): Fmoc-Gly, Fmoc-Ala, Fmoc-Val, Fmoc-Pro, Fmoc-Ser(O<sup>t</sup>Bu), Fmoc-Asn, Fmoc-Glu(O<sup>t</sup>Bu), Fmoc-Lys(Boc), Fmoc-Phe, Fmoc-His(Trt); are divided into two equal aliquots and are separately treated first with 20% piperidine in DMF for 20 min (followed by washing with DMF (3x) and CH<sub>2</sub>Cl<sub>2</sub>), then 2-nitrobenzenesulfonyl chloride (10 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) containing pyridine (10 mmol), followed by washing with DMF (3x) and CH<sub>2</sub>Cl<sub>2</sub>. The first aliquots of resin are suspended in 1:1 v/v anhydrous THF/CH<sub>2</sub>Cl<sub>2</sub> (15 mL) and triphenylphosphine (10 mmol) and 3-N-Alloc-aminopropan-1-ol (10 mmol) are added. The reaction mixture is cooled to 0 °C under nitrogen and diisopropyl azodicarboxylate (DIAD, 10 mmol) in 1:1 v/v anhydrous THF/CH<sub>2</sub>Cl<sub>2</sub> (3 mL) added dropwise. The mixture is then agitated at room temperature for 3 h and the resin filtered and

washed with anhydrous DMF, MeOH and CH<sub>2</sub>Cl<sub>2</sub> and dried *in vacuo*. This Mitsunobu coupling protocol is repeated using the second aliquots of resin with 5-N-Alloc-aminopentan-1-ol.

The twenty resin samples are next treated for 1 h at room temperature with a 1M solution of PhSNa in anhydrous DMF (10 mL) to remove the nitrobenzensulfonyl protecting group and the resins washed with DMF. Each resin sample is divided into 10 equal sized aliquots for coupling to 0.5 mmol of one of the 10 following protected amino acids: Boc-Gly, Boc-Ala, Boc-Val, Fmoc-Pro, Boc-Ser(O<sup>t</sup>Bu), Boc-Asn, Boc-Glu(O<sup>t</sup>Bu), Boc-Lys(Boc), Boc-Phe, Boc-His(Boc); in DMF solutions (2 mL) containing HOBt (0.75 mmol), DIEA (0.6 mmol) and DIC (0.75 mmol). After agitating the reaction mixtures for 12 h the resins are filtered and washed with DMF, MeOH and CH<sub>2</sub>Cl<sub>2</sub> then dried *in vacuo*.

Each sample is next treated with a solution of tetrakis(triphenylphosphine)-palladium(0) (0.02 mmol) in THF (2 mL) followed by addition of tetrabutylammonium fluoride (0.3 mmol) and azidotrimethylsilane (0.8 mmol) in THF (2 mL). After 30 min. the reactions are drained and the resins washed with CH<sub>2</sub>Cl<sub>2</sub> then dried *in vacuo*. Each sample is then reacted with 4-chloro-7-nitrobenzofurazan (NCB-Cl, 0.5 mmol) in a 1:1 v/v mixture of DMF and EtOH for 1 h at 65-70 °C. The samples are cooled, washed with DMF, MeOH and CH<sub>2</sub>Cl<sub>2</sub> and dried *in vacuo*. Each resin aliquot is finally treated for 1 h with 1 mL of a 1:1 v/v mixture of TFA and CH<sub>2</sub>Cl<sub>2</sub> to cleave the NBD-containing dipeptides from resin. The 200 samples are dried *in vacuo*.

### 3. Sub-library C

As illustrated in Fig. 14, a 1 g sample of Wang resin loaded with α-N-Fmoc-β-N-Boc-diaminopropionic acid (at 1 mmol/g) is treated with 20% piperidine in DMF for 20 min (followed by washing with DMF (3x) and CH<sub>2</sub>Cl<sub>2</sub>), then divided into 10 equally sized aliquots for coupling to 0.5 mmol of one of the 10 following protected amino acids: Boc-Gly, Boc-Ala, Boc-Val, Fmoc-Pro, Boc-Ser(O<sup>t</sup>Bu), Boc-Asn, Boc-Glu(O<sup>t</sup>Bu), Boc-Lys(Boc), Boc-Phe, Boc-His(Boc); in DMF solutions (2 mL) containing HOBt (0.75 mmol), DIEA (0.6 mmol) and DIC (0.75 mmol). After agitating the reaction mixtures for 12 h the resins are filtered and washed with DMF, MeOH and CH<sub>2</sub>Cl<sub>2</sub> then dried *in vacuo*. Each sample is next treated with a solution of tetrakis(triphenylphosphine)-palladium(0) (0.02 mmol) in THF (2 mL) followed by addition of tetrabutylammonium fluoride (0.3 mmol) and azidotrimethylsilane (0.8 mmol) in THF (2 mL). After 30 min. the reactions are drained and



the resins washed with  $\text{CH}_2\text{Cl}_2$  then dried *in vacuo*. Each sample is then reacted with 4-chloro-7-nitrobenzofurazan (NCB-Cl, 0.5 mmol) in a 1:1 v/v mixture of DMF and EtOH for 1 h at 65-70 °C. The samples are cooled, washed with DMF, MeOH and  $\text{CH}_2\text{Cl}_2$  and dried *in vacuo*. Each resin aliquot is finally treated for 1 h with 1 mL of a 1:1 v/v mixture of TFA and  $\text{CH}_2\text{Cl}_2$  to cleave the NBD-containing dipeptides from resin. The 10 samples are dried *in vacuo*.

## II. Screening Sub-Libraries

The various sub-libraries prepared according to the foregoing procedures can then be screened for activity with the transport protein hPEPT1 according to the methods and protocols described in the examples and specification above. Active compounds are isolated and characterized to identify chemical and/or structural motifs common to the active compounds. Such common features indicate elements that are important in conferring activity with PEPT1.

### EXAMPLE 5


#### Distinguishing Between Inhibitors (Surface-bound Complexes) and Substrates – Internally Quenched Reporters

Certain methods utilize complexes having the general structure R-X-Y-Q, where: X is an actively transported moiety (i.e., a substrate), R is a reporter that includes a fluorescent moiety, Q is a fluorescence quencher moiety (quencher), and Y is a linker, typically an enzymatically labile linker.


Such a complex can be prepared by covalent attachment of a fluorescent moiety (e.g., 2-aminobenzoic acid, 7-methoxycoumarin, etc.) (reporter) to the substrate backbone and attachment of a fluorescence quencher moiety (e.g., O-(2,4-dinitrophenyl)-ethylenediol, N-(2,4-dinitrophenyl)-ethylenediamine, etc.) (quencher) to the substrate backbone by any suitable enzymatically labile linker (e.g., ester, carbonate, carbamate, etc.). Such a compound is not significantly fluorescent due to intramolecular resonance energy transfer between the fluorescent moiety and the quencher. However, intracellular enzymatic cleavage of the labile linker results in loss of the quencher moiety, leading to increased fluorescence of the remaining substrate-reporter conjugate. Hence, such complexes can be used to demonstrate cellular uptake of the substrate moiety. Extracellular fluorescence is

generally negligible. A statistically significant increase in fluorescence indicates cellular uptake of the complex and cleavage of the labile linker, thereby releasing the quencher from the reporter to produce the increase in fluorescence.

One example of a suitable conjugate is shown below. This particular conjugate uses 2-aminobenzoic acid as the reporter, O-(2,4-dinitrophenyl)-ethylenediol as the quencher, and contains an esterase labile linker; :



A second suitable conjugate uses 7-methoxycoumarin as the reporter and O-(2,4-dinitrophenyl)-ethylenediol as the quencher, with an esterase labile linker:



#### EXAMPLE 6

Distinguishing Between Inhibitors (Surface-bound Complexes)  
and Substrates -- Reporter Binding to Intracellular Agent

This assay utilizes a “conditional” reporter or tag in which the reporter includes a DNA-binding dye that is not fluorescent until it is transported into the cell by the transporter of interest. Upon entry into the cell, the reporter, either with or without being  
5 cleaved from the rest of the complex by intracellular hydrolases, is available to interact with the DNA in the nucleus of the cell. The method is performed as follows:

Day 1: Seed transporter-expressing cells at 100K/well into clear bottom black 96-well tissue culture treated plates.

10 Day 2: Wash cells 2x with 100 µl appropriate buffer.  
Add 50 µl of various concentrations of compounds dissolved in buffer or buffer alone to each well.

Incubate 1 hr. at RT.

Wash each well 4x with 100 µl/well buffer at 4 °C.

15 Add 50 µl/well buffer.

Determine the amount of fluorescent substrate transported by measuring Fluorescent Units (FU) in wells using the Tecan Spectrafluor instrument, measuring from the bottom of the well and using appropriate excitation and emission wavelengths for the particular dyes employed.

20 CHO K1 cells are used as control for non-transporter dependent transport.

A wide variety of DNA-binding fluorophores can be utilized. The dyes should be cell impermeant so that only when the dye is transported into the cell is the dye available for binding to the cellular DNA. Exemplary cell-impermeant dyes include, but are not  
25 limited to, SYTOX Blue, SYTOX Green, SYTOX Orange, POPO-1, BOBO-1, YOYO-1, TOTO-1, JOJO-1, POPO-3, LOLO-1, BOBO-3, YOYO-3, TOTO-3, PO-PRO-1, BO-PRO-1, YO-PRO-1, TO-PRO-1, JO-PRO-1, PO-PRO-3, LO-PRO-3, BO-PRO-3, YO-PRO-3, TO-PRO-3, TO-PRO-5, all of which are commercially-available from Molecular Probes.

### 30 EXAMPLE 7

Distinguishing Between Inhibitors (Surface-bound Complexes)  
and Substrates -- Reporter Includes Substrate for Intracellular Enzyme

Another approach for selective detection of complexes that have been internalized through the action of a transport protein is for the complex to include a substrate for an enzyme that resides within the cells utilized in the assay. As indicated *supra*, the reporter can include a substrate for a number of different enzymes. The following examples describe methods in which the reporter comprises luciferin, a substrate for luciferase, which enzyme is expressed intracellularly from an exogenous expression cassette.

#### I. Transfection and Selection of Luciferase Clones

CHO K1 cells ( $10^7$ /ml) were transfected by electroporation (400V, 250  $\mu$ farads) with 40  $\mu$ g of pcDNA3 luciferase with zeocin as the selectable marker (pcDNA3.1/zeo(+)-Luc (see Fig. 15). After allowing two days for integration of the DNA into the cellular genome, zeocin (0.6 mg/ml) was added. The cells were selected for ten days. The selected population was then cloned using a Cytomation MoFlo flow cytometer gated on the live cell population (forward vs. side scatter). The resultant clones were transferred to replica plates and assayed for luciferase activity. Several clones with high and medium levels of expression were selected for long-term stability studies in the absence of zeocin. Selected clones can be used for expressing transporters that can be selected using an additional selectable marker.

#### II. Isolation of Clonal Cell Lines Constitutively Expressing Luciferase

Day 1: Cloned cells to be assayed were seeded at 100K cells/well in black clear-bottom 96-well plates. Replica plates were made in clear 96-well plates for use in protein determination assays.

Day 2: Media was removed from wells and cells were washed 2x with 100  $\mu$ l/well of PBS.

For luciferase assays:

100  $\mu$ l per well of commercially-available luciferase detection reagent was added to each well (e.g., Steady-Glo (Promega) or Luc-lite (Packard))

The plate containing the cells was shaken for 5 minutes on a plate mixer

Luminescence was detected by reading on a Wallac microbeta scintillation/luminescence microplate reader.

For protein assays:

Cells were solubilized in 30  $\mu$ l/well of 0.1 NaOH. 10  $\mu$ l of this solution was removed to a fresh plate and mixed with 200  $\mu$ l of a 1:5 dilution of BioRad protein assay dye.

After 5 min, absorbance was read at 595 on the Tecan plate reader.

5

Luminescence from each well was normalized for amount of protein determined in each well. A number of cell lines that efficiently expressed luciferase were identified according to this protocol.

## 10 II. General Assay Protocol

Day 1: Cells expressing luciferase and transporter of interest are seeded at 100K/well in black or white clear-bottom 96-well plates.

Day 2: Cells are washed 2x with 100  $\mu$ l/well of the appropriate buffer for the transporter being studied (HBSS for bile acid, pH 6.0 buffer for PEPT1).

15 Luciferin-tagged compounds at various concentrations are added in 50  $\mu$ l assay buffer to the wells and the plate is incubated at RT or at 37  $^{\circ}$ C.

Plates are read on the Wallac Microbeta scintillation/luminescence microplate reader every 20 mins for up to two hours to monitor increase in luciferase-generated light production.

20 To increase signal by providing excess ATP and Coenzyme A, necessary cofactors for the luminescence assay, 100  $\mu$ l of assay buffer (made fresh daily) is added to the wells, and the plate is monitored as above on the microplate reader. The assay buffer includes: 0.1 M  $\text{KHPO}_4$ , 1 mM DTT, 2 mM EDTA, 30 mM Tricine, 15 mM  $\text{MgSO}_4$ , 3 mM ATP, 10 mM DTT and 1 mM CoA.

25 As a positive control to monitor luciferase enzyme activity in lysed cells, 1% Triton X-1000 and 1 mM luciferin is added to the above buffer and plates read as above.

## IV. Synthesis of Luciferin Conjugated Substrates for PEPT1

30 The main steps in a method for synthesizing a dipeptide conjugated to luciferin (referred to as GP5-71) is set forth in Fig. 16. To a 100 mL round-bottom flask was added asparagine t-butyl ester hydrochloride (675 mg), DIEA (0.52 mL, 1 eq) and dichloromethane (10 mL).  $\alpha$ -N-Boc- $\beta$ -N-Fmoc diaminopropionic acid (1.28 g, 1 eq) and DIC (0.47 mL, 1 eq) were added and the mixture stirred at room temperature for 16 h. The reaction mixture was diluted with dichloromethane (30 mL) and extracted with 1M HCl

solution (2 x 10 mL) then saturated sodium bicarbonate solution (2 x 10 mL). The organic layer was dried over anhydrous sodium sulfate and the solvent removed *in vacuo*. 20% piperidine in DMF (5 mL) was added and the reaction mixture stirred at room temperature for 5 min. The solvent was removed *in vacuo* and column chromatography on silica gel gave the pure dipeptide product (1.0 g, 89% yield based on asparagine t-butyl ester hydrochloride).

This product was dissolved in dichloromethane (10 mL) and 6-tetrahydropyranoxy-hexanoic acid (0.58 g, 1 eq) and DIC (0.42 mL, 1 eq) were added. The mixture was stirred at room temperature for 16 h, then diluted with dichloromethane (30 mL) and extracted with 1M HCl solution (2 x 5 mL) then saturated sodium bicarbonate solution (2 x 5 mL). The organic layer was dried over anhydrous sodium sulfate and the solvent removed *in vacuo*. Methanol (10 mL) and pyridinium *p*-toluenesulfonate (60 mg) were added to this residue, the reaction mixture was heated at 60 °C for 2 h, and the solvent removed *in vacuo*. The residue was dissolved in dichloromethane (20 mL) and shaken with saturated sodium bicarbonate solution (2 mL). The organic layer was dried over anhydrous sodium sulfate and the solvent removed *in vacuo*. Column chromatography on silica gel gave the dipeptide alcohol (636 mg, 49% yield based on 6-tetrahydropyranoxyhexanoic acid).

To a sample of the above alcohol (100 mg) in dichloromethane (2 mL) was added a mixture of D-(-)-2-(6'-hydroxy-2'-benzothiazolyl)-thiazoline-4-carboxylic acid (i.e. D-luciferin) (86 mg, 1.5 eq), 2,6-dichlorobenzoyl chloride (0.029 mL, 3 eq) and pyridine (0.066 mL, 4 eq) in DMF (3 mL). The reaction mixture was stirred at room temperature for 18 h, then diluted with dichloromethane (20 mL) and extracted with 1M HCl solution (2 x 3 mL) then saturated sodium bicarbonate solution (1 x 3 mL). The organic layer was dried over anhydrous sodium sulfate and the solvent was removed *in vacuo*. The luciferin-peptide conjugate was isolated after preparative TLC purification and treated with TFA (5 mL) at room temperature for 4 h. The solvent was removed *in vacuo* and the product purified by preparative HPLC to afford the desired luciferin-conjugated dipeptide GP5-71 (36 mg, 30% yield based on starting alcohol). Electrospray mass spectrometry showed the expected molecular ion at  $m/z = 595$  ( $M+H^+$ ).

#### V. Synthesis of Luciferin-Conjugated Substrates for Intestinal or Liver Bile Acid Transport Protein

The following synthesis for a luciferin conjugate of glycocholic acid (referred to as CZ15-73) is shown in Fig. 17. Glycocholic acid *tert*-butyl ester: Cholic acid (408 mg, 1 mmol) was dissolved in dry THF (20 mL) in a 100 mL round-bottom flask provided with a

magnetic stirrer. DIC (157  $\mu$ L, 1 mmol) was added and after 10 minutes, a solution of glycine *tert*-butyl ester hydrochloride (167 mg, 1 mmol) and DIEA (174  $\mu$ L, 1 mmol) in dry THF (30 ml) was added dropwise, followed by a catalytic amount of 4-dimethylaminopyridine (10 mg). The reaction mixture was stirred at room temperature for 18 h. Solvent removal *in vacuo* afforded the crude product, which was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (100 mL) and washed with brine (2 x 15 mL). The organic phase was dried over MgSO<sub>4</sub> and concentrated to give the crude product, which was purified by flash chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 95:5) to give pure glycocholate ester (470 mg, 90% yield). Electrospray mass spectrometry showed the expected molecular ion at  $m/z = 522$  (M+H<sup>+</sup>).

6-Tetrahydropyranoxyhexanoic acid: A solution of ethyl 6-hydroxyhexanoate (162  $\mu$ L, 1 mmol), 3,4-dihydro-2H-pyran (137  $\mu$ L, 1.5 mmol) and pyridinium *p*-toluenesulfonate (25 mg, 0.1 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was stirred at room temperature for 4 h. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and washed with brine (2 x 5 mL). The organic phase was dried over MgSO<sub>4</sub> and the solvent removed *in vacuo*. The residue was treated with aqueous 0.5 M NaOH (10 mL) and MeOH (10 mL) at 55 °C for 2 h. After removal of MeOH and washing with CH<sub>2</sub>Cl<sub>2</sub> (10 mL), the aqueous phase was acidified with citric acid. Extraction with ether (3 x 15 mL) and concentration of the organic phase gave the protected hexanoic acid product (216 mg, 100% yield). Electrospray mass spectrometry showed the expected molecular ion at  $m/z = 215$  (M-H<sup>-</sup>). This material was used in the next reaction without further purification.

To a solution of 6-tetrahydropyranoxyhexanoic acid (216 mg, 1 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added pyridine (97  $\mu$ L, 1.2 mmol) followed by 2,6-dichlorobenzoyl chloride (143  $\mu$ L, 1 mmol). After 10 min. a solution of glycocholic acid *tert*-butyl ester (418 mg, 0.8 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added dropwise. The reaction mixture was heated to 50 °C with stirring. Additional pyridine/2,6-dichlorobenzoyl chloride (in ratio 1.2:1) was added in several small portions until a trace amount of di-ester was detected by TLC. (TLC analysis: eluent CH<sub>2</sub>Cl<sub>2</sub>-MeOH 97:3). The reaction mixture was washed with saturated sodium bicarbonate solution (10 mL) and saturated citric acid solution (2 x 10 mL). The organic phase was dried over MgSO<sub>4</sub> and concentrated *in vacuo* to give the crude ester, which was purified by flash chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>-MeOH 97:3) to give the pure 3-(6-tetrahydropyranoxyhexanoyl)-glycocholic acid *tert*-butyl ester product (230 mg, 32% yield). Electrospray mass spectrometry showed the expected molecular ion at  $m/z = 742$  (M+Na<sup>+</sup>).

The THP group from the above ester (230 mg, 0.32 mmol) was removed by treatment with pyridinium *p*-toluenesulfonate (8 mg, 0.032 mmol) in ethanol (10 mL) at 55 °C for 4 h. The solvent was removed *in vacuo*, and the residue chromatographed on a silica gel column to afford the pure alcohol product (159 mg, 78% yield). Electrospray mass spectrometry showed the expected molecular ion at  $m/z = 636$  ( $M+H^+$ ).

To a solution of D-luciferin (50 mg, 0.18 mmol) in dry THF (5 mL) containing pyridine (18  $\mu$ L, 0.22 mmol) was added 2,6-dichlorobenzoyl chloride (26  $\mu$ L, 0.18 mmol). After stirring for 10 min. a solution of the above alcohol (117 mg, 0.18 mmol) in dry  $CH_2Cl_2$  (5 mL) was added dropwise. The reaction mixture was further stirred at room temperature for 48 h. Additional pyridine/2,6-dichlorobenzoyl chloride (in ratio 1.2:1) was added in several small portions to drive the reaction to completion. (TLC analysis: eluent  $CH_2Cl_2$  - EtOAc 60:40). The reaction mixture was diluted with  $CH_2Cl_2$  (10 mL), then washed with saturated sodium bicarbonate solution (5 mL) and saturated citric acid solution (2 x 5 mL). The organic phase was dried over  $MgSO_4$  then concentrated to give the crude luciferin conjugate, which was purified by using a silica solid phase extraction (SPE) cartridge, eluting sequentially with  $CH_2Cl_2$  (50 mL), 20% EtOAc/ $CH_2Cl_2$  (50 mL), 40% EtOAc/ $CH_2Cl_2$  (50 mL), 60% EtOAc/ $CH_2Cl_2$  (50 mL), and 80% EtOAc/ $CH_2Cl_2$  (50 mL). The *tert*-butyl ester product was collected in the 80% EtOAc/ $CH_2Cl_2$  fraction, which upon concentration *in vacuo* gave the desired thiazoline product (118 mg, 73% yield) contaminated with 30% (by weight) of the oxidized thiazole adduct. Electrospray mass spectrometry showed the expected molecular ion at  $m/z = 898$  ( $M+H^+$ ) for the thiazoline and  $m/z = 896$  ( $M+H^+$ ) for the oxidized thiazole product.

This *tert*-butyl ester (118 mg, 0.13 mmol) was treated with a mixture of trifluoroacetic acid/ $CH_2Cl_2$ / $H_2O$  (50:49:1, 5 mL) at room temperature for 4 h. After removal of solvent *in vacuo*, the resulting residue was treated with 50% piperidine in  $CH_2Cl_2$  at room temperature for 30 min. The solvent was removed *in vacuo* and the residue dissolved in  $CH_2Cl_2$  (10 mL) and extracted with saturated sodium bicarbonate solution (20 mL). The aqueous phase was collected, acidified with citric acid then extracted again with EtOAc (3 x 20 mL). The combined organic phases were dried over anhydrous sodium sulfate and concentrated *in vacuo*. The desired luciferin-glycocholate ester product CZ15-73 was isolated by preparative TLC (eluent: 5% HOAc/EtOAc), and further purified by preparative HPLC (column: Phenomenex, luna C18; mobile phase:  $H_2O$ /MeOH) to give the pure conjugate (18



mg, 22% yield). Electrospray mass spectrometry showed the expected molecular ion at  $m/z = 842$  ( $M+H^+$ ).

## VI. Synthesis and Screening of Library of Bile Acid-Luciferin Conjugates

### A. Synthesis

A method for synthesizing a library of bile acid-luciferin conjugates is shown in Fig. 18. To 0.5 g of Wang resin (Novabiochem) (loading  $\sim 1$  mmole/g) is added 5 mL of a DMF solution containing D-luciferin (Sigma) (2.5 mmol), HATU (2.5 mmol) and DIEA (5 mmol). The suspension is stirred for 8 h and the resin washed with DMF (3x). The resin is shaken for 30 min with 5 mL of a 0.2 M solution of potassium carbonate in 50% aqueous MeOH to hydrolyze any phenolic ester formed, and then washed with DMF,  $CH_2Cl_2$ , MeOH, and  $CH_2Cl_2$  again, then dried *in vacuo*. The resin is divided into 4 equal portions and then treated with 5 mL of a DMF solution containing 1 mmol of either (i) N- $\alpha$ -Fmoc-L-aspartic acid- $\alpha$ -*tert*-butyl ester, (ii) N- $\alpha$ -Fmoc-D-aspartic acid- $\alpha$ -*tert*-butyl ester, (iii) N- $\alpha$ -Fmoc-L-glutamic acid- $\alpha$ -*tert*-butyl ester or (iv) N- $\alpha$ -Fmoc-D-glutamic acid- $\alpha$ -*tert*-butyl ester, together with diisopropylcarbodiimide (DIC, 0.5 mmol) and DMAP (0.1 mmol). After stirring for 4 h, the resins are washed with DMF (3x).

Each batch of resin is next treated with 1 mL of a 5% (v/v) solution of DBU in DMF for 20 min then washed with DMF (3x),  $CH_2Cl_2$ , MeOH, and  $CH_2Cl_2$  again, then dried *in vacuo*. The four resin samples are each divided into five equal aliquots for coupling to one of five different bile acids (i.e. cholic acid, deoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid and lithocholic acid). These reactions contained 0.2 mmol of the bile acid in DMF (2 mL) with HATU (0.2 mmol) and DIEA (0.4 mmol), and after 4 h, the resins are washed with DMF (3x),  $CH_2Cl_2$ , MeOH, and  $CH_2Cl_2$  again, then dried *in vacuo*. Each of the 20 samples is cleaved from resin by treatment with 1 mL of a 50% (v/v) solution of TFA in  $CH_2Cl_2$  for 1 h, the resins washed with  $CH_2Cl_2$  (0.5 mL) and the filtrates evaporated to dryness using a Genevac concentrator.

### B. Screening of Bile Acid-Luciferin Conjugates

CHO cell lines expressing the human ileal sodium bile acid cotransporter transfected with a vector directing the expression of firefly luciferase are prepared as described in sections I and II of this example. A parental CHO-K1 cell line also expressing firefly luciferase is utilized as a negative control. The library of bile acid-luciferin conjugates synthesized in section VI.A of this example are screened according the protocol described in

section III of this example. Samples that give selective emission from the ABST-expressing cells are identified as substrates for the ileal bile acid cotransporter.

### EXAMPLE 8

#### 5                   Distinguishing Between Inhibitors (Surface-bound Complexes)                           and Substrates – Masked Fluorescent Dipeptides

                  The following methods describe approaches for synthesizing fluorescent dipeptides that can be utilized to study transport into a cell expressing the PEPT1 transport  
10           protein. The following compounds include a “masked” hydroxy-coumarin moiety; this masking moiety is cleaved from the compound by an intracellular esterase to yield a hydroxy-coumarin derivative that fluoresces strongly.

#### I.       Synthesis of the Conditionally Fluorescent Dipeptide GP5-75-2

15                   The major steps in synthesizing this “masked” dipeptide are shown in Fig. 19. To a 100 mL round-bottomed flask was added asparagine t-butyl ester hydrochloride (675 mg), DIEA (0.52 mL, 1 eq) and dichloromethane (10 mL).  $\alpha$ -N-Boc- $\beta$ -N-Fmoc  
                  diaminopropionic acid (1.28 g, 1eq) and DIC (0.47 mL, 1 eq) were added and the mixture stirred at room temperature for 16 h. The reaction mixture was diluted with dichloromethane  
20           (30 mL) and extracted with 1M HCl solution (2 x 10 mL) then saturated sodium bicarbonate solution (2 x 10 mL). The organic layer was dried over anhydrous sodium sulfate and the solvent removed *in vacuo*. 20% piperidine in DMF (5 mL) was added and the reaction  
                  mixture stirred at room temperature for 5 min. The solvent was removed *in vacuo* and column chromatography on silica gel gave the pure dipeptide product (1.0 g, 89% yield based  
25           on asparagine t-butyl ester hydrochloride).

                  7-Acetoxycoumarin-3-carboxylic acid (51 mg) was dissolved in dichloromethane (2 mL) containing triethylamine (43  $\mu$ L, 1.5 eq) and the reaction mixture cooled to 0 °C. Ethyl chloroformate (20  $\mu$ L) in dichloromethane (0.5 mL) was added, and  
                  after stirring at 0 °C for 10 min, this solution was added to a sample of the above dipeptide  
30           (76 mg, 1eq). After stirring at 0 °C for 30 min, the reaction mixture was diluted with dichloromethane (10 mL) and extracted with 1M HCl solution (2 mL) then saturated sodium bicarbonate solution (2 mL). The organic layer was dried over anhydrous sodium sulfate and the solvent removed *in vacuo*. Acetic anhydride (2 mL) and pyridine (2 mL) were added to

this residue and after stirring at room temperature for 20 min., the solvent was again removed *in vacuo*. The protected conditionally fluorescent dipeptide was purified by preparative TLC and then treated with TFA (3 mL) for 4 h. Solvent was removed *in vacuo* to afford the conditionally fluorescent dipeptide GP5-75-2. Electrospray mass spectrometry showed the expected molecular ion at  $m/z = 449$  ( $M+H^+$ ).

## II. Synthesis of the Conditionally Fluorescent Dipeptide GP5-77

The synthesis of this masked dipeptide is set forth in Fig. 20. To a 100 mL round-bottomed flask was added asparagine t-butyl ester hydrochloride (564 mg), DIEA (1.04 mL, 2 eq) and dichloromethane (20 mL). N-Boc-Cys-OH (660 mg, 1 eq) and HATU (1.14 g, 1 eq) were added and the mixture stirred at room temperature for 16 h. The reaction mixture was diluted with dichloromethane (30 mL) and extracted with 1M HCl solution (2 x 10 mL) then saturated sodium bicarbonate solution (2 x 10 mL). The solvent was removed *in vacuo* and column chromatography on silica gel gave the pure dipeptide product (1.04 g, 89% yield based on asparagine t-butyl ester hydrochloride).

A sample of the above dipeptide (250 mg) was dissolved in DMF (2 mL) and 7-acetoxy-4-(bromomethyl)-coumarin (190 mg) added. The mixture was heated at 60 °C for 14 h and the solvent was removed *in vacuo*. The protected conditionally fluorescent dipeptide was purified by column chromatography on silica gel and then treated with TFA (2 mL) for 5 h. Solvent was removed *in vacuo* to afford the conditionally fluorescent dipeptide GP5-77. Electrospray mass spectrometry showed the expected molecular ion at  $m/z = 452$  ( $M+H^+$ ).

## III. Synthesis of the Conditionally Fluorescent Dipeptide GP5-00

A sample of the protected dipeptide prepared as just described in section II of this example (93 mg) was stirred in MeOH (5 mL) with potassium carbonate (30 mg, 1.1 eq) at room temperature for 2 h (see Fig. 21). The solvent was removed *in vacuo* and dry DMF (5 mL) and additional potassium carbonate (30 mg, 1.1 eq) added to the residue. Bromomethyl acetate (30 mg, 1eq) in dry DMF (1 mL) was added dropwise and the reaction mixture stirred at room temperature for 4 h. The solvent was removed *in vacuo* and the residue dissolved in dichloromethane and shaken with saturated sodium bicarbonate solution (2 mL). The organic layer was dried over anhydrous sodium sulfate and the protected conditionally fluorescent dipeptide purified by column chromatography on silica gel. The

product was treated with TFA (1 mL) for 1h and the solvent removed *in vacuo* to afford the conditionally fluorescent dipeptide GP5-00. Electrospray mass spectrometry showed the expected molecular ion at  $m/z = 482$  ( $M+H^+$ ).

5

### EXAMPLE 9

#### Distinguishing Between Inhibitors (Surface-bound Complexes) and Substrates – Detection by Microscopy

Day 1: Seed CHO hPEPT1 cells at 100K/well into clear bottom black 96-well  
10 tissue culture treated plates.

Day 2: Wash cells 2x with pH 6.0 buffer (1 mM  $CaCl_2$ , 1 mM  $MgCl_2$ , 150 mM NaCl, 3 mM KCl, 1 mM  $NaH_2PO_4$ , 5 mM D-glucose and 5 mM MES) at RT.

Add 50  $\mu$ l of 1 mM XP10486 (NBD-labeled DAP-Asn dipeptide) in pH 6.0 buffer to cells.

15 Incubate 1 hr at RT. Wash 2x 100  $\mu$ l/well with pH 6.0 buffer at 4 °C. Add 100  $\mu$ l/well of the same buffer, let sit for 10 min. at RT. Wash 2x 100  $\mu$ l/well with pH 6.0 buffer at 4 °C. This washing procedure helps minimize the non-specific adherence of fluorescent compounds to the outside of the cells.

Add 50  $\mu$ l of 10  $\mu$ g/ml of Texas Red-labeled Wheat-germ agglutinin (in HBSS  
20 buffer) to cells and incubate at 4 °C for 30 min. This reagent binds to the glycosylated proteins on the surface of the cells.

Wash cells 2x with 100  $\mu$ l/well with HBSS buffer at 4 °C. Add 50  $\mu$ l of cold HBSS buffer to each well.

25 Image each well with the Universal Imaging Automated Fluorescent Microscope System with a 10x objective using appropriate excitation and emission filters for the two fluorophores.

Untransfected CHO K1 cells used as control for non-transporter dependent transport.

30

### EXAMPLE 10

#### Reporter as Surrogate for Pharmaceutical Agent

The screening methods described herein provide a way to screen for activity of conjugates between substrates and pharmaceutical agents with particular transport proteins

without having to develop a specific screen for the pharmaceutical agent of interest. In screening methods utilizing reporter-substrate complexes, the reporter can be viewed as serving as a surrogate for a wide variety of pharmaceutical agents. Initially screening complexes with reporter rather than pharmaceutical agent has the advantage that the reporter is easily detectable whereas the pharmaceutical agent frequently is not. Once it has been demonstrated that a complex including a reporter is a substrate for a transport protein, a pharmaceutical agent (typically having similar physical and chemical characteristics) can be substituted for the reporter and activity retested.

The following syntheses (syntheses I.A., I.B. and I.C.) illustrate the application of this concept. Conjugation of the NBD reporter group to the epsilon amino group of cholyl-Lysine generates a fluorescent substrate (synthesis I.A. below) for the intestinal bile acid transporter that is effectively absorbed orally in rat. The analogous compound in which the NBD moiety is replaced by the anti-inflammatory pharmaceutical agent Naproxen (as an epsilon carboxamide; synthesis I.B. below) affords a conjugate that also serves as a bile acid substrate, and upon oral absorption is hydrolyzed (by some uncharacterized amidase activity) to release the parent naproxen. This observation can be further extended to provide an oral propharmaceutical agent of the anti-Parkinson's agent L-Dopa, where the structural analogy between NBD-Lysine and L-Dopa (another  $\alpha$ -amino acid) indicates a strategy for conjugating the pharmaceutical agent to cholic acid to afford an orally absorbed substrate of the bile acid transporter (see synthesis I.C.).

Once the reporter is substituted with a pharmaceutical agent, techniques for detecting transport of the substrate/pharmaceutical agent are needed because, as just noted, often the pharmaceutical agent is not readily detectable. Sections II.A. and II.B. of this example describe two approaches that permit the facile detection of substrate/pharmaceutical agents that have been internalized within a cell. One approach utilizes a liquid chromatography (LC) and mass spectroscopy (MS) to detect transport, more specifically LC/MS/MS (section II.A.). A trans-stimulation approach can also be used; this technique is described *supra*, illustrated in Fig. 4 and described further in Example 11.

I. Synthesis of Complexes in which Pharmaceutical Agent is Substituted for Reporter  
A. Synthesis of Cholyl-Lysine-( $\epsilon$ -NBD)-OH

Fig. 22 depicts the major steps in the synthesis of this complex that includes the NBD reporter. Cholic acid (408 mg, 1 mmol) was dissolved in dry THF (20 mL) in a 100

mL round-bottom flask provided with a magnetic stirrer. DIC (157  $\mu$ L, 1 mmol) was added and after 10 min., a solution of lysine- $\epsilon$ -N-Fmoc-*tert*-butyl ester hydrochloride (410 mg, 1 mmol) and DIEA (174  $\mu$ L, 1 mmol) in dry THF (30 mL) was added dropwise. The reaction mixture was stirred at room temperature for 18 h. The solvent was removed *in vacuo* and the residue dissolved in  $\text{CH}_2\text{Cl}_2$  (100 mL) and washed with brine (2 x 15 mL). The organic phase was dried over  $\text{MgSO}_4$  and concentrated to give the crude product, which was purified by flash chromatography on silica gel ( $\text{CH}_2\text{Cl}_2$ -MeOH 95:5) to give pure protected cholyl-lysine conjugate (720 mg, 90% yield). The product was treated with 20% v/v piperidine in DMF (5 mL) for 20 min. and the solvent removed *in vacuo*. The residue was treated with 4-chloro-7-nitrobenzofurazan (NCB-Cl, 0.22 g, 1.1 eq) in ethanol (15 mL) at 55  $^\circ\text{C}$  for 1 h, then cooled to room temperature and the solvent was removed *in vacuo*. The protected NBD conjugate was purified by chromatography on silica gel then treated in 1:1 v/v TFA/ $\text{CH}_2\text{Cl}_2$  for 1 h at room temperature. The solvent was removed *in vacuo* to afford cholyl-lys-( $\epsilon$ -NBD)-OH (550 mg, 80% yield). Electrospray mass spectrometry showed the expected molecular ion at  $m/z = 686$  ( $\text{M}+\text{H}^+$ ).

#### B. Synthesis of Cholyl-Lysine-( $\epsilon$ -Naproxen)-OH

Fig. 23 shows the primary steps in preparing this complex in which the pharmaceutical agent Naproxen is substituted for NBD reporter. Cholyl-Lys-( $\epsilon$ -Fmoc)-O<sup>t</sup>Bu (400 mg, 0.5 mmol) prepared as described above is treated with 20% v/v piperidine in DMF (5 mL) for 20 min. and the solvent removed *in vacuo*. The residue is dissolved in dichloromethane (10 mL) and a solution containing DIC (80  $\mu$ L, 0.5 mmol), naproxen (127 mg, 0.5 mmol) and DIEA (87  $\mu$ L, 0.5 mmol) in dichloromethane (10 mL) is added dropwise. The reaction mixture is stirred at room temperature for 18 h and the solvent removed *in vacuo*. The product is purified by column chromatography on silica gel and then treated with a 1:1 v/v mixture of TFA/ $\text{CH}_2\text{Cl}_2$  (5 mL) for 1 h. The solvent is removed *in vacuo* to afford pure cholyl-lysine-( $\epsilon$ -naproxen)-OH (280 mg, 75% yield). Electrospray mass spectrometry shows the expected molecular ion at  $m/z = 749$  ( $\text{M}+\text{H}^+$ ).

#### C. Synthesis of Cholyl L-Dopa

This compound is synthesized according to the steps shown in Fig. 24. Cholic acid (10 mmol) is dissolved in dry dioxane (100 mL) containing tri-*n*-butylamine (20 mmol), cooled to 0  $^\circ\text{C}$ , and ethyl chloroformate (10 mmol) added dropwise. After stirring for 20 min a solution of L-Dopa (20 mmol) in 2 M aqueous NaOH (10 mL) is slowly added and the

mixture warmed to room temperature with stirring for 2 h. The mixture is poured into water (200 mL), neutralized with 1M aqueous HCl, and extracted thoroughly with ethyl acetate containing 5% (v/v) methanol. The organic layer is dried over MgSO<sub>4</sub> and chromatographed on silica gel to afford the pure choly-L-Dopa.

5

### EXAMPLE 11

#### Detecting Internalization of Complexes that Lack Reporters

##### I. Determination of Complex Internalization by LC/MS/MS

10 Control CHO K1 cells or PEPT1-transfected, epitope-tagged CHO EE 412 cells (Covitz, et al., (1998) *Biochemistry* 37:15214-15221) (100,000 cells per well) were exposed to 50 µL of 200 µM Gly-Sar in pH 6.0 buffer (1 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 150 mM NaCl, 3 mM KCl, 1 mM NaH<sub>2</sub>PO<sub>4</sub>, 5 mM D-glucose and 5 mM MES) for 0, 10, 20, 30, 40, 50, 60, 70, 80 minutes. Cells were washed twice with 100 µL of pH 6.0 buffer to remove  
15 extracellular Gly-Sar. Washed cells were then lysed before analysis by addition of 100 µL of water followed by sonication for 5 min. A standard curve was constructed in blank (untreated) lysed cells. A stock solution of Gly-Sar (1 M) was prepared in HPLC grade water and diluted 1:100 to provide a 10 mM working stock solution. This solution was further diluted to 10 µM solution using water. A serial dilution of 1:2 was then performed to  
20 produce final standard solutions with Gly-Sar concentrations ranging from 0.039 to 10 µM.

One hundred microliters of each of these standards were added to a 96 well plate containing blank CHO K1 cells or blank CHO EE 412 cells (100,000 cells per well) followed by sonication for 5 min to lyse the cells. All lysed cell samples (treated and control) were then transferred to 200 µL vials and analyzed using an API 2000 LC/MS/MS system  
25 (PE Sciex) equipped with a TurboIonSpray source, an Model 1100 binary pump system (Agilent), and temperature controlled autosampler. The analytical column was a BDS Hypersil 2\*50 mm column (Keystone) heated to 45 °C. The mobile phase consisted of 0.1% formic acid in water (A) and acetonitrile/0.1% formic acid (B). The gradient condition was 5% B for 1 min, increasing to 90% B over 0.2 min, maintained for 2.8 min, and returning to  
30 5% B for 2 min. The analysis was performed in positive ion mode and an MRM transition of 147/90 was used to selectively detect Gly-Sar. The injection volume was 10 µl.

The resulting chromatograms were integrated using Analyst™ quantitation software (PE Sciex). The analytical method was linear over the Gly-Sar concentration range

of 3.9 pmoles/ $10^5$  cells to 1 nmole/ $10^5$  cells. The detection limit was 3.9 pmoles/ $10^5$  cells (0.39 pmoles on-column). Results are shown in Fig. 25 and demonstrate the ability to monitor uptake of substrate lacking reporter into the cells.

5 II. Detection of Complex Internalization by Trans-Stimulation

A. Protocol

1. Plate cells expressing IBAT, LBAT, or PEPT1 in 96-well white clear bottom plates (100,000 cells/well). Let attach overnight.

10 2. Wash cells 2X with HSBS (bile acid) or pH 6.0 buffer (PEPT1)-no serum.

3. Load cells with  $^3\text{H}$  labeled substrates (bile acids-taurocholate, 200,000 cpm/well- 2  $\mu\text{M}$  unlabeled taurocholate, in HSBS, 60 min., room temp.) or (PEPT1-GlySar, 200,000 cpm/well- 200  $\mu\text{M}$  unlabeled GlySar, in pH 6.0 buffer, 60 min., room temp.).

4. Wash cells 6-8X (over a total 10 min. period) with solutions from step 2.

15 5. Aspirate wash solution. Transfer solutions containing unlabeled test compounds to the pre-loaded cells using the Cybi-Well transfer apparatus (120  $\mu\text{L}$ /well).

6. Measure  $^3\text{H}$ -labeled substrate efflux at room temperature. Remove 40  $\mu\text{L}$  from each well using the Cybi-Well transfer apparatus (at 10 minutes and 15 minutes) for scintillation counting. Also measure radioactive substrates remaining in the cells. Normalize  
20 efflux to the total amount of uptake (CPM efflux + CPM remaining in cells) to control for well-to-well variability in cell number.

7. For both bile acid and peptide transporters, saturating concentrations of unlabeled transported substrates in the medium during the efflux assay stimulate release of  $^3\text{H}$ -labeled compounds by 2-3 fold. Non-transported antagonists do not stimulate efflux.

25

B. Results

Results for trans-stimulation assays conducted with CHO cells expressing PEPT1 and contacted with tritiated Gly-Sar and unlabeled Gly-Sar are shown in Fig. 26A. The results shown in this figure show the efflux of tritiated Gly-Sar once the cells were  
30 contacted with various concentrations of untritiated Gly-Sar. Similar experimental results performed with CHO cells expressing LBAT and contacted with tritiated taurocholate and unlabeled cholate analogs (either Gly-CDC-acid or Gly-CDC-ethyl ester) are presented in



Fig. 26B. In this experiment, the efflux of tritiated taurocholate is measured once the cells are contacted with untritiated taurocholate.

## EXAMPLE 12

### Assay of Uptake by Inhibition Assays

#### I. Protocol

An alternative to detecting internalization of signal generated from complexes that have been taken up into a cell to identify ligands for a transport protein is to determine whether a test complex inhibits internalization of a known substrate. A protocol by which such assays can be conducted is set forth in Example 2, sections III A and B.

Fig. 27A shows results of inhibition assays for CHO cells expressing the IBAT transporter conducted in the presence of varying concentrations of the known substrates cholic acid or taurocholate in the presence of a fixed concentration of the tritiated substrate taurocholate. The amount of labeled taurocholate bound to the cells is determined by scintillation counting. Fig. 27B shows results for related inhibition studies. In this case, CHO cells expressing PEPT1 are contacted with either of the known substrates Gly-Sar or Enalapril with tritiated Gly-Sar as inhibitor.

## EXAMPLE 13

### Particle-Based Library Screening Method for Cells Expressing Receptor-Type Transport Proteins

#### I. Screening a 400-Member Dipeptide Library on Fluorescent Nanoparticles

##### A. Split-Pool Synthesis of Library

Five mL of an aqueous suspension of 200 nm diameter red fluorescent amino-functionalized polystyrene nanoparticles (Molecular Probes) is centrifuged to pellet the particles, which are washed and resuspended in DMF (0.5 mL). To 1 mL of a DMF solution containing methoxy-PEG-propionic acid, MW 5000, (Shearwater Polymers) (0.1 mmol) and Boc- $\beta$ -Ala (0.02 mmol) is added HATU (0.12 mmol) and DIEA (0.24 mmol). This mixture is immediately added to the nanoparticles and the suspension shaken for 4 h. After centrifugation, the supernatant is removed and the pellet washed with DMF (3x) and Et<sub>2</sub>O. The nanoparticles are shaken with 2 mL of a 1:1 (v/v) mixture of TFA and MeCN for 1 h to remove the Boc protecting group from the PEGylated amino nanoparticles.

The particles are then divided into 20 equal aliquots and these are treated with solutions containing one of 20 different protected amino acids (0.5 mmol each) [i.e. Fmoc-Gly, Fmoc-Ala, Fmoc-Val, Fmoc-Leu, Fmoc-Ile, Fmoc-Met, Fmoc-Pro, Fmoc-Cys(Trt), Fmoc-Ser(O<sup>t</sup>Bu), Fmoc-Thr(O<sup>t</sup>Bu), Fmoc-Asn(Trt), Fmoc-Gln(Trt), Fmoc-Asp(O<sup>t</sup>Bu), Fmoc-Glu(O<sup>t</sup>Bu), Fmoc-Lys(Boc), Fmoc-Arg(Pmc), Fmoc-Phe, Fmoc-Tyr(O<sup>t</sup>Bu), Fmoc-His(Trt), Fmoc-Trp(Boc)] together with HATU (0.5 mmol) and DIEA (1 mmol) for 4 h. The resins are washed with DMF, Et<sub>2</sub>O, MeOH, and Et<sub>2</sub>O again, pooled together and then dried *in vacuo*. The particles are shaken with 1 mL of a 20% (v/v) solution of piperidine in DMF for 20 min, pelleted by centrifugation and washed with DMF (3x). The particles are then redivided into 20 equal aliquots and these are treated with solutions containing one of 20 different protected D-amino acids (0.5 mmol each) [i.e., Fmoc-Gly, Fmoc-D-Ala, Fmoc-D-Val, Fmoc-D-Leu, Fmoc-D-Ile, Fmoc-D-Met, Fmoc-D-Pro, Fmoc-D-Cys(Trt), Fmoc-D-Ser(O<sup>t</sup>Bu), Fmoc-D-Thr(O<sup>t</sup>Bu), Fmoc-D-Asn(Trt), Fmoc-D-Gln(Trt), Fmoc-D-Asp(O<sup>t</sup>Bu), Fmoc-D-Glu(O<sup>t</sup>Bu), Fmoc-D-Lys(Boc), Fmoc-D-Arg(Pmc), Fmoc-D-Phe, Fmoc-D-Tyr(O<sup>t</sup>Bu), Fmoc-D-His(Trt), Fmoc-D-Trp(Boc)] together with HATU (0.5 mmol) and DIEA (1 mmol) for 4 h. The resins are washed with DMF (3x). Each of the 20 pools is then treated with 1 mL of a 20% (v/v) solution of piperidine in DMF for 20 min, pelleted by centrifugation and washed with DMF, Et<sub>2</sub>O, MeOH, and Et<sub>2</sub>O again, and then dried *in vacuo*. Finally, the acid-labile side-chain protecting groups are removed by treatment of each pool with 1 mL of a 90:5:5 solution of TFA: H<sub>2</sub>O: Et<sub>3</sub>SiH. The dipeptide-functionalized nanoparticles are washed with MeCN, Et<sub>2</sub>O, MeOH, and Et<sub>2</sub>O again, and then dried *in vacuo*.

#### B. Screening for Cellular Uptake/Transcytosis of Surface-Decorated Fluorescent Nanoparticles

Caco-2 cells are cultured onto 1.2 cm diameter Costar Transwell-Clear filters at a density of  $5 \times 10^5$  cells/cm<sup>2</sup> for confocal fluorescence microscopy studies. For each pool of dipeptide-decorated nanoparticles prepared according to the procedure described in the immediately preceding section (i.e., section I.B of this example),  $\sim 10^6$  particles in 1 mL Hanks Balanced Salt Solution (HBSS) are added to the apical side of the monolayer at either 4 °C or 37 °C on an orbital shaker for 2 h. The cells are then rigorously washed with HBSS (3x) to remove non-adherent particles. The filters are counter-stained with FITC-labeled dihexadecanoylglycerolphosphoethanolamine to label the external cellular membranes, then the monolayers are washed and mounted apical-side to coverslip for confocal microscopy.

Optical sections of the Caco cells indicated a monolayer depth of ~ 20  $\mu$ m with fluorescent particles accumulating throughout the cytoplasm up to a depth corresponding to the basolateral membrane of the cells. Pools showing the greatest degree of nanoparticle uptake and/or basolateral trafficking are deconvoluted by synthesizing the corresponding 20 individual dipeptide-coated nanoparticle components, and retesting them in this assay.

#### EXAMPLE 14

##### Screening for Intestinal Absorption of Surface-Decorated Fluorescent Nanoparticles

Nanoparticles (2 mg in 0.1 mL water) from each pool of the dipeptide library displayed on fluorescent nanoparticles described supra in Example 13 are administered to Wistar rats by oral gavage daily over 5 days. The rats are starved overnight before each dose, with food being resumed 1 h later. After the final dose the animals are fasted overnight but allowed water to clear the gut of any unabsorbed nanoparticles. 2 mL of blood is collected into heparin-coated vials from each rat by cardiac puncture. The samples are centrifuged to pellet the particles and counted to quantitate the fraction of administered dose appearing in the systemic circulation. Pools showing the greatest degree of nanoparticle absorption are deconvoluted by synthesizing the corresponding 20 individual dipeptide-coated nanoparticle components, and retesting them in this assay.

#### EXAMPLE 15

##### Intestinal Absorption of Fluorescent Zanamivir Bile Acid Pro pharmaceutical Agents in Rats

##### I. Preparation of Library of Fluorescent Zanamivir Bile Acid Pro pharmaceutical agents of Type 1

Preparation of this library is summarized in Fig. 28. The influenza neuraminidase inhibitor Zanamivir is esterified at its carboxyl moiety with protected amino alcohols under standard conditions and elaborated to provide Zanamivir amino esters of general structure A. Wang resin loaded with a disulfide-protected form of cysteine is deprotected, and the resulting thiol resin reacted with various ortho-phthaldialdehydes in the presence of compounds A to give resin-bound fluorescent isoindole products. The Fmoc protecting group is removed with piperidine and cholic acid is coupled to the support under

standard conditions. Cleavage from the resin with TFA in  $\text{CH}_2\text{Cl}_2$  afforded a set of fluorescent bile acid pro pharmaceutical agents of the antiviral compound Zanamivir.

II. Preparation of Library of Fluorescent Zanamivir Bile Acid Pro pharmaceutical agents of Type 2

As shown in Fig. 29, the influenza neuraminidase inhibitor Zanamivir is esterified at its primary alcohol moiety with protected amino acids under standard conditions and elaborated to provide Zanamivir amino esters of general structure B. Wang resin loaded with a disulfide-protected form of cysteine is deprotected, and the resulting thiol resin reacted with various ortho-phthaldialdehydes in the presence of compounds B to give resin-bound fluorescent isoindole products. The Fmoc protecting group is removed with piperidine and cholic acid is coupled to the support under standard conditions. Cleavage from the resin with TFA in  $\text{CH}_2\text{Cl}_2$  afforded a set of fluorescent bile acid pro pharmaceutical agents of the antiviral compound Zanamivir.

III. Preparation of Library of Fluorescent Zanamivir Bile Acid Pro pharmaceutical agents of Type 3

The 3- $\alpha$ -tosylate of methyl cholate, prepared according to literature methods, is treated with S-acetamidomethyl-protected 2-mercaptoethanol under basic conditions and elaborated to give a Wang resin-bound 3 $\beta$ -mercapto-cholate compound. The resulting thiol resin is reacted with various ortho-phthaldialdehydes in the presence of compounds A to yield fluorescent isoindole products. Cleavage from the resin with TFA in  $\text{CH}_2\text{Cl}_2$  afforded a set of fluorescent bile acid pro pharmaceutical agents of the antiviral compound Zanamivir. The synthesis is summarized in Fig. 30.

IV. Detection of Intestinal Absorption

Male Wistar rats are anesthetized and an inlet cannula inserted into the intestinal lumen 8 cm proximal to the ileo-cecal valve. A second incision is made into the cecum for placement of the outlet cannula and the cannulae connected to a loop of silicone tubing via a peristaltic pump. The loop (total volume 2 mL) is filled with buffer (140 mM NaCl, 0.9 mM  $\text{CaCl}_2$ , 0.5 mM  $\text{MgCl}_2$ , 8 mM  $\text{Na}_2\text{HPO}_4$ , 2.7 mM KCl, 1.5 mM  $\text{KH}_2\text{PO}_4$ , pH 7.4) and the intestine flushed by flow at 0.25 mL/min. A test compound from one of the foregoing Zanamivir bile acid libraries is introduced into this buffer at 1 mM. The superior

mesenteric vein is isolated and blood collected at various time points after perfusion of the test compound and analyzed for appearance of absorbed sample. The blood is centrifuged and the serum analyzed by TLC or HPLC with fluorescence detection for the appearance of both the starting fluorescent pro pharmaceutical agent as well as the fluorescent byproduct resulting from hydrolysis of the pro pharmaceutical agent ester.

### EXAMPLE 16

#### Examples of *in vivo* screening for Nanoparticle Transport

##### A. Initial Screen

A library of tetra peptides is constructed from a building block set consisting of the 39 L- and D-forms of the 20 genetically-encoded amino acids. The library is built by split and pool synthesis on  $\sim 10^{15}$  amino derivatized, 100 nm polystyrene nanoparticles according to the method of Example 13. This results in the production of  $\sim 10^9$  equivalents of the >2 million member library. Following the final coupling step, the beads from all reaction vessels are pooled, washed, and resuspended in 5 mL of saline. The particles are derivatized with biotin, and exposed to a suspension of streptavidin coated, colloidal magnetic particles to attach several magnetic particles to each nanoparticle library support. 0.5 mL of the library suspension is then placed in the small intestine of each fasted rat. In some cases the particles are administered by oral gavage to the duodenal region of the small intestine and allowed to traverse the intestine at a normal rate.

Alternatively, the animals are anesthetized and the small intestine surgically exposed. Portions several cm long of the jejunal and ileal regions of the intestine are isolated by gentle ligation, and 0.5 mL of library suspension injected into the lumen of the isolated loop. In some experiments, blood is taken from the mesenteric vein at periods of 0.5 to 24 h following the administration of the particles. For continuous collection of absorbed particles, a shunt is installed in the mesenteric vein. Blood from the vein is diverted through the shunt to a "particle capture filter" and returned immediately to the vein. The particle capture filter contains a bed of Teflon-coated ferrous fibers with an effective mesh size of greater than 20  $\mu\text{m}$ . The filter is constructed so as to provide minor impedance to the passage of blood cells. During nanoparticle collection, high field permanent magnets (Dynal, Inc) are placed in proximity to the filter housing, temporarily inducing high local magnetic fields in the ferrous fiber bed. This "magnetic filter" permits the efficient recovery of the magnetic nanoparticles from the flowing blood. Periodically, to recover the captured particles, the filter is removed

from the shunt circuit and washed with saline to remove residual blood, the external magnetic field is released, and the filter flushed and back-flushed with saline to elute to particles. Recovered beads are washed and concentrated in preparation for analysis. The compounds are cleaved from the beads and analyzed by LC-MS as described in Example 11.

5

B. Optional re-screening

In some experiments, the beads recovered from the screening process described above are re-screened by loading as above into the intestine of a second animal. By beginning with a sufficient number of library equivalents, this process of re-selection can be repeated several times.

10

C. Whole Body Scintigraphy

As a preliminary assessment of the activity of a particular library or sub-library pool of compounds, whole body scintigraphy is employed. A library constructed as described in Examples 13 and part A of this example is prepared. In a final step, the beads are labeled with  $^{99}\text{Tc}$ .  $10^9$  to  $10^{12}$  particles (depending on specific activity) of the bead library are administered to fasted rats by any of the methods described in part A of this example. The animals are immobilized and periodically imaged by multiple view gamma cameras to monitor the emigration of nanoparticles to the blood. In some cases, to obtain increased sensitivity and resolution, a solution of non-absorbed radioquencher is added to the intestinal lumen, reducing the background contributed by the bulk of the beads remaining in the intestinal lumen. Decreasing the background produced by the non-mobile beads, allows a more sensitive detection and quantitation of the beads that have moved from the lumen and into the circulation, and it allows a more precise determination of the localization of the absorbed particles. With the appropriately-labeled beads, a variety of 3D imaging technologies can be used in this way: NMR, PET, CAT, thermal imaging, IR fluorescence.

15

20

25

EXAMPLE 17

Assays Utilizing Membrane Vesicles

30

I. General

Plasma membrane vesicles can be used to study the transport characteristics of solute transporters. Vesicles are prepared from cells that express the transporter of interest and exposed to a substrate labeled in such a way as to be conveniently detected within the

vesicles. One useful application of vesicle-based assay of transporters is their use in the study of efflux transporters, such as those members of the ATP-binding cassette (ABC) family. In order to study transport mediated by these unidirectional transporter in intact cells, the cells are first be loaded with the compound under study, and the efflux of the compound from the cells is followed. Membrane vesicles can be prepared so that a significant proportion of the vesicles are “inside out,” that is the efflux transporters are oriented so that they pump substrates into the interior of the vesicles. The free external compound is then removed, by centrifugation of the vesicles for example, and the compound that has entered the vesicles is determined.

II. Membrane vesicles prepared from CHO cells expressing spgp (sister of P-glycoprotein) used in assay of taurocholate uptake.

Sister of P-glycoprotein is the major canalicular bile acid transporter in the mammalian liver, and is also called the “Bile Salt Export Pump” (BSEP).

A. Preparation of Vesicles

The rat BSEP is transfected into CHO cells and expressed at a high level in the plasma membrane. Cells are scrapped from the culture plates and centrifuged at 1400 x g , the pellet recovered and homogenized with a Teflon/glass homogenizer in 50 mM mannitol, 2 mM EGTA, 50mM tris pH 7.0, 1µg leupeptin/antipain, and 0.5 mM phenylmethylsulfonyl fluoride. Undisrupted cells, nuclear debris, and mitochondria are pelleted by centrifuging at 500 x g for 10 min. The supernatant is centrifuged at 100,000 x g for 1 h. The resulting pellet is resuspended in bile acid uptake buffer consisting of 50 mM sucrose, 100 mM KNO<sub>3</sub>, 12.5 mM Mg(NO<sub>3</sub>)<sub>2</sub>, and 10 mM HEPES/TRIS pH 7.4. The vesicles can be stored in liquid nitrogen prior to use in assays.

B. Assays for ATP-Dependent Compound Uptake

To an appropriate aliquot of the vesicle preparation is added 2 µM of the fluorescent reporter-tagged test compound and 5mM ATP. Assay is incubated at RT for 20 min. At the end of the incubation period, reaction is stopped by placing the incubations on ice. The incubation medium is filtered through glass fiber filters and washed to remove the unincorporated test compound, and the fluorescence of the filters is measured to determine uptake of the test compound.

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent  
5 applications cited herein are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent or patent application were specifically and individually indicated to be so incorporated by reference.



WHAT IS CLAIMED IS:

1                   1.       A method of screening for a carrier-type transport protein and/or a  
2   ligand thereto, comprising:

3                   (a)     providing a library comprising different complexes, each complex  
4   comprising a compound and a reporter, the compound varying between different complexes;

5                   (b)     providing a population of cells, one or more of which expresses one or  
6   more carrier-type transport proteins;

7                   (c)     contacting the population of cells with a plurality of complexes from  
8   the library; and

9                   (d)     detecting a signal from the reporter of a complex that is bound to a cell  
10   or internalized within a cell, the signal providing an indication that a complex whose reporter  
11   generated the signal comprises a compound that is a ligand for a carrier-type transport  
12   protein.

1                   2.       The method of claim 1, wherein the reporter preferentially generates  
2   the signal once the reporter is internalized within the cell, the signal thus providing an  
3   indication that a complex whose reporter generated the signal comprises a compound that is a  
4   potential substrate for a carrier-type transport protein.

1                   3.       The method of claim 2, wherein the reporter contains a cleavable site  
2   and the reporter is cleaved at the cleavable site after the complex is internalized within the  
3   cell.

1                   4.       The method of claim 2, wherein reporter comprises an agent that  
2   causes a morphological change upon internalization within a cell, and if a compound  
3   complexed with the reporter is a substrate for the carrier-type protein, the complex is  
4   transported by the carrier-type protein into a cell expressing the carrier-type protein, whereby  
5   the agent triggers a detectable morphological change in the cell.

1                   5.       The method of claim 3, wherein the agent inhibits cytoskeleton  
2   formation.

1           6.       The method of claim 2, wherein the reporter comprises a fluorophore  
2     and a quencher moiety, and if a compound complexed with the reporter is a substrate for the  
3     carrier-type transporter protein, the complex is transported by the carrier-type transport  
4     protein into a cell expressing the carrier-type transporter protein, whereby the quencher  
5     moiety becomes separated from the fluorophore such that a fluorescent signal is emitted by  
6     the fluorophore within the cell, and the detection step comprises detecting the fluorescent  
7     signal.

1           7.       The method of claim 6, wherein the reporter further comprises a  
2     cleavable linker that links the fluorophore and quencher moiety, the cleavable linker being  
3     cleaved after entry of the reporter into the cell.

1           8.       The method of claim 6, wherein the fluorophore and quencher moiety  
2     are joined via a linker that contains a site cleavable by an enzyme, and the population of cells  
3     express the enzyme.

1           9.       The method of claim 8, wherein the enzyme is an endogenous enzyme.

1           10.      The method of claim 8, wherein the enzyme is expressed from an  
2     exogenous sequence harbored by the population of cells.

1           11.      The method of claim 8, wherein the enzyme is a hydrolase.

1           12.      The method of claim 2, wherein the reporter comprises a detection  
2     moiety disposed to interact with an intracellular agent, the cells have the intracellular agent,  
3     and if a compound complexed with the reporter is a substrate for the carrier-type protein, the  
4     complex is transported by the carrier-type transport protein into a cell expressing the carrier-  
5     type transport protein, whereby the detection moiety interacts with the intracellular agent to  
6     generate a detectable signal, and the detection step comprises detecting the detectable signal.

1           13.      The method of claim 12, wherein the detection moiety is a nucleic-acid  
2     binding dye and the intracellular agent is a nucleic acid.

1           14.      The method of claim 2, wherein the reporter comprises a substrate for  
2     an enzyme, and if a compound complexed with the reporter is a substrate for the carrier-type  
3     protein, the complex is transported by the carrier-type transport protein into a cell expressing

the carrier-type protein and the enzyme, whereby the enzyme metabolizes the enzyme substrate to form a detectable product, and the detecting step comprises detecting the detectable product.

15. The method of claim 14, wherein the enzyme is selected from the group consisting of luciferase, alkaline phosphatase,  $\beta$ -galactosidase, and  $\beta$ -glucouronidase.

16. The method of claim 15, wherein the reporter comprises luciferin, and wherein the population of cells express luciferase, and the luciferase metabolizes the luciferin to generate the detectable product.

17. The method of claim 16, wherein the luciferin is derivatized to bear a polar moiety to reduce passive uptake of complex.

18. The method of claim 17, wherein luciferin is joined to the complex via a cleavable site and an intracellular enzyme cleaves luciferin from the complex before luciferin can be metabolized by luciferase.

19. The method of claim 2, wherein the contacting step results in at least one complex being internalized within a cell through the activity of the carrier-type transport protein, the reporter promotes aggregation of subunits of a multimeric enzyme expressed within the population of cells, and the enzyme catalyzes production of a product that generates a detectable signal, the detecting step comprising detecting the detectable signal.

20. The method of claim 2, wherein the contacting step results in at least one complex being internalized in a cell through the activity of the carrier-type transport protein, the reporter promotes transcription from a promoter within a cell resulting in expression of an expression product that generates a detectable signal, and the detecting step comprises detecting the detectable signal.

21. The method of claim 20, wherein the expression product is an enzyme that catalyzes the production of the detectable signal.

22. The method of claim 2, wherein the contacting step results in at least one complex being internalized in at least one cell through the activity of the carrier-type transport protein, the reporter confers a selective advantage within the cell(s), and the

detecting step comprises propagating the population of cells under conditions that enrich for cell(s) on which the selective advantage has been conferred.

23. The method of claim 1, wherein the contacting step results in at least one complex being internalized in a cell through the activity of the carrier-type transport protein, and the method further comprises washing cells to remove unincorporated complexes before the detecting step, whereby signal from reporter internalized within the cell is preferentially detected.

24. The method of claim 1, wherein the contacting step results in at least one complex being internalized in a cell through the activity of the carrier-type transport protein, the reporter is a fluorescent molecule, and the method further comprises contacting cells with a fluorescence quencher incapable of entering the cells to quench fluorescence of unincorporated complexes before the detecting step, whereby signal from reporter internalized within the cell is preferentially detected.

25. The method of claim 1, wherein

(a) the population of cells comprise different cells that are located in a single reaction vessel;

(b) contacting results in at least one complex being bound to or internalized within one of the cells; and

(c) detecting comprises detecting the signal from the at least one complex.

26. The method of claim 25, wherein

(a) the different cells comprise test cells and counterpart control cells, the test cells expressing one of the one or more carrier-type transport proteins while the control cells fail to express the transport protein expressed by the test cells;

(b) the at least one complex is bound to or internalized within one of the test cells; and

(c) detecting further comprises detecting signal, if any, from the control cells.

1                   27.     The method of claim, 25, further comprising:

2                   (e)     separately contacting the different cells with each of the plurality of  
3 complexes; and

4                   (f)     determining the identity of the cell(s) to which the at least one complex  
5 is bound or internalized within.

1                   28.     The method of claim 25, wherein different cells have different  
2 distinguishable characteristics, and the method further comprises:

3                   (e)     determining the identity of the cell to which the at least one complex is  
4 bound or internalized within from its distinguishable characteristic.

1                   29.     The method of claim 28, wherein the distinguishable characteristics are  
2 different cellular morphologies.

1                   30.     The method of claim 28, wherein the distinguishable characteristics are  
2 different stains on the cells.

1                   31.     The method of claim 28, wherein the distinguishable characteristics are  
2 different markers located at the surface of the cells.

1                   32.     The method of claim 31, wherein the different markers are different  
2 epitopes, the different epitopes being differentially stained with antibodies specific for the  
3 different epitopes, antibodies for different epitopes bearing different labels.

1                   33.     The method of claim 32, wherein one or more of the different epitopes  
2 is expressed from an endogenous nucleic acid sequence.

1                   34.     The method of claim, 32, wherein one or more of the different epitopes  
2 is expressed from an exogenous nucleic acid sequence.

1                   35.     The method of claim 1, wherein

2                   (a)     the population of cells are contained in a single reaction vessel; and

(b) contacting comprises contacting the cells within the reaction vessel with a plurality of different complexes, different complexes comprising different compounds, whereby at least one complex is bound to or internalized within the cells; and

(c) detecting comprises detecting signal from the at least one complex.

36. The method of claim 35 further comprising:

(d) separately contacting the population of cells within different reaction vessels with the different complexes such that cells within the same reaction vessel receive the same complex while cells in at least some of the different reaction vessels receive different complexes; and

(e) determining the identity of the at least one complex.

37. The method of claim 35, wherein

(a) the reporter varies between different complexes and different reporters are disposed to generate different signals; and

(b) detecting comprises detecting the signal from the reporter of the at least one complex, the signal from the at least one complex providing an indication of the identity of the compound of the at least one complex.

38. The method of claim 37, wherein different reporters comprise different labels, the different labels selected from the group consisting of a radiolabel, a mass label, a spin label, a fluorophore, a chromophore and a luminescent moiety.

39. The method of claim 37, wherein different reporters comprise substrates for different enzymes expressed within the one or more cells.

40. The method of claim 37, wherein the population of cells is a plurality of different cells, different cells having different distinguishable characteristics, and further comprising determining the identity of the cell to which the at least one complex is bound or internalized from its distinguishing characteristic.

41. The method of claim 1, wherein detecting comprises detecting a signal from a reporter internalized within the one or more cells to identify at least one complex that

is internalized within the one or more cells, the compound complexed to the internalized complex being a substrate potentially able to transport an agent into cells expressing a carrier-type transport protein, the method further comprising:

(e) providing a modified complex, the modified complex comprising the compound identified in the detecting step (d) and an agent;

(f) contacting one or more cells with the modified complex; and

(g) determining whether the modified complex is internalized within one of the one or more cells by detecting the modified complex within the one or more cells, such detection providing an indication that the compound can serve as a substrate for transporting agents into cells expressing carrier-type transport proteins.

42. The method of claim 41, wherein the agent is a pharmaceutical agent.

43. The method of claim 42, wherein the reporter is attached to the complex of the at least one complex at an attachment site and the pharmaceutical agent replaces the reporter in the modified complex such that the pharmaceutical agent is attached to the attachment site in the modified complex.

44. The method of claim 43, wherein the providing step comprises synthesizing the modified complex.

45. The method of claim 43, wherein the modified complex further comprises a reporter attached at a site other than the attachment site.

46. The method of claim 1, wherein contacting results in at least one complex being internalized in a cell, detecting comprises detecting signal from the reporter of the at least one complex and the method further comprises

(e) determining the identity of the compound in the at least one complex detected in step (d);

(f) providing a focused library, the focused library comprising a plurality of complexes, each complex in the focused library comprising a compound that is a variant of the compound identified in step (e);

(g) contacting one or more cells with one or more of the complexes of the focused library, the one or more cells expressing a carrier-type transport protein; and

11 (h) detecting a signal from a reporter of a complex internalized within one  
12 of the one or more cells, the signal providing an indication that the compound of the  
13 internalized complex is a substrate for a carrier-type transport protein.

1 47. The method of claim 1, wherein the population of cells has been  
2 transformed with a DNA library encoding the one or more transport proteins.

1 48. The method of claim 47, further comprising:

2 (e) isolating a cell that has bound the reporter or internalized the reporter;  
3 and

4 (f) isolating a DNA molecule encoding a carrier-type transport protein  
5 from the isolated cell to identify the carrier-type transport protein that exhibits activity with  
6 the compound of the complex that is bound to or internalized within the isolated cell.  
7

1 49. The method of claim 1, wherein the carrier-type transport protein is  
2 selected from the group of an amino acid transporter, a dipeptide transporter, an oligopeptide  
3 transporter, a simple sugar transporter, a bile acid transporter, a vitamin transporter, a  
4 phosphate transporter, a monocarboxylic acid transporter, an organic anion transporter, an  
5 organic cation transporter, fatty acid transporter, a nucleoside transporter, and a ABC  
6 transporter.

1 50. The method of claim 49, wherein the transport protein is selected from  
2 the group consisting of PEPT1, sodium-dependent glucose transport protein (SGLT1), liver  
3 bile acid transporter (NTCP) and ileal bile acid transporter (ASBT).

1 51. The method of claim 1, wherein the one or more carrier-type proteins  
2 are endogenous proteins.

1 52. The method of claim 1, wherein the one or more carrier-type proteins  
2 are expressed from an exogenous sequence harbored by the population of cells.

1 53. The method of claim 52, wherein the cells of the population of cells is  
2 selected from the group consisting of Chinese hamster ovary (CHO) cells, VERO cells,



3 HeLA cells, COS-7 cells, MDCK cells, HEK cells, CaCo-2 cells, HCT-8 cells, T84 cells and  
4 HT29 cells.

1 54. The method of claim 53, wherein the cells are treated to yield  
2 membrane preparations or vesicles and the complexes are contacted with the membrane  
3 preparations or vesicles.

1 55. The method of claim 1, wherein the test compound is directly joined to  
2 the reporter via a chemical bond.

1 56. The method of claim 1, wherein the complex further comprises a linker  
2 joining the test compound and the reporter.

1 57. The method of claim 1, wherein the linker contains a cleavage site.

1 58. The method of claim 1, wherein the linker is a stable linker lacking a  
2 cleavage site.

1 59. The method of claim 1, wherein the reporter is selected from the group  
2 consisting of a fluorophore, a chromophore, a radioisotope, a magnetic particle, a mass label  
3 and a spin label.

1 60. The method of claim 59, wherein the reporter is a fluorophore.

1 61. The method of claim 1, wherein the detection step is performed by  
2 brightfield, phase contrast or fluorescence microscopy.

1 62. The method of claim 1, wherein the detection step is performed using a  
2 confocal microscope.

1 63. The method of claim 62, wherein the confocal microscope has multiple  
2 wavelength detection capability.

1 64. The method of claim 1, wherein the different compounds are  
2 compounds from a combinatorial library.

1 65. The method of claim 1, wherein the different compounds are variants  
2 of a known substrate for a carrier-type transport protein.

1                   66.     The method of claim 1, wherein the different compounds are small  
2 molecules.

1                   67.     The method of claim 1, wherein the plurality of different compounds  
2 are peptides.

1                   68.     The method of claim 1, wherein the population of cells of step (b)  
2 comprise a test population and the method further comprises

3                   (e)     providing a population of control cells the same as the population of  
4 test cells of step (b), except that the control cells fail to express the one or more carrier-  
5 mediated transport proteins; and

6                   (f)     repeating steps (c) and (d) with the control cells, wherein a statistically  
7 significant difference in the signal from the reporter in the population of test cells relative to  
8 the signal from the control cells provides a further indication that the complex whose reporter  
9 generated the signal comprises a compound that is a ligand for a carrier-type transport  
10 protein.

1                   69.     A method of screening for a carrier-type transport protein and/or a  
2 substrate thereto, comprising:

3                   (a)     providing one or more cells, each cell expressing a carrier-type  
4 transport protein;

5                   (b)     contacting the one or more cells with one or more complexes, each  
6 complex comprising a compound and a reporter; and

7                   (c)     selectively detecting a signal from a reporter internalized within one or  
8 more of the cells as compared to signal from reporter outside the cell to indicate that a  
9 complex whose reporter generated the signal comprises a compound that is a substrate for a  
10 carrier-type transport protein.

1                   70.     The method of claim 69, wherein the reporter comprises a fluorophore  
2 and a quencher moiety, and if a compound complexed with the reporter is a substrate for the  
3 carrier-type transporter protein, the complex is transported by the carrier-type transport  
4 protein into a cell expressing the carrier-type transporter protein, whereby the quencher  
5 moiety becomes separated from the fluorophore such that a fluorescent signal is emitted by

6 the fluorophore within the cell, and the detection step comprises detecting the fluorescent  
7 signal.

1           71. The method of claim 69, wherein the contacting step results in at least  
2 one complex being internalized in a cell, the reporter is a fluorophore that fluoresces upon  
3 binding to a nucleic acid within the cell, which fluorescence is detected in the detecting step.

1           72. The method of claim 69, wherein the reporter comprises a substrate for  
2 an enzyme, and if a compound complexed with the reporter is a substrate for the carrier-type  
3 protein, the complex is transported by the carrier-type transport protein into a cell expressing  
4 the carrier-type protein and the enzyme, whereby the enzyme metabolizes the substrate to  
5 form a detectable product, and the detecting step comprises detecting the detectable product.

1           73. The method of claim 69, wherein the contacting step results in at least  
2 one complex being internalized in a cell, the reporter promotes aggregation of subunits of a  
3 multimeric enzyme expressed within the population of cells, and the enzyme catalyzes  
4 production of a product that generates a detectable signal, and detecting comprises detecting  
5 the detectable signal.

1           74. The method of claim 69, wherein the contacting step results in at least  
2 one complex being internalized in a cell, the reporter promotes transcription of a promoter  
3 within a cell resulting in expression of an enzyme that catalyzes production of a product that  
4 generates a detectable signal, and detecting comprises detecting the detectable signal.

1           75. A method of screening for a carrier-type transport protein and/or a  
2 ligand thereto, comprising:

3           (a) providing a plurality of different cells that are located within a single  
4 reaction vessel, each cell expressing a carrier-type transport protein, and different cells  
5 having different distinguishable characteristics;

6           (b) contacting the plurality of different cells with one or more complexes,  
7 each complex comprising a compound and a reporter, whereby at least one complex is bound  
8 to or internalized within one of the cells;

9           (c) detecting a signal from the reporter of the at least one complex bound  
10 to or internalized within the cell in step (b); and

11 (d) determining the identity of the cell in step (b) from its distinguishable  
12 characteristic.

1 76. A method of screening for a carrier-type transport protein and/or a  
2 ligand thereto, comprising:

3 (a) providing one or more cells, each cell expressing a carrier-type  
4 transport protein, and located in a single reaction vessel;

5 (b) contacting the one or more cells with a plurality of different  
6 complexes, each complex comprising a compound and a reporter, the compound and reporter  
7 varying between different complexes and different reporters disposed to generate different  
8 signals, whereby at least one complex is bound to or internalized within the one or more  
9 cells; and

10 (c) detecting the signal from the reporter of the at least one complex, the  
11 signal providing an indication of the identity of the compound borne by the at least one  
12 complex.

1 77. A method of screening for a carrier-type transport protein and/or a  
2 substrate thereto, comprising:

3 (a) providing one or more cells, each cell expressing a carrier-type  
4 transport protein;

5 (b) contacting the one or more cells with one or more complexes, each  
6 complex comprising a compound and a reporter;

7 (c) detecting a signal from a reporter internalized within the one or more  
8 cells to identify at least one complex that is internalized within the one or more cells, the  
9 compound of the internalized complex being a substrate potentially disposed to transport a  
10 pharmaceutical agent into a cell via the activity of a carrier-type transport protein;

11 (d) preparing a modified complex, the modified complex comprising the  
12 compound identified in step (c) and a pharmaceutical agent;

13 (e) repeating steps (a) and (b) with the modified complex; and

(f) determining whether the modified complex is internalized within one of the one or more cells by detecting the modified complex within the one or more cells, such detection providing an indication that the compound of the modified complex can serve as a substrate for transporting a pharmaceutical agent into cells expressing carrier-type transport proteins.

78. A method of screening for a receptor-type transport protein and/or a ligand thereto, comprising:

(a) providing a library comprising different complexes, each complex comprising a compound and a reporter, the compound varying between different complexes;

(b) providing a population of cells, one or more of which expresses one or more receptor-type transport proteins;

(c) contacting the population of cells with a plurality of complexes from the library; and

(d) detecting a signal from the reporter of a complex that is bound to a cell, internalized within a cell or has been transported through a cell, the signal providing an indication that a complex whose reporter generated the signal comprises a compound that is a ligand for a receptor-type transport protein.

79. The method of claim 78, wherein the reporter comprises a fluorophore and a quencher moiety, and if a compound complexed with the reporter is a substrate for the receptor-type transporter protein, the complex is transported by the receptor-type transport protein into a cell expressing the receptor-type transporter protein, whereby the quencher moiety becomes separated from the fluorophore such that a fluorescent signal is emitted by the fluorophore within the cell, and the detection step comprises detecting the fluorescent signal.

80. The method of claim 78, wherein the contacting step results in at least one complex being internalized within a cell through the activity of the receptor-type transport protein, the reporter comprises a nucleic-acid binding dye, and whereby the dye interacts with a nucleic acid within one of the cells to generate a detectable signal, and the detection step comprises detecting the detectable signal.

1                   81.     The method of claim 78, wherein the detection moiety is a nucleic-acid  
2 binding dye and the intracellular agent is a nucleic acid.

1                   82.     The method of claim 78, wherein the contacting step results in at least  
2 one complex being internalized within a cell through the activity of the receptor-type  
3 transport protein, the reporter comprises a substrate for an enzyme, the population of cells  
4 express the enzyme, and whereby the enzyme metabolizes the substrate to form a detectable  
5 product, and the detecting step comprises detecting the detectable product.

1                   83.     The method of claim 78, wherein the contacting step results in at least  
2 one complex being internalized within a cell through the activity of the receptor-type  
3 transport protein, the reporter promotes aggregation of subunits of a multimeric enzyme  
4 expressed within the population of cells, and the enzyme catalyzes production of a product  
5 that generates an optical signal, the detecting step comprising detecting the optical signal.

1                   84.     The method of claim 78, wherein the contacting step results in at least  
2 one complex being internalized in a cell through the activity of the receptor-type transport  
3 protein, the reporter promotes transcription from a promoter within a cell resulting in  
4 expression of an enzyme that generates an optical signal, and the detecting step comprises  
5 detecting the optical signal.

1                   85.     The method of claim 78, wherein the contacting step results in at least  
2 one complex being internalized in at least one cell through the activity of the receptor-type  
3 transport protein, the reporter confers a selective advantage within the cell(s), and the  
4 detecting step comprises propagating the population of cells under conditions that enrich for  
5 cell(s) on which the selective advantage has been conferred.

1                   86.     The method of claim 78, wherein  
2                               (a)     the population of cells comprise different cells, the different  
3 cells expressing different receptor-type transport proteins, having different distinguishable  
4 characteristics and being located in a single reaction vessel;  
5                               (b)     contacting results in at least one complex being bound to,  
6 internalized within, or transported through one of the cells;

(c) detecting comprises detecting the signal from the reporter of the at least one complex; and

(d) the method further comprises determining the identity of the cell to which the at least one complex is bound, internalized within or transported through from its distinguishable characteristic.

87. The method of claim 78, wherein

(a) the population of cells are contained in a single reaction vessel;

(b) contacting comprises contacting the cell(s) within the reaction vessel with a plurality of different complexes, the reporter varying between different complexes and different reporters being disposed to generate different signals, whereby at least one complex is bound to, internalized within, or transported through the cells;

(c) detecting comprises detecting the signal from the reporter of the at least one complex; and

(d) the method further comprises determining the identity of the cell to which the at least one complex is bound, internalized within or transported through from its distinguishable characteristic.

88. The method of claim 87, wherein the population of cells is a plurality of different cells, different cells having different distinguishable characteristics, and further comprising determining the identity of the cell to which the at least one complex is bound or internalized from its distinguishing characteristic.

89. The method of claim 78, wherein each complex further comprises a support, the compound and reporter being linked to the support.

90. The method of claim 89, wherein the supports are nanoparticles.

91. The method of claim 89, wherein the supports are molecular scaffolds.

92. The method of claim 89, wherein each complex further comprises a tag encoding at least one step in synthesis of the compound of the complex.

1                   93.     The method of claim 92, further comprising characterizing the  
2 compound by decoding the tag.

1                   94.     The method of claim 93, wherein decoding the tag defines the  
2 complete structure of the compound.

1                   95.     The method of claim 78, wherein the one or more transport proteins  
2 include a human intestinal epithelium transport protein.

1                   96.     The method of claim 78, wherein the population of cells has been  
2 transformed with a DNA library encoding the one or more transport proteins.

1                   97.     The method of claim 96, wherein the DNA library is a cDNA library  
2 from human intestinal epithelial cells.

1                   98.     The method of claim 78, wherein the population of cells are polarized  
2 cells arranged in a monolayer.

1                   99.     The method of claim 78, wherein the reporter generates an optical  
2 signal and the detecting method comprises confocal imaging of the position of reporter  
3 relative to the cells in the monolayer.

1                   100.    The method of claim 99, wherein the confocal imaging is performed at  
2 intervals to monitor internalization of a complex into a cell, the cell internalizing the complex  
3 is isolated, and a support bearing a compound is isolated from the isolated cell.

1                   101.    The method of claim 98, wherein the polarized cells are layered above  
2 a membrane that is impermeable to the complexes.

1                   102.    The method of claim 99, wherein the confocal microscopy is  
2 performed from below the membrane and detects transport of a complex through the cell to  
3 the membrane.

1                   103.    The method of claim 102, wherein the reporter is a substrate for an  
2 enzyme, the membrane is impregnated with the enzyme, and after transport of a complex  
3 through a cell, the enzyme metabolizes the reporter of the complex to generate a product  
4 generating an optical signal.



1                   104.    The method of claim 102, wherein a second membrane is between the  
2 polarized cells and the membrane, the second membrane being permeable to the complexes.

1                   105.    The method of claim 104, wherein the reporter is disposed to induce a  
2 metabolic event generating an optical signal in indicator cells, and the second membrane is  
3 impregnated with the indicator cells, whereby at least one complex is transported through the  
4 monolayer of cells, induces a metabolic event generating an optical signal in the indicator  
5 cells, and passes through the second membrane to the first membrane; the detecting step  
6 comprises detecting the optical signal, and a support bearing a compound is isolated from the  
7 membrane by virtue of its proximity to the optical signal in the second membrane.

1                   106.    The method of claim 78, wherein the complexes used in the contacting  
2 step are produced by:

3                   (a)    introducing into a body compartment or tissue of an animal a starting  
4 population of complexes, each complex comprising a support, a test compound, and a  
5 reporter, the test compound varying between complexes, and the reporter being the same for  
6 different complexes; and

7                   (b)    recovering complexes by means of their reporter from a tissue or fluid  
8 of the animal after transport of at least some of the complexes through cells lining the body  
9 compartment, the recovered complexes providing the population of complexes for contacting  
10 with the cell population.

1                   107.    A method of screening for a substrate of a transport protein,  
2 comprising:

3                   (a)    introducing into a body compartment of an animal a population of  
4 complexes, each complex comprising a support, a test compound, and a reporter, the test  
5 compound varying between complexes; and

6                   (b)    recovering complexes by means of their reporter from a tissue or fluid of  
7 the animal after transport of at least some of the complexes through cells lining the body  
8 compartment.

1                   108. The method of claim 107, further comprising repeating the method  
2 with recovered complexes from step (b) of one cycle forming the population of complexes to  
3 be introduced into the body compartment of the animal in the next cycle.

1                   109. The method of claim 108, wherein a different animal is used in each  
2 cycle of the method.

1                   110. The method of claim 107, wherein the body compartment is the lumen  
2 of the gastrointestinal tract.

1                   111. The method of claim 107, wherein the tissue or fluid is the blood or  
2 lymphatic fluid of the animal.

1                   112. The method of claim 107, further comprising sealing the body  
2 compartment around the introduced population of complexes to increase the available time  
3 for transport of complexes through cells lining the compartment.

1                   113. The method of claim 107, wherein the reporter is a capture tag, and the  
2 recovering step is by affinity enrichment for the capture tag using a capture tag receptor.

1                   114. The method of claim 107, wherein the reporter is an optically  
2 detectable label and the recovering step comprises recovering the complexes using FACS  
3 sorting.

1                   115. The method of claim 107, wherein the reporter is a magnetic  
2 substance, and the recovering step comprises exposing the tissue or fluid to a magnet to  
3 isolate the complexes.

1                   116. The method of claim 107, wherein each complex further comprises an  
2 encoding tag encoding at least one synthesis step in the synthesis of the compound of the  
3 complex, and the method further comprises decoding the encoding tag(s) of recovered  
4 complex(es).

1                   117. The method of claim 107, further comprising classifying compounds of  
2 the recovered complexes by similarity in chemical structure.

118. The method of claim 117, further comprising ranking groups by number of members, the ranking providing an indication of the efficacy of compounds in a group as substrates of a transport protein in the cells lining the body compartment.

119. The method of claim 107, further comprising

(c) contacting recovered complexes with a population of polarized cells transformed with a DNA library at least some members of which encode potential transport proteins, the cells being arranged as a monolayer on a membrane and the complexes contacting the apical side of the cells;

(d) detecting complexes transported through the polarized cells to the membrane by virtue of the reporter of the complexes;

(e) recovering polarized cells in proximity to the transported complexes; and

(f) clonally expanding the recovered polarized cells.

120. The method of claim 119, further comprising

(g) forming a monolayer of cells on a membrane for each of a plurality of clonally expanded recovered polarized cells;

(h) contacting each monolayer with another sample of recovered complexes from the animal; and

(i) recovering further recovered complexes that have been transported through the monolayers of cells, the complexes passing through a monolayer having complexes that are substrates for a receptor-type transport protein expressed by the cells in the monolayer.

121. The method of claim 119, further comprising

(g) recovering complexes contacted with one of the monolayers that are not transported through the monolayer, and contacting the recovered complexes with a second monolayer.

1                   122. The method of claim 107, wherein the introducing step comprises  
2 introducing a plurality of populations of complexes into the body compartment of the animal,  
3 the different populations having different reporters, and the recovering step comprises  
4 recovering a plurality of subpopulations of complexes, the different subpopulations having  
5 the different reporters.

1                   123. The method of claim 122, wherein each subpopulation is recovered by  
2 affinity chromatography using a different receptor for each different reporter.

1                   124. The method of claim 122, further comprising ranking the recovered  
2 subpopulations by number of members.

1                   125. The method of claim 122, wherein the different reporters give different  
2 optically detectable signals.

1                   126. The method of claim 125, wherein the different reporters are  
2 fluorescent molecules emitting at different wavelengths.

1                   127. A pharmaceutical composition comprising a nanoparticle, a drug  
2 within or linked to the nanoparticle and a ligand linked to or within the nanoparticle, the  
3 ligand being effective to promote cellular uptake and/or transport of the particle by receptor-  
4 type transport proteins.

1                   128. The pharmaceutical composition of claim 127, wherein the ligand is  
2 substrate for a receptor-type transport receptor.

1                   129. The pharmaceutical composition of claim 127, further comprising a  
2 second ligand linked to or within the nanoparticle.

1                   130. The pharmaceutical composition of claim 129, wherein the ligand  
2 binds to a first cellular receptor, and the second ligand binds to a transport protein, which  
3 binding results in internalization of the nanoparticle.

1                   131. The pharmaceutical composition of claim 130, wherein the second  
2 ligand is contained within the nanoparticle and is released on binding of the first ligand to the  
3 cellular receptor.

1                   132.   The pharmaceutical composition of claim 129, wherein the ligand  
2 binds to a receptor-type transport protein, which binding results in internalization of the  
3 nanoparticle, and the second ligand binds to a second transport protein within a cell that  
4 effects basolateral trafficking of the internalized nanoparticle to the basolateral exterior of the  
5 cell.

1                   133.   The pharmaceutical composition of claim 127, further comprising an  
2 agent linked to or within the particle.

1                   134.   The pharmaceutical composition of claim 133, wherein the agent is a  
2 buffering agent.

1                   135.   The pharmaceutical composition of claim 133, wherein the agent is an  
2 antacid.

1                   136.   The pharmaceutical composition of claim 133, wherein the agent is a  
2 lysing agent.

1                   137.   The pharmaceutical composition of claim 127, further comprising a  
2 compound that after internalization of the nanoparticle into a cell targets the nanoparticle to a  
3 target organelle.




FIG. 1

Intestinal lumen




FIG. 2B

Blood




FIG. 2A




FIG. 3



Substrate-mediated Efflux  
"Trans-stimulation"




FIG. 4




FIG. 5

# LBAT Competition in 96 and 384 Well Formats

Fig. 6A

96 Well





Fig. 6B

384 Well



## 10 Pools from 200-Member Fluorescent Dipeptide Library




FIG. 7

## Synthesis of a Dipeptide Library




FIG. 8


Synthesis of  $\beta$ -Lactam Library

FIG. 9.

# Synthesis of Fluorescent PEPT1 Substrate XP10486




FIG. 10

Using Combinatorial Potential of Dipeptide Motif to Rapidly Establish

Structure-Activity Relationships for PEPT1




FIG. 11







FIG. 12



(i) Piperidine, DMF







DIAD,  $\text{PPh}_3$ , THF(i)  $\text{PhSNa}$ , DMFDIC, DIEA, HOBT,  $\text{CH}_2\text{Cl}_2$ (iii)  $[\text{Pd}(\text{PPh}_3)]_4$ ,  $\text{Me}_3\text{SiN}_3$ , THF(iv) NBD-Cl,  $\text{K}_2\text{CO}_3$ , EtOH(v) TFA,  $\text{CH}_2\text{Cl}_2$ 

FIG. 13



(i) Piperidine, DMF

(ii)




DIC, DIEA, CH<sub>2</sub>Cl<sub>2</sub>(i) [Pd(PPh<sub>3</sub>)<sub>4</sub>], Me<sub>3</sub>SiN<sub>3</sub>, THF(ii) NBD-Cl, K<sub>2</sub>CO<sub>3</sub>, EtOH(iii) TFA, CH<sub>2</sub>Cl<sub>2</sub>

FIG. 14




FIG. 15

# Synthesis of Luciferin-Conjugated Dipeptide GP5-71




Fig. 16

# Synthesis of Luciferin-Glycocholate Ester Conjugate CZ15-73




FIG. 17

## Bile Acid - Luciferin Conjugate Library




FIG. 18

## Synthesis of Conditionally Fluorescent Dipeptide GP5-75-2




Fig. 19



# Synthesis of Conditionally Fluorescent Dipeptide GP5-77




FIG. 2D

# Synthesis of Conditionally Fluorescent Dipeptide GP5-00




FIG. 21

# Preparation of Cholyl-L-Lys-( $\epsilon$ -NBD)-OH




Fig. 22

# Preparation of Choly-Lysine Conjugate of Naproxen




FIG. 23

## Preparation of Cholyl L-Dopa




Fig. 24




FIG. 25

# Trans-stimulation Assays

<sup>3</sup>H-GlySar efflux by unlabeled GlySar in CHO-PEPT1 cells




FIG. 26 A

<sup>3</sup>H-Taurocholate efflux by Cholates analogs in CHO-LBAT cells




FIG. 26 B

# Inhibitory Activity of Known Substrates




FIG. 27A

FIG. 27B






FIG. 28




FIG. 29




FIG. 30

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/25439

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : Please See Extra Sheet.

US CL : 435/6, 320.1, 455; 436/501, 63; 536/23.1

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 320.1, 455; 436/501, 63; 536/23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST, DIALOG

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,932,424 A (AMARA et al.) 03 August 1999 (03.08.1999), abstract, examples 3-6.	1, 23, 25-33, 35, 36, 49, 51, 65, 66, 68, 75, 78
Y	US 5,750,362 A (FROMMER et al.) 12 May 1998 (12.05.1998) abstract, columns 2-8 and claims	1, 23, 25-33, 35-40, 46, 49-51, 55-60, 64-68, 75, 76, 78, 80, 98
Y	US 5,902,609 A (LEE) 11 May 1999 (11.05.1999), abstract, columns 8-9.	1, 23, 25-33, 35, 36, 49, 51, 65, 66, 68, 75, 78

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* & * document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

15 DECEMBER 2000

Date of mailing of the international search report

07 FEB 2001

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

  
WILLIAM SANDALS

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/25439

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,719,043 A (FROMMER) 17 February 1998 (17.02.1998), abstract, columns 9, 13.	1, 23, 25, 35, 49, 51, 78
Y	US 5,866,123 A (MAC LEOD) 02 February 1999 (02.02.1999), abstract, columns 16-20.	1, 23, 25-33, 35, 36, 49, 51, 65, 66, 68, 75, 78

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/25439**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1, 23, 25-33, 35-40, 46, 49-51, 55-60, 64-68, 75, 76, 78, 80, 95, 98

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (7):

G01N 33/566, 33/48; C12Q 1/68; C12N 1/68, 15/63, 15/85; C07H 21/04

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1, 23, 25-33, 35-40, 46, 49-51, 55-60, 64-68, 75, 76, 78, 80, 95, 98, drawn to a method of screening for a carrier type transport protein and/or a ligand thereto.

Group II, claim(s) 2, 3, 12-16, 69, 68, drawn to a method for screening for a carrier-type transport protein and/or a substrate thereto.

Group III, claim(s) 4, 5, drawn to a method of screening for a carrier-type transport protein and/or substrate thereto with a reporter which causes a morphological change in a host cell.

Group IV, claim(s) 6-11, 24, 69, 70-72, 79, drawn to a method of screening for a carrier-type protein and/or a substrate thereto with a reporter which is a fluorophore and with a quencher thereto.

Group V, claim(s) 17, 18, drawn to a method of screening for a carrier-type protein with a reporter that inhibits uptake.

Group VI, claim(s) 19, 73, 83, drawn to a method of screening for a carrier-type protein with a reporter that promotes aggregation of a multienzyme complex.

Group VII, claim(s) 20, 21, 74, 84, drawn to a method of screening for a carrier-type protein with a reporter that promotes transcription of a detectable signal.

Group VIII, claim(s) 22, 85, drawn to a method of screening for a carrier-type protein with a reporter that confers selective advantage.

Group IX, claim(s) 34, drawn to a method of screening for a carrier-type protein in a cell which has been transfected with a gene expressing a cell surface marker.

Group X, claim(s) 41-43, 45, 77, 81, drawn to a method of screening for a carrier-type protein and a substrate which can transport an agent into a cell.

Group XI, claim(s) 44, drawn to a method of screening for and synthesizing a carrier-type protein complexed with a pharmaceutical agent.

Group XII, claim(s) 46, drawn to a method of screening for a carrier-type protein and a variant compound.

Group XIII, claim(s) 47, 48, 52, 53, 96, 97, drawn to a method of screening for a carrier-type protein and a ligand in cells which are transformed with a DNA which encodes a transport protein.

Group XIV, claim(s) 54, drawn to a method of screening for a carrier-type protein and a ligand in cells which are transformed with a DNA which encodes a transport protein and making vesicles from the cells and contacting a transport protein-ligand complex with said vesicles.

Group XV, claim(s) 61-63, 99, 100, drawn to a method of screening for a carrier-type protein and a ligand and a microscope apparatus.

Group XVI, claim(s) 86-88, drawn to a method of screening for a carrier-type protein and a ligand and a method of transcytosis.

Group XVII, claim(s) 89-91, drawn to method of screening for a carrier-type protein and a ligand and a reporter linked to a support.

Group XVIII, claim(s) 92-94, drawn to method of screening for a carrier-type protein and a ligand comprising a tag and at least one step of synthesis of the formed complex.

Group XIX, claim(s) 101-104, drawn to a method of screening for a carrier-type protein and a ligand and a method of transcytosis and an apparatus.

Group XX, claim(s) 105, drawn to a method of screening for a carrier-type protein and a ligand and a method of transcytosis and a reporter which induces a metabolic event generating an optical signal.

Group XXI, claim(s) 106-113, 117, 118, 122-126, drawn to a method of screening a carrier-type protein and a ligand comprising administering a test compound, reporter, protein complex to an animal, and a method of recovery of the protein-ligand complexes from a tissue or fluid from an animal and contacting cells with the recovered complexes.

Group XXII, claim(s) 114, drawn to a method of screening for a carrier-type protein and a ligand comprising administering a test compound, reporter, protein complex to an animal, and a method of recovery of the protein-ligand complexes from a tissue or fluid from an animal and contacting cells with the recovered complexes, wherein the recovering is comprising a FACS apparatus.

Group XXIII, claim(s) 115, drawn to a method of screening for a carrier-type protein and a ligand comprising administering a test compound, reporter, protein complex to an animal, and a method of recovery of the protein-ligand complexes from a tissue or fluid from an animal and contacting cells with the recovered complexes, wherein the

recovering is comprising a magnetic apparatus.

Group XXIV, claim(s) 116, drawn to a method of screening for a carrier-type protein and a ligand comprising administering a test compound, reporter, protein complex to an animal, and a method of recovery of the protein-ligand complexes from a tissue or fluid from an animal and contacting cells with the recovered complexes, wherein the recovering is comprising at least one step of synthesis of the complex and also comprising a tag.

Group XXV, claim(s) 119-121, drawn to a method of screening for a carrier-type protein and a ligand comprising administering a test compound, reporter, protein complex to an animal, and a method of recovery of the protein-ligand complexes from a tissue or fluid from an animal and contacting cells with the recovered complexes, and which also comprises a cell transfected with a DNA which encodes a transport protein.

Group XXVI, claim(s) 127, drawn to a pharmaceutical composition comprising a nanoparticle comprising a drug and a ligand where the ligand promotes cellular uptake.

Group XXVII, claim(s) 128, drawn to a pharmaceutical composition comprising a nanoparticle comprising a drug and a substrate where the ligand promotes cellular uptake.

Group XXVIII, claim(s) 129-131, drawn to a pharmaceutical composition comprising a nanoparticle comprising a drug and a ligand where the ligand promotes cellular uptake and a second ligand which may be released when the first ligand binds to a cellular receptor.

Group XXIX, claim(s) 132, drawn to a pharmaceutical composition comprising a nanoparticle comprising a drug and a ligand where the ligand promotes cellular uptake and a second ligand which promotes transcytosis.

Group XXX, claim(s) 133-136, drawn to a pharmaceutical composition comprising a nanoparticle comprising a drug and a ligand where the ligand promotes cellular uptake further comprising an agent.

Group XXXI, claim 137, drawn to a pharmaceutical composition comprising a nanoparticle comprising a drug and a ligand where the ligand promotes cellular uptake and an agent which targets the nanoparticle to an intracellular organelle.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as follows:

The species claimed in claims 49, 50 and 95 are: an amino acid transporter, a dipeptide transporter, an oligopeptide transporter, a simple sugar transporter, a bile acid transporter, a vitamin transporter, a phosphate transporter, a monocarboxylic transporter, an organic anion transporter, an organic cation transporter, a fatty acid transporter, a nucleoside transporter, an ABC transporter a PEPT1 transporter, a sodium-dependent glucose transport protein (SGLT1), a liver bile acid transporter (NTCP) and an ileal bile acid transporter (ASBT).

The claims are deemed to correspond to the species listed above in the following manner:

The claims of Group I, 1, 23, 25-33, 35-40, 46, 49-51, 55-60, 64-68, 75, 76, 80, 95 and 98.

The following claims are generic: 1, 23, 25-33, 35-40, 46, 51, 55-60, 64-68, 75, 76, 80 and 98.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: Each of the named transport groups or proteins is a unique and well defined biological or chemical entity which has been established with special and different identified characteristics.



专利名称(译)	转运蛋白的底物和筛选方法		
公开(公告)号	<a href="#">EP1212619A1</a>	公开(公告)日	2002-06-12
申请号	EP2000966735	申请日	2000-09-14
[标]申请(专利权)人(译)	什诺波特有限公司		
申请(专利权)人(译)	XENOPORT INC.		
当前申请(专利权)人(译)	XENOPORT INC.		
[标]发明人	DOWER WILLIAM J GALLOP MARK BARRETT RONALD W CUNDY KENNETH C CHERNOV ROGAN TANIA		
发明人	DOWER, WILLIAM, J. GALLOP, MARK BARRETT, RONALD, W. CUNDY, KENNETH, C. CHERNOV-ROGAN, TANIA		
IPC分类号	A61K49/00 C07B61/00 C07C271/22 C07D271/08 C07D277/32 C07D311/16 C07K1/04 C12N15/10 G01N33/50 G01N33/533 G01N33/566 G01N33/92 G01N33/542		
CPC分类号	G01N33/5088 A61K49/0004 C07C271/22 C07C2603/18 C07D271/08 C07D277/32 C07D311/16 C07K1/047 C12N15/1034 C12N15/1086 C40B40/00 G01N33/5008 G01N33/533 G01N33/566 G01N33/92		
优先权	60/154071 1999-09-14 US		
其他公开文献	EP1212619A4 EP1212619B1		
外部链接	<a href="#">Espacenet</a>		

#### 摘要(译)

提供了多种用于测定测试化合物文库作为转运蛋白的配体和/或底物的方法，包括载体型和受体型转运蛋白。公开了体外和体内筛选方法。还提供了用于筛选DNA文库以鉴定编码转运蛋白的成员的方法。还提供了包含通过筛选方法鉴定的化合物的药物组合物。